ZA200601389B

ZA200601389B - Amino acids with affinity for the alpha2delta-protein

Info

Publication number: ZA200601389B
Application number: ZA200601389A
Authority: ZA
Inventors: Deur Christopher James; Kolz Christine Nylund; Osuma Augustine Tobi; Plummer Mark Stephen; Schwarz Jacob Bradley; Thorpe Andrew John; Wustrow David Juergen
Original assignee: Warner Lambert Co
Priority date: 2003-09-25
Filing date: 2006-02-16
Publication date: 2007-06-27
Also published as: CN1886363A

Description

AMINO ACIDS WITH AFFINITY FOR THE 023-PREOTEIN

BACKGROUND OF THE INVENTION

~ This invention relates to certain -amino acids that bind to the alpha-2- delta (023) subunit of a calcium channel. These compounds &nd their pharmaceutically accceptable salts are useful in the treatment &f a variety of psychiatric, pain, ard cther disorders.

SUMMARY OF THE INVENTION

This inventiom provides compounds of formula |,

Ra Ry fs NH,

Rs R, Rs

COxH and their pharmaceutically acceptable salts, wherein

R, is a hydrogen atom or (C,-Cg)alkyl optionally substitu ted with from one to five fluorine atoms; :

R: is a hydrogaen atom or (C4-Cg)alkyl optionally substituted with from one to five fluorine atoms; or

Rand Ry, toge ether with the carbon to which they are attached, form a three- to six-membered cycloalkyl ring;

Rs is a hydrogen atom, (C4-Cg)alkyl, (Cs-Ce)cycloalkyl, (Cs-

Ce)cycloalkyl-(Cy-Ca)aalkyl, phenyl, phenyl-(C1-Ca)alkyl, pyridyl, er pyridyl-(C;-

Ca)alkyl, wherein the alkyl and cycloalkyl moieties or substituen-ts are optionally substituted with from one to five fluorine atoms, prefe=rably with from zero to three fluorine atoms, and the phenyl and pyridyl substittaents and the phenyl and pyridyl moieties of the phenyl-(C4-Cs)alkyt and the peyridyl-(C4-

Cs)alkyl substituents are optionally substituted with from one to five substituents, preferably with from zero to two substituents, indegoendently —

seleczted from chloro, fluoro, amino, nitro, cyano, hydroxy, (CC1-Cs)alkylamino, (C1-C3)alky! optionally substituted with from one to three flueorine atoms, and (C,-C=a)alkoxy optionally substituted with from one to three fluorine atoms;

Rs is a hydrogen atom or (C4-Cg)alkyl optionally substituted with from one teo five fluorine atoms;

Rs is a hydrogen atom or (C4-Cg)alkyl optionally subs-tituted with from one to five fluorine atoms; ‘Rs and Rs, together with the carbon to which they are attached, form a three- to six-membered cycloalkyl ring; and

Rs is a hydrogen atom or (C1-Ce)alkyl; with the proviso that Ry, Rz, Rs, Rs, Rs, and Rg are not simultaneously hydrogen atoms.

Specific compounds of formula | include the following compounds and their pharmaceutically acceptable salts: 3-Amino-4,5-dimethyl-hexanoic acid; =3-Amino-4,5-dimethyl-heptanoic acid; =3-Amino-4,5-dimethyl-octanoic acid; 33-Amino-4,5-dimethyl-nonanoic acid; 3-Amino-4,5-dimethyl-decanoic acid; 33-Amino-4-ethyl-5-methyl-heptanoic acid; 3-Amino-4-ethyl-5-methyl-octanoic acid; ) 3:-Amino-4-ethyl-5-methyl-nonanoic acid, 3-Amino-4-ethyl-5,6-dimethyl-heptanoic acid; 3-Amino-4-ethyl-5,7-dimethyl-octanoic acid; 3 -Amino-4-ethyl-5,8-dimethyl-nonanoic acid; 3-—Amino-5-ethyl-4-methyl-octanoic acid; 3—Amino-5-ethyl-4-methyl-nonanoic acid; 3—Amino-4,5-diethyl-heptanoic acid; 3—Amino-4,5-diethyl-octanoic acid; 3-Amino-4,5-diethyl-nonanoic acid; 3-.Amino-5-ethyl-4,7-dimethyl-octanoic acid; 3-.Amino-5-ethyl-4,8-dimethyl-nonanoic acid; —_0

3-Amino-4,5-diethyl-ES-methyl-heptanoic acid; 3-Amino-4,5-diethyl-a-methyl-octanoic acid; 3-Amino-4,5-diethyl-E3-methyl-nonanoic acid; 3-Amino-4,5,6-trimetlhyl-heptanoic acid;

3-Amino-4,5,7-trimetlhyl-octanoic acid; 3-Amino~4,5,8-trimetkhyl-nonanoic acid; 3-Amino-4-ethyl-5-mesthyl-hexanoic acid; 3-Amino-5-ethyl-4-meathyl-octanoic acid; 3-Amino-5-ethyl-4-mesthyl-heptanoic acid;

3-Amino-4-methyl-5-propyl-octanoic acid; 3-Amino-4-methyl-6-e=thyl-octanoic acid; 3-Amino-4-methyl-6-exthyl-nonanoic acid; 3-Amino-4,6-diethyl-cactanoic acid; 3-Amino-4,6-diethyl-rmonanoic acid;

3-Amino-6-cyclopentyy/i-4,5-dimethyl-hexanoic acid; 3-Amino-7-cyclopenty/I-4,5-dimethyl-heptanoic acid; 3-Amino-5-ethyl-4,6-cdimethyl-heptanoic acid; 3-Amino-5-ethyl-4,7-climethyl-octanoic acid; 3-Amino-5-ethyl-4,8-climethyl-nonanoic acid;

(3R,4R)-3-Amino-4,5—dimethyl-hexanoic acid; (3R/4R,5R)-3-Amino--4,5-dimethyl-heptanoic acid; (3R,4R,5R)-3-Amino--4,5-dimethyl-octanoic acid; (3R,4R,5R)-3-Amino--4,5-dimethyl-nonanoic acid; (3R,4R,5R)-3-Amino--4,5-dimethyl-decanoic acid;

3-Amino-5-cyclopropy/i-4-ethyl-hexanoic acid; 3-Amino-6-cyclopropy/i-4-ethyl-5-methyl-hexanoic acid; 3-Amino-5-cyclobutyl—4-ethyl-hexanoic acid; 3-Amino-6-cyclobutyl—4-ethyl-5-methyl-hexanoic acid; 3-Amino-5-cyclopentyw|-4-methyl-hexanoic acid,

3-Amino-6-cyclopentywi-4-gthyl-5-methyi-hexanoic acid; 3-Amino-5-cyclohexyl -4-ethyl-hexanoic acid; 3-Amino-6-cyclohexyl ~4-ethyl-5-methyl-hexanoic acid;

3-Amino-5-cyclopropyl-4-methyi-hexanoic acid; 3-Amino-6-cyclopropyl-4,5-dimethyl-hexanoic acid; 3-Amino-5-cyclobutyl-4-methyl-hexanoic acid; 3-Amino-6-cyciobutyl-4,5-dimethyi-hexanoic acid;

3-Amino-5-cyclopentyl-4-methyl-hexanoic acid; 3-Amino-6-cyclopentyl-4,5-dimethyl-hexanoic acid; 3-Amino-5-cyclohexyl-4-methyl-hexanoic acid; 3-Amino-6-cyclohexyl-4,5-dimethyl-hexanoic acid; 3-Amino-8-cyclohexyl-4,5-dimethyl-octanoic acid;

3-Amino-8-cyclohexyl-4,5-dimethyl-octanoic acid; 3-Amino-4,6-dimnethyl-heptanoic acid, 3-Amino-4,6-dimnethyl-octanoic acid; 3-Amino-4,6-dinnethyl-nonanoic acid; 3-Amino-4,6-dinnethyl-decanoic acid;

3-Amino-4,6,7-trimethyl-octanoic acid; 3-Amino-4,6,8-trimethyl-nonanoic acid; 3-Amino-4,6,9-trimethyl-decanoic acid; 3-Amino-6-cyclopropyl-4-methyl-heptanoic acid;

3-Amino-6-cyclosbutyl-4-methyl-heptanoic acid;

3-Amino-6-cyclospentyl-4-methyl-heptanoic acid; 3-Amino-6-cyclohexyl-4-methyl-heptanoic acid; 3-Amino-7-cyclopropyl-4,6-dimethyl-heptanoic acid; 3-Amino-7-cyclobutyl-4,6-dimethyl-heptanoic acid; 3-Amino-7-cyclopentyl-4,6-dimethyl-heptanoic acid;

3-Amino-7-cyclo hexyl-4,6-dimethyl-heptanoic acid, 3-Amino-8-cyclo propyl-4,6-dimethyl-octanoic acid;

. 3-Amino-8-cyclo butyl-4,6-dimethyi-octanoic acid; 3-Amino-8-cyclo pentyl-4,6-dimethyl-octanoic acid; 3-Amino-8-cyclo hexyl-4,6-dimethyl-octanoic acid;

3-Amino-6-(3-ch loro-phenyl)-4-methyl-heptanoic acid; 3-Amino-6-(3,4-dichloro-phenyl)-4-methyl-heptanoic acid;

: 3-Amino-4-methyl-6-(3-trifluoromethyl-phenyl)-heptanoi c acid;

3-Amino-4-methyl-6-(4-tri-fluoromethyl-phenyl)-heptanoic acid; 3-Amino-7-(3-chloro-pheryl)-4,6-dimethyl-heptanoic acid; 3-Amino-7-(3,4-dichloro-phenyl)-4 6-dimethyl-heptanoic acid; 3-Amino-4,6-dimethyl-7-(3-trifluoromethyl-phenyl)-heptanoic acid;

= 3-Amino-4,6-dimethyl-7-(<3-triflucromethyl-phenyl)-heptanoic acid;

3-Amino-8-(3-chloro-phersyl)-4,6-dimethyl-octanoic acid; 3-Amino-8-(3,4-dichloro-p henyl)-4,6-dimethyl-octanoic acid;

3-Amino-4,6-dimethyl-8-(3-trifluoromethyl-phenyl)-octanoic acid;

3-Amino-4,6-dimethyl-8-(4-trifluoromethyl-phenyl)-octanoic acid; - 3-Amino-~4-ethyl-6-methyl-octanoic acid; 3-Amino-4-ethyi-6-methyl- nonanoic acid; 3-Amino-4-ethyl-6-methyl-decanoic acid; 3-Amino-4-ethyl-6,7-dimet hyl-octanoic acid; 3-Amino-4-ethyl-6,8-dimethhyl-nonanoic acid,

3-Amino-4-ethyl-6,9-dimethhyl-decanoic acid; 3-Amino-6-cyclopropyl-4-e thyl-heptanoic acid; 3-Amino-6-cyclobutyl-4-ethyl-heptanoic acid; 3-Amino-6-cyclopentyl-4-ethyl-heptanoic acid; 3-Amino-6-cyclohexyl-4-ethyl-heptanoic acid;

3-Amino-7-cyclopropyl-4-egthyi-6-methyl-heptanoic acid; 3-Amino-7-cyclobutyl-4-etheyl-6-methyl-heptanoic acid;

. 3-Amino-7-cyclopentyl-4-ethyl-6-methyl-heptanoic acid; 3-Amino-7-cyclohexyl-4-ethyl-6-methyl-heptanoic acid; 3-Amino-8-cyclopropyi-4-ethyl-8-methyl-octanoic acid;

3-Amino-8-cyclobutyl-4-ethyi-6-methyl-octanoic acid;

3-Amino-8-cyclopentyl-4-et hyl-6-methyl-octanoic acid; 3-Amino-8-cyclohexyl-4-ethayl-6-methyl-octanoic acid;

: 3-Amino-6-(3-chloro-phenyil)-4-ethyl-heptanoic acid; 3-Amino-6-(3,4-dichloro-phenyl)-4-ethyl-heptanoic acid;

3-Amino-4-ethyl-6-(3-trifluoromethyl-phenyl)-heptanoic acid; 3-Amino-4-ethyl-6-(4-trifluor-omethyl-phenyl)-heptanoic acid; 3-Amino-7-(3-chioro-phenyl )-4-ethyl-6-methyl-heptanoic acid,

3-Amino-7-(3,4-dichloro-phenyl)-4 -ethyl-6-methyl-heptanoic acid; 3-Amino-4-ethyl-6-methyl-7-(3-trifl uoromethyl-phenyl)-heptanoic acid; 3-Amino-4-ethyl-6-methyl-7-(4-trifl uoromethyl-phenyl)-heptanoic acid; 3-Amino-8-(3-chloro-phenyl)-4-ethayl-6-methyl-octanoic acid;

3-Amino-8-(3,4-dichloro-phenyl)-4—ethyl-6-methyl-octanoic acid; 3-Amino-4-ethyl-6-methyl-8-(3-trifl: uoromethyl-phenyl)-octanoic acid ; 3-Amino-4-ethyl-6-methyi-8-(4-triflmuoromethyl-phenyl)-octanoic acid ; 3-Amino-4-methyl-heptanoic acid; 3-Amino-4,6-dimethyi-heptanoic aecid;

3-Amino-4,7-dimethyl-octanoic aci-d; 3-Amino-4,8-dimethyl-nonanoic acsid; 3-Amino-4-methyl-hexanoic acid;

: 3-Amino-4-methyl-heptanoic acid; 3-Amino-4-methyl-octanoic acid;

3-Amino-4-methyl-nonanoic acid; 3-Amino-5-cyclopropyl-4-methyl-pentanoic acid; 3-Amino-6-cyclopropyl-4-methyl-hexanoic acid; 3-Amino-7-cyclopropyl-4-methyl-hexptanoic acid; 3-Amino-5-cyclobutyl-4-methyl-peratanoic acid;

3-Amino-6-cyciobutyl-4-methyl-hexzanoic acid;

oo 3-Amine-7-cyclobutyl-4-methyl-hepotanoic acid; 3-Amino-5-cyclopentyl-4-methyl-pe=ntanoic acid; 3-Amino-6-cyclopentyl-4-methyl-hesxanoic acid; 3-Amino-7-cyclopentyl-4-methyl-he=ptanoic acid;

3-Amino-5-cyciohexyl-4-methyl-pertanoic acid; 3-Amino-6-cyclohexyl-4-methyl-hex<anoic acid, 3-Amino-7-cyciohexyl-4-methyl-hepianoic acid; 3-Amino-5-cyclopropyl-4-ethyi-penanoic acid; 3-Amino-6-cyclopropyl-4-ethyl-hexa&anoic acid;

3-Amino-7-cyclopropyl-4-ethyi-hept-anoic acid; 3-Amino-5-cyclobutyl-4-ethyl-penta noic acid; 3-Amino-6-cyclobutyl-4-ethyl-hexarmoic acid;

3-Amino-7-cyciobutyl-4-ethyl-heptanoic acid; 3-Amino-5-cyclopentyl-4-ethyl-pentanoic acid; 3-Amino-6-cyclopentyl-4-ethyl-hexanoic acid, 3-Amino-7-cyclopentyl-4-ethyi-heptanoic acid; 3-Amino-5-cyclohexyl-4-ethyl-pentanoic acid; 3-Amino-6-cyclohexyl-4-ethyl-hexanoic acid; 3-Amino—-7-cyclohexyl-4-ethyl-heptanoic acid; 3-Amino-4,4,5-trimethyi-heptanoic acid; 3-Amino-4,4,5-trimethyl-octanoic acid; 3-Amino-4,4,5-trimethyl-hexanoic acid; 3-Amino-4,5,5-trimethyl-heptanoic acid; 3-Amino-4,5,5-trimethyl-octanoic acid; and 3-Amino-4,5,5-trimethyl-hexanoic acid.

Other cormpounds of formula ! include the following compounds, and their pharmaceutically acceptable salts: 3-Amino-4-methyl-5-phenyl-pentanoic acid; 3-Amino-4-methyl-6-phenyl-hexanoic acid; : . 3-Amino-4-methyl-7-phenyli-heptanoic acid; 3-Amino-5-(2-chloro-phenyl)-4-methyl-pentanoic acid; 3-Amino-5-(3-chloro-phenyl)-4-methyl-pentanoic acid; 3-Amino-5-(4-chloro-phenyl)-4-methyi-pentanoic acid; 3-Amino-5-(2,4-dichloro-phenyl)-4-methyl-pentanoic acid; 3-Amino-5-(3,4-dichloro-phenyl)-4-methyl-pentanoic acid; © 3-Amino-4-(2-chloro-benzyl)-hexanoic acid; 3-Amino-4-(3-chloro-benzyl)-hexanoic acid; 3-Amino-4-(4-chloro-benzyl)-hexanoic acid; 3-Amino-4-(2,4-dichloro-benzyl)-hexanoic acid; : 3-Amino-4-(3,4-dichloro-benzyl)-hexanoic acid; 3-Amino-6-(2-chloro-phenyl)-4-methyl-hexanoic acid; 3-Amino-6-(3-chloro-phenyl)-4-methyl-hexanoic acid; 3-Amino-6-(4-chloro-phenyl)-4-methyl-hexanoic acid; 3-Amino-6-(2,4-dichloro-phenyl)-4-methyl-hexanoic acid;

3-Amino-6-(3,4-dichk oro-phenyl)-4-methyl-hexanoic acid; 3-Amino-6-(2-chioro—phenyl)-4-ethyl-hexanoic acid; 3-Amino-6-(3-chloro—phenyl)-4-ethyl-hexanoic acid; ~ 3-Amino-6-(4-chloro—phenyl)-4-ethyl-hexanoic acid; 3-Amino-6-(2,4-dichl oro-phenyl)-4-ethyl-hexanoic acid; 3-Amino-6-(3,4-dichl oro-phenyl)-4-ethyl-hexanoic acid; 3-Amino-7-(2-chloro—phenyl)-4-methyl-heptanoic acid; 3-Amino-7-(3-chloro—phenyl)-4-methyl-heptanoic acid; 3-Amino-7-(4-chloro—phenyl)-4-methyl-heptanoic acid; 3-Amino-7-(2,4-dichloro-phenyl)-4-methyl-heptanoic acid; 3-Amino-7-(3,4-dichloro-phenyi)-4-methyl-heptanoic acid; 3-Amino-7-(2-chloro—phenyl)-4-ethyl-heptanoic acid; 3-Amino-7-(3-chioro—phenyl)4-ethyl-heptanoic acid; 3-Amino-7-(4-chloro—phenyl)-4-ethyl-heptanoic acid; 3-Amino-7-(2,4-dichloro-phenyl)-4-ethyl-heptanoic acid; and . 3-Amino-7-(3,4-dichloro-phenyl)-4-ethyl-heptanoic acid.

This invention also provides compounds of formula Il

Rs

See

Ry

HOC i" and their pharmaceutically acceptable salts, wherein Ry, Rs, and 3, are as defined above in formula I, with the proviso that R; is not a hydroggen atom.

Specific compounds «of formula I include the following comgoounds and their pharmaceutically acceptable salts: 3-Amino-4,5-dimethy I-hexanoic acid; 3-Amino-4,5-dimethy J-heptanoic acid; 3-Amino-4,5-dimethy #-octanoic acid; . 3-Amino-4,5-dimethy§-nonanoic acid; 3-Amino-4-ethyl-5-mesthyl-heptanoic acid;

3-Amino-4-ethyl-5-methyl-octanoic acid; 3-Mmino-4-ethyl-5-methyl-nonanoic acid; : 3-Aamino-4-ethyl-5,6-dimethyl-heptanoic acid; 3-Aamino-4-ethyl-5,7-dimethyl-octanoic acid,

3-Aamino-4-ethyl-5,8-dimethyl-nonanoic acid; 3-A-mino-5-ethyl-4-methyl-octanoic acid; 3-A_mino-5-ethyl-4-methyl-nonanoic acid; 3-A_mino-4,5-diethyl-heptanoic acid;

3-A mino-4,5-diethyl-octanoic acid;

3-A mino-4,5-diethyl-nonanoic acid; 3-Amino-5-ethyl-4,7-dimethyl-octanocic acid; 3-Ammino-5-ethyl-4,8-dimethyl-nonanoic acid; 3-Ammino-4,5-diethyl-6-methyl-heptanoic acid; 3-Ammino-4,5-diethyl-7-methyi-octanoic acid;

3-Ammino-4,5-diethyl-8-methyl-nonanoic acid;

. 3-Armino-4,5,6-trimethyl-heptanoic acid; 3-Arnino-4,5,7-trimethyl-octanoic acid; 3-Armino-4,5,8-trimethyl-nonanoic acid, 3-Arnmino-4-ethyl-5-methyl-hexanoic acid;

3-Arnino-5-ethyl-4-methyl-octanoic acid; 3-Armino-5-ethyl-4-methyl-heptanoic acid; 3-Armino-4-methyl-5-propyl-octanoic acid; 3-Arnino-6-cyclopentyl-4,5-dimethyl-hexanoic acid; 3-Armino-7-cyclopentyl-4,5-dimethyl-heptanoic acid;

3-Armnino-5-ethyl-4,6-dimethyl-heptanoic acid; 3-Armino-5-ethyl-4,7-dimethyl-octancic acid; 3-Annino-5-ethyl-4,8-dimethyl-nonanoic acid; (3R,=4R)-3-Amino-4,5-dimethyl-hexanoic acid; (3R,~4R,5R)-3-Amino-4,5-dimethyl-heptanoic acid;

(3R,=4R,5R)-3-Amino-4,5-dimethyl-octanoic acid; (3R,=4R,5R)-3-Amino-4,5-dimethyl-nonanoic acid; (3R,4R,5R)-3-Amino-4,5-decanoic acid;

3-Amino-5-cy clopropyi-4-sthyl-hexanoic acid; 3-Amino-6-cy clopropyl-4-ethyl-5-methyl-hexanoic acid; 3-Amino-5-cy clobutyl-4-ethyl-hexanoic acid; : . : 3-Amino-6-cy clobutyl-4-ethyl-5-methyl-hexanoic acid; 3-Amino-5-cy clopentyl-4-methyl-hexanoic acid; 3-Amino-6-cy<lopentyl-4-ethyl-5-methyi-hexanoic acid; 3-Amino-5-cyclohexyl-4-ethyl-hexanoic acid; 3-Amino-6-cy«clohexyl-4-ethyl-5-methyl-hexanoic acid; 3-Amino-5-cyclopropyl-4-methyl-hexanoic acid; 3-Amino-6-cyclopropyl-4,5-dimethyl-hexanoic acid; 3-Amino-5-cyclobutyl-4-methyl-hexanoic acid; " 3-Amino-6-cyclobutyl-4,5-dimethyl-hexanoic acid; 3-Amino-5-cyciopentyl-4-methyl-hexanoic acid; 3-Amino-6-cyclopentyl-4,5-dimethyl-hexanoic acid; 3-Amino-5-cyclohexyl-4-methyl-hexanoic acid; 3-Amino-6-cyclohexyl-4,5-dimethyl-hexanoic acid; - 3-Amino-8-cyclohexyl-4,5-dimethyl-octanoic acid and 3-Amino-8-cyclohexyl-4,5-dimethyl-octanoic acid.

This invention also provides compounds of formula ill

CH, “yY Rs

Ry

HO.C 1] and their pharmaceutically acceptable salts, wherein Ry and Rs are as defined above in formula 1, wiith the proviso that R; and Rs are not hydrogen atoms.

Specific compounds of formula Ill include the following compounds and their pharmaceutically acceptable salts: 3-Amino-4,5-d imethyl-hexanoic acid; 3-Amino-4,5-d imethyl-heptanoic acid; 3-Amino-4,5-d imethyl-octanoic acid;

3-Amino-4,5-dimethyl-nonanoic acid; 3-Amnino-4,5,6-trimethyl-theptanoic acid; 3-Amino-4,5,7-trimethyl-©ctanoic acid; 3-Amino-4,5,8-trimethyl-monanoic acid; 3-Amino-4-methyl-5-propyl-octanoic acid; 3-Amino-6-cyclopentyl-4 ,5-dimethyl-hexanoic acid; : 3-Amino-7-cyclopentyl-4 ,5-dimethyl-heptanoic acid;

Co 3-Amino-5-ethyl-4,6-dimethyl-heptanoic acid; 3-Amino-5-ethyl-4,7-dimethyl-actanoic acid; 3-Amino-5-ethyi-4,8-dimethyl-nonanoic acid; (3R,4R)-3-Amino-4,5-dimsethyl-hexanoic acid; (3R,4R,5R)-3-Amino-4,5—dimethyl-heptanoic acid; (3R,4R,5R)-3-Amino-4,5—dimethyi-octanoic acid; (3R,4R,5R)-3-Amino-4,5-dimethyi-nonanoic acid; (3R,4R,5R)-3-Amino-4,5- dimethyi-decanoic acid; 3-Amino-5-cyclopentyl-4- methyl-hexanoic acid; 3-Amino-5-cyclopropyl-4- methyl-hexanoic acid; 3.Amino-6-cyclopropyl-4,5-dimethyl-hexanoic acid; 3-Amino-5-cyclobutyl-4-muethyl-hexanoic acid; 3-Amino-6-cyclobutyl-4,5~dimethyl-hexanoic acid; 3-Amino-5-cyclopentyl-4-rmethyi-hexanoic acid; 3-Amino-6-cyclopentyl-4,5-dimethyi-hexanoic acid; 3.Amino-5-cyclohexyl-4-methyl-hexanoic acid; 3.Amino-6-cyclohexyl-4,5-dimethyl-hexanoic acid; 3-Amino-8-cyclohexyl-4,56—dimethyl-octanoic acid and 3-Amino-8-cyclohexyl-4,5—dimethyl-octanoic acid. —f

This invention also providess compounds of formula [V

CH

HN A Rs

TT

HOC

Iv and their pharmaceutically acceptable salts, wherein Rs is as defined above in formula 1, with the proviso that Rs #is not a hydrogen atom. -

Specific compounds of formula IV include the following compounds and their pharmaceutically acceptable salts: (3R,4R)-3-Amino-4,5-dimethyl-hexanoic acid; (3R,4R,5R)-3-Amino-4,5-dimmethyl-heptanoic acid; (3R,4R,5R)-3-Amino-4,5-dimmethyl-octanoic acid; : (3R,4R,5R)-3-Amino-4,5-dimmethyl-nonanoic acid and (3R,4R,5R)-3-Amino-4,5-dismethyl- decanoic acid.

This invention also relates ®o compounds of fomulaV

HO,C Res py : Toss

Ho -15 v and their pharmaceutically accept-able salts, wherein Ri, Rz, Rs, Rs, and Rs are as defined above in formula I, with the proviso that Ry, Rz, Rs, Rs, and Rs are not simultaneously hydrogen atoms.

Specific compounds of formula V include the following compounds and their pharmaceutically acceptable= salts: 2-Aminomethyl-4-(2-fluoro—phenyl)-pentanoic acid; 2-Aminomethyl-4-(3-fluoro—phenyl)-pentanoic acid; 2-Aminomethyl-4-(4-fluoro—phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,3-diflu oro-phenyl)-pentanoic acid; —1o0—

!

2-Aminomethyl-4-(2,4-difluoro-phenyl)-pentzanoic acid; 2-Aminomethyl-4-(2,5-difluoro-phenyl)-pentaanoic acid; 2-Aminomethyl-4-(2,6-difluoro-phenyl)-pentanoic acid; 2-Aminomethyl-4-(3,4-difluoro-phenyl)-pentaanoic acid;

2-Aminomethyl-4-(3,5-difluoro-phenyl)-pent anoic acid; 2-Aminomethyl-4-(2,3,4-trifluoro-phenyl)-pe ntanoic acid; 2-Aminomethyl-4-(2,3,5-trifluoro-phenyl)-pe=ntanoic acid; 2-Aminomethyl-4-(2,3,6-trifluoro-phenyl)-pexntanoic acid;

: 2-Aminomethyi-4-(2,4,6-trifluoro-phenyl)-pexntanocic acid;

2-Aminomethyl-4-(2,3,4,5-tetrafluoro-phenysl)-pentanoic acid; 2-Aminomethyl-4-(2,3,4,6-tetrafluoro-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,3,5,6-tetrafluoro-phenyyl)-pentanoic acid;

2. Aminomethyl-4-pentafluorophenyi-pentamnoic acid; 2.Aminomethyl-4-(2-flucro-phenyl)-hexanoric acid;

16 2-Aminomethyl-4-(3-fluoro-phenyl)-hexanosic acid; 2-Aminomethyi-4-(4-fluoro-phenyl)-hexanaeic acid; 2-Aminomethyl-4-(2,3-difluoro-phenyl)-hexcanoic acid; 2-Aminomethyl-4-(2,4-difluoro-phenyl)-hexxanoic acid; 2-Aminomethyl-4-(2,5-difluoro-phenyl)-he><anoic acid;

2-Aminomethyl-4-(2,6-difluoro-phenyl)-hex>anoic acid; 2-Aminomethyl-4-(3,4-difluoro-phenyl)-hex<anoic acid; 2-Aminomethyi-4-(3,5-difluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-(2,3,4-trifluoro-phenyl)-thexanoic acid; 2-Aminomethyl-4-(2,3,5-trifluoro-phenyl)-hexanoic acid;

2-Aminomethyl-4-(2,3,6-trifluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-(2,4,6-trifluoro-phenyl)-Inexanoic acid;

~ 2-Aminomethyl-4-(2,3,4,5-tetrafluoro-phemyl)-hexanoic acid; 2-Aminomethyl-4-(2,3,4,6-tetrafluoro-phe nyl)-hexanoic acid; 2-Aminomethyl-4-(2,3,5,6-tetrafluoro-phe-nyl)-hexanoic acid;

2-Aminomethyl-4-pentafluorophenyi-hexanoic acid; 2-Aminomethyl-5-(2-flucro-phenyl)-4-metthyl-pentanoic acid; 2-Aminomethyl-5-(3-fluoro-phenyl)-4-metthyl-pentanoic acid;

2-Aminomethyl-5-(4-fluoro-pahenyl)-4-methyl-pentanoic acid; 2-Aminomethyl-5-(2,3-difluo- ro-phenyl)-4-methyl-pentanoic acid; 2-Aminomethyl-5-(2,4-difluo ro-phenyl)-4-methyl-pentanoic acid; 2-Aminomethyl-5-(2,5-difluo ro-phenyl)-4-methyl-pentanoic acid;

2-Aminomethyl-5-(2,6-difluo ro-phenyl)-4-methyl-pentanoic acid; 2-Aminomethyl-5-(3,4-difluo ro-phenyl)-4-methyl-pentanoic acid; 2-Aminomethyl-5-(3,5-difluo To-phenyl)-4-methyl-pentanoic acid; 2-Aminomethyi-4-methyi-5-(=2,3,4-trifluoro-phenyl)-pentanoic acid; 2-Aminomethyl-4-methyl-5-(=2,3,5-trifluoro-phenyl)-pentanoic acid;

2-Aminomethyl-4-methyl-5-(=2,3,6-trifluoro-phenyl)-pentanoic acid; 2-Aminomethyl-4-methyl-5-(=2,4,6-trifluoro-phenyl)-pentanoic acid; 2-Aminomethyl-4-methyl-5-(=2,3,4 5-tetrafluoro-phenyl)-pentanoic acid; 2.Aminomethyl-4-methyl-5-(=2,3,46-tetrafluoro-phenyl)-pentanoic acid; 2-Aminomethyl-4-methyl-5-(=2,3,5,6-tetrafluoro-phenyl)-pentanoic acid;

2-Aminomethyl-4-methyl-5-peentatiuorophenyl-pentancic acid; 2-Aminomethyl-5-(2-fluoro-p dhenyl)-4-methyl-hexanoic acid;

2-Aminomethyl-5-(3-flucro-p lhenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(4-flucro-plhenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(2,3-difluor-o-phenyl)-4-methyl-hexanoic acid;

2.Aminomethyl-5-(2,4-difluor-o-phenyl)-4-methyl-hexanoic acid;

© 2-Aminomethyl-5-(2,5-difluor-o-phenyl)-4-methyl-hexanoic acid; 2.Aminomethyl-5-(2,6-difluor-o-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(3,4-difluor-o-phenyl)-4-methyl-hexanoic acid; 2-Aminomethy}-5-(3,5-difluor-o-phenyi)-4-methyl-hexanoic acid;

2-Aminomethyl-4-methyi-5-(2,3,4-trifluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-methyl-5-(22,3,5-triflucro-phenyl)-hexanoic acid; 2.Aminomethyl-4-methyl-5-(22,3,6-trifluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-methyl-5-(2,4,6-triflucro-phenyl)-hexanoic acid; 2-Aminomethyl-4-methyl-5-(2,3,4,5-tetrafluoro-phenyl)-hexanoic acid;

2.Aminomethyl-4-methyl-5-(=22,3,4,6-tetrafluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-methyl-5-(22,3,5,6-tetrafluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-methyl-5-peentafluorophenyl-hexanoic acid;

2-Aminomethyl-63-(2-fluoro-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-6-(3-fluoro-phenyl)-4-methyl-hexanoic ~acid; 2-Aminomethyl-&-(4-fluoro-phenyl)-4-methyl-hexanoic acid;

2-Aminomethyl-&-(2,3-difluoro-phenyl)-4-methyl-hexarmoic acid;

2-Aminomethyl-86-(2,4-difluoro-phenyl)-4-methyl-hexarmoic acid; 2-Aminomethyl-6-(2,5-difluoro-phenyl)-4-methyl-hexaroic acid; 2-Aminomethyl-6-(2,6-difluoro-phenyl)-4-methyl-hexaroic acid;

2-Aminomethyl-@6-(3,4-difluoro-phenyl)-4-methyl-hexaroic acid; 2-Aminomethyl-85-(3,5-difluoro-phenyl)-4-methyl-hexaroic acid;

2-Aminomethyl-=4-methyl-6~(2,3,4-trifiuoro-phenyl)-hexcanoic acid; 2-Aminomethyl-4-methyl-6-(2,3,5-trifluoro-phenyl)-hexxanoic acid; 2-Aminomethyl--4-methyl-6-(2,3,6-trifluoro-phenyl)-he)&anoic acid; 2-Aminomethyl--4-methyl-6-(2,4,6-trifluoro-phenyl)-hexxanoic acid; 2-Aminomethyl--4-methyi-6-(2,3,4,5-tetrafluoro-phenyl)-hexanoic acid;

2-Aminomethyl- 4-methyl-6-(2,3,4,6-tetrafluoro-phenyl )-hexanoic acid; 2-Aminomethyl-4-methyl-6-(2,3,5,6-tetrafluoro-phenyk)-hexanoic acid; 2-Aminomethyl- 4-methyl-6-pentafiuorophenyl-hexanaeic acid; 2-Aminomethyi—5-(2-fluoro-phenyl)-4-ethyl-pentanoic acid; 2.Aminomethyl—5-(3-flucro-phenyl)-4-ethyl-pentanoic acid;

2-Aminomethyl—5-(4-fluoro-phenyl)-4-ethyl-pentanoic acid; 2-Aminomethyl—5-(2,3-difluoro-phenyl)-4-ethyl-pentaroic acid; 2-Aminomethyl—5-(2,4-difluoro-phenyl)-4-ethyl-pentaroic acid; 2-Aminomethyl—5-(2 5-difluoro-phenyl)-4-ethyl-pentaroic acid; 2-Aminomethyl—5-(2,6-difluoro-phenyl)-4-ethyl-pentaroic acid;

2-Aminomethyl—5-(3,4-difluoro-phenyl)-4-ethyl-pentamoic acid; 2-Aminomethyl—5§-(3,5-difluoro-phenyl)-4-ethyl-pentamnoic acid; 2-Aminomethyl—4-ethyl-6-(2,3,4-trifluoro-phenyl)-pen-tanoic acid; 2-Aminomethyl—4-ethyl-5-(2,3,5-trifluoro-phenyl)-pen:tancic acid; 2-Aminomethyl—4-ethyl-5-(2,3,6-trifluoro-phenyl)-perstanoic acid;

2-Aminomethyl—4-ethyl-5-(2,4,6-trifluoro-phenyl)-perwtanoic acid; 2-Aminomethyl—4-ethyl-5-(2,3,4,5-tetrafluoro-phenyl-pentanoic acid; 2-Aminomethyl—4-ethyl-5-(2,3,4,6-tetrafluoro-phenyli-pentanoic acid;

2-Aminomethyl-4-ethyl-55-(2,3,5,6-tetrafluoro-phenyl)-pentanoic acid; 2-Aminomethyl-4-ethyl-S-pentafluorophenyl-pentanoic acid; 2-Aminomethyl-6-(2-flucro-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(3-flucro-phenyl)-4-ethyl-hexanoic acid;

2-Aminomethyl-6-(4-flucro-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyi-6-(2,3-d ifluoro-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(2,4-d ifluoro-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(2,5-ck ifluoro-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(2,6-dBifluoro-phenyl)-4-ethyl-hexanoic acid;

2-Aminomethyl-6-(3,4-dlifluoro-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(3,5-dBifluoro-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-4-ethyl-#6-(2,3,4-triflucro-phenyl)-hexanoic acid; 2-Aminomethyi-4-ethyl-=6-(2,3,5-trifluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-ethyi--6-(2,3,6-trifluoro-phenyl)-hexanoic acid; :

2-Aminomethyl-4-ethyl- 6-(2,4,6-trifluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-ethyl—6-(2,3,4,5-tetrafluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-ethyl—6-(2,3,4,6-tetrafluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-ethyl—6-(2,3,5,6-tetraflucro-phenyl)-hexanoic acid; 2-Aminomethyl-4-ethyl—6-pentaflucrophenyi-hexanoic acid;

2-Aminomethyl-7-(2-flu-oro-phenyl)-4-methyl-heptanoic acid; 2-Aminomethyl-7-(3-flu oro-phenyl)-4-methyl-heptanoic acid; 2-Aminomethyl-7-(4-flu oro-phenyi)-4-methyl-heptanoic acid; 2.Aminomethyl-7-(2,3-cdifluoro-phenyl)-4-methyl-heptanoic acid; 2.Aminomethyl-7-(2,4-adifluoro-phenyl)-4-methyl-heptanoic acid;

2-Aminomethyl-7-(2,5-adifluoro-phenyl)-4-methyl-heptanoic acid; 2-Aminomethyl-7-(2,6-«difluoro-phenyl)-4-methyl-heptanoic acid; 2.Aminomethy}-7-(3,4-«difluoro-phenyl)-4-methyl-heptanoic acid; 2.Aminomethyl-7-(3,5- difluoro-phenyl)-4-methyl-heptanoic acid; 2.Aminomethyl-4-mettyl-7-(2,3,4-trifluoro-phenyl)-heptanoic acid;

2.Aminomethyl-4-metiyi-7-(2,3,5-trifluoro-phenyl)-heptanoic acid; 2.Aminomethyl-4-metiyi-7-(2,3,6-trifluoro-phenyl)-heptanoic acid; 2-Aminomethyl-4-metiyl-7-(2,4,6-trifluoro-phenyl)-heptanoic acid;

2-Aminomethyl—~4-methyl-7-(2,3,4,5-tetrafluoro-phenyli)-heptanoic acid; 2-Aminomethyl—4-methyi-7-(2,3,4,6-tetrafluoro-phenyll)-heptanoic acid; 2-Aminomethyl—~4-methyl-7-(2,3,5,6-tetrafluoro-phenyll)-heptanoic acid; 2-Aminomethyl—4-methyl-7-pentafluorophenyl-heptan-oic acid;

2-Aminomethyl—7-(2-fluoro-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl—7-(3-fluoro-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl—7-(4-fluoro-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl—7-(2,3-difluoro-phenyl)-4-ethyl-heptarmoic acid; 2-Aminomethyl—7-(2,4-diflucro-phenyl)-4-ethyl-heptarmoic acid;

2-Aminomethyl—7-(2,5-difluoro-phenyl)-4-ethyi-heptarmoic acid;

2.Aminomethyl—7-(2,6-difluoro-phenyl)-4-ethyl-heptarmoic acid; 2.Aminomethyl—7-(3,4-diflucro-phenyl)-4-ethyl-heptarmoic acid; 2-Aminomethyl—7-(3,5-difluoro-phenyl)-4-ethyl-heptarnoic acid; 2-Aminomethyl—4-ethyl-7-(2,3 4-trifluoro-phenyl)-heptanoic acid;

2-Aminomethyl—4-ethyl-7-(2,3,5-trifluoro-phenyl)-hept-anoic acid; - 2-Aminomethyl—4-ethyl-7-(2,3,6-trifluoro-phenyl)-hept. anoic acid; 2-Aminomethyl—a4-sthyl-7-(2,4,6-trifluoro-phenyl)-hept anoic acid; 2-Aminomethyl—4-ethyl-7-(2,3,4,5-tetrafluoro-phenyl)- - heptanoic acid; 2-Aminomethyl—4-ethyl-7-(2,3,4,6-tetrafiuoro-phenyl)- - heptanoic acid;

2-Aminomethyl--4-ethyl-7-(2,3,5,6-tetrafluoro-phenyl)—heptanoic acid; 2-Aminomethyl—4-ethyl-7-pentafluorophenyl-heptanoi-c acid; 2.Aminomethyl—4-(2-chloro-phenyt)-pentanoic acid; »-Aminomethyl—4-(3-chloro-phenyl)-pentanoic acid; 2-Aminomethyl—-4-(4-chloro-phenyl)-pentanoic acid;

2-Aminomethyl—4-(2,3-dichloro-phenyl)-pentanoic aciid; 2-Aminomethyl—4-(2 4-dichloro-phenyl)-pentanoic acid; 2-Aminomethyl- 4-(2,5-dichloro-phenyl)-pentanoic acid; 2-Aminomethyl- 4-(2,6-dichloro-phenyl)-pentanoic acid; 2_Aminomethyl- 4-(3,4-dichloro-phenyl)-pentanoic acid;

2-Aminomethyl--4-(3,5-dichloro-phenyl)-pentanoic acid; 2-Aminomethyl--4-(2,3,4-trichloro-phenyl)-pentanoic &xcid; 5-Aminomethyl4-(2,3,5-trichioro-phenyl)-pentanoic acid;

2-Aminomethyl-4-(2,3 .6-trichloro-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,4 ,6-trichioro-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,3 ,4,5-tetrachloro-phenyl)-pentanoic acid;

2-Aminomethyl-4-(2,3 ,4,6-tetrachloro-phenyl)-pentanoic acid;

2-Aminomethyl-4-(2,3-,5,6-tetrachloro-phenyl)-pentanoic acid; 2-Aminomethyl-4-pens tachlorophenyl-pentanoic acid; 2-Aminomethyi-4-(2-chioro-phenyl)-hexanoic acid; 2-Aminomethyl-4-(3-chloro-phenyl)-hexanoic acid; 2-Aminomethyl-4-(4-chloro-phenyl)-hexanoic acid;

2-Aminomethyi-4-(2,3-dichloro-phenyi)-hexanoic acid; 2-Aminomethyl-4~(2,48-dichloro-phenyl)-hexanoic acid; 2-Aminomethyl-4-(2,5-dichioro-phenyl)-hexanoic acid; 2-Aminomethyi-4-(2,6-dichloro-phenyl)-hexanoic acid; 2-Aminomethyl-4-(3,«4-dichloro-phenyl)-hexanoic acid;

2-Aminomethyl-4-(3,5-dichloro-phenyl)-hexanoic acid, 2-Aminomethyl-4-(2, 3,4-trichloro-phenyl)-hexanoic acid; 2-Aminomethyl-4-(2, 3,5-trichloro-phenyl)-hexanoic acid;

2-Aminomethyl-4-(2 , 3,6-trichloro-phenyl)-hexanoic acid; 2-Aminomethyl-4-(2 _ 4,6-trichloro-phenyl)-hexanoic acid;

2-Aminomethyl-4-(2 ,3,4,5-tetrachloro-phenyl)-hexanoic acids 2-Aminomethyl-4-(2 ,3,4,6-tetrachloro-phenyl)-hexanoic acid ;

2-Aminomethyl-4-(2 ,3,5,6-tetrachloro-phenyl)-hexanoic acid. ; 2-Aminomethyl-4-pentachlorophenyl-hexanoic acid;

2-Aminomethyi-5-(2-chloro-phenyl)-4-methyl-pentanoic acicl;

2-Aminomethyl-5-(3-chloro-phenyl)-4-methyl-pentanoic acicd; 2-Aminomethyl-5-(4@&-chloro-phenyl)-4-methyl-pentanoic acid; 2-Aminomethyl-5-(2,3-dichloro-phenyl)-4-methyl-pentanoic acid; 2-Aminomethyl-5-(2 ,4-dichioro-phenyi)-4-methyl-pentanoic. acid; 2-Aminomethyl-5-(2,5-dichloro-phenyl)-4-methyl-pentanoics acid;

2-Aminomethyl-5-(22 6-dichloro-phenyl)-4-methyl-pentanoics acid; 2-Aminomethyl-5-(33,4-dichloro-phenyl)-4-methyl-pentanoics acid;

2-Aminomethyi-5-(3,5-dichloro-phenyl)-4-methyi-pentanoicz acid;

2-Aminomethyi-4-mmethyl-5-(2,3,4-trichloro-phenyl)-pentanoic acid;. 2-Aminomethyl-4- Tnethyl-5-(2,3,5-tfrichloro-phenyl)-pentanoic acid= 2-Aminomethyl-4- methyl-5-(2,3,6-trichloro-phenyl)-pentanoic acid3 2-Aminomethyl-4—methyl-5-(2,4,6-trichioro-phenyl)-pentanoic acid ;

2-Aminomethyl-4—methyl-5-(2,3,4,5-tetrachloro-phenyl)-pentanoic acid; 2-Aminomethyl-4—methyi-5-(2,3,4,6-ietrachloro-phenyl)-pentanoic acid; 2-Aminomethyl-4—methyl-5-(2,3,5,6-tetrachloro-phenyl)-pentanoic- acid; 2-Aminomethyl-4—methyl-5-pentachlorophenyl-pentanoic acid; 2-Aminomethyl-5—(2-chloro-phenyl)-4-methyl-hexanoic acid;

2-Aminomethyl-5—(3-chloro-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyi-5—(4-chloro-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5—(2,3-dichloro-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5 -(2,4-dichloro-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyi-5 -(2,5-dichloro-phenyl)-4-methyl-hexanoic acid;

2-Aminomethyl-5»=-(2,6-dichloro-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(3,4-dichioro-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5+(3,5-dichloro-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyi-&-methyl-5-(2,3,4-trichloro-phenyl)-hexanoic acid,

2-Aminomethyi-4-methyl-5-(2,3,5-trichloro-phenyl)-hexanoic acicl;

2-Aminomethyl-a-methyl-5-(2,3,6-trichloro-phenyt)-hexanoic acied; 2-Aminomethyl-3-methyl-5-(2,4,6-trichloro-phenyl)-hexanocic acied; 2-Aminomethyl-=}-methyl-5-(2,3,4,5-tetrachloro-phenyl)-hexanoisc acid; 2-Aminomethyl-=4-methyl-5-(2,3,4,6-tetrachloro-phenyl)-hexanoi: ¢ acid; 2-Aminomethyli-<4-methyl-5-(2,3,5,6-tetrachioro-phenyl)-hexanoiic acid;

2-Aminomethyi-«4-methyl-5-pentachiorophenyl-hexanoic acid; 2-Aminomethyl-5-(2-chloro-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(3-chloro-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl- 5-(4-chloro-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(2,3-dichioro-phenyl)-4-methyl-hexanoic acidl;

2-Aminomethyl—5-(2,4-dichloro-phenyl)-4-methyl-hexanoic acidll; 2-Aminomethyl—5-(2,5-dichloro-phenyi)-4-methyl-hexanoic acicH; 2-Aminomethyl—5-(2,6-dichloro-phenyl)-4-methyl-hexanoic acicd;

2-Amirmomethyl-5-(3,4-dichloro-phenyl)-4-rnethyl-hexanoic acid; Co 2-Amirmomethyl-5-(3,5-dichloro-phenyl)-4-rnethyl-hexanoic acid; 2-Amiromethyl-4-methyl-5-(2,3,4-trichloro -phenyl)-hexanoic acid; 2-Amiromethyl-4-methyl-5-(2,3,5-trichloros-phenyl)-hexanoic acid;

2-Amiromethyl-4-methyl-5-(2,3,6-trichlorae-phenyt)-hexanoic acid; 2-Amiromethyl-4-methyl-5-(2,4,6-trichlorc-phenyl)-hexanoic acid; 2-Amiromethyl-4-methyl-5-(2,3,4,5-tetrac hioro-phenyl)-hexanoic acid; 2-Amiromethyl~4-methyl-5-(2,3,4,6-tetrac= hloro-phenyl)-hexanoic acid; 2-Amiromethyl-4-methyl-5-(2,3,5,6-tetrac=hioro-phenyl)-hexanoic acid;

2-Amienomethyl-4-methyl-5-pentachloropienyl-hexanoic acid; 2-Amimnomethyl-5-(2-chioro-phenyl)-4-gth=yl-pentanoic acid; 2-Amimnomethyl-5-(3-chioro-phenyl)-4-eth-yl-pentanoic acid; 2-Amimnomethyl-5-(4-chioro-phenyt)-4-ethyl-pentanoic acid; 2-Amimnomethyl-5-(2,3-dichloro-phenyl)-4—ethyl-pentanoic acid;

2-Ami- nomethyl-5-(2 4-dichloro-phenyl)-4—ethyl-pentanoic acid; 2-Ami nomethy!-5-(2,5-dichloro-phenyf)-4- -ethyl-pentanoic acid; 2-Ami_nomethyl-5-(2,6-dichloro-phenyl)-4--ethyl-pentanoic acid; 2-Amia nomethyl-5-(3,4-dichloro-phenyl)-4--sthyl-pentanocic acid; 2-Amiinomethyl-5-(3,5-dichloro-phenyl)-4-ethyl-pentanoic acid;

2-Aminomethyl-4-ethyl-5-(2,3,4-trichioro—phenyl)-pentanoic acid; : 2-AmZinomethyl-4-ethyl-5-(2,3,5-trichloro ~phenyl)-pentanoic acid; : 2-Am inomethyl-4-ethyl-5-(2,3,6-trichloro~-phenyl)-pentanoic acid; 2-Amsinomethyl-4-ethyl-5-(2,4,6-trichloras-phenyl)-pentanoic acid; 2-Armminomethyl-4-ethyi-5-(2,3,4,5-tetraclhloro-phenyl)-pentanoic acid;

2-Amminomethyl-4-ethyl-5-(2,3,4,6-tetrac hloro-phenyl)-pentanoic acid; 2-Armninomethyl-4-ethyl-5-(2,3,5,6-tetrac=hloro-phenyl)-pentanoic acid; 2-Aminomethyl-4-ethyl-5-pentachloroptenyl-pentanoic acid; 2-Arminomethyl-6-(2-chioro-phenyl)-4-e&hyi-hexanoic acid; 2-Arminomethyl-6-(3-chloro-phenyl)-4-ethyl-hexanoic acid;

2-Aminomethyl-6-(4-chloro-phenyl)-4-e-thyl-hexanoic acid; 2-Arminomethyl-6-(2,3-dichloro-phenyl)—4-ethyl-hexanoic acid; 2-Arminomethyl-6-(2,4-dichloro-phenyl)—4-ethyl-hexanoic acid;

2-Aminomethyl-6-(2,5-dichloro-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(2,6-dichloro-phenyl)-4-ethyl-hexanoic acid; 2.Aminomethyl-6-(3,4-dichloro-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(3,5-dichloro-phenyl)-4-sthyl-hexanoic acid;

2-Aminomethyl-4-e-thyl-6-(2,3,4-trichloro-phenyl)-hexanoic acid; 2-Aminomethyl-4-e=thyl-6-(2,3,5-trichioro-phenyl)-hexanoic acid; 2-Aminomethyl-4-esthyl-8-(2,3,6-trichloro-phenyl)-hexanoic acid; 2-Aminomethyl-4-exthyl-6-(2,4,6-trichloro-phenyl)-hexanoic acid;

2-Aminomethyl-4-ethyl-6-(2,3,4,5-tetrachloro-phenyl)-hexanoic acid;

2-Aminomethyl-4-ethyl-6-(2,3,4 6-tetrachloro-phenyl)-hexanoic acid; 2-Aminomethyi-4-ethyl-6-(2,3,5,6-tetrachioro-phenyl)-hexanoic acid; 2-Aminomethyl-4-esthyl-6-pentachlorophenyl-hexanoic acid; 2-Aminomethyl-7-C2-chloro-phenyl)-4-methyl-heptanoic acid; 2-Aminomethyl-7-3-chloro-phenyl)-4-methyl-heptanoic acid;

2-Aminomethyl-7-g4-chloro-phenyl)-4-methyl-heptanoic acid; 2-Aminomethyl-7-«2,3-dichloro-phenyl)-4-methyl-heptanoic acid; : 2-Aminomethyl-7-42,4-dichlore-phenyl)-4-methyl-heptanoic acid; 2-Aminomethyl-7- {2,5-dichloro-phenyl)-4-methyl-heptanoic acid; 2-Aminomethyi-7- (2,6-dichioro-phenyt)-4-methyl-heptanoic acid;

2-Aminomethyl-7~(3,4-dichloro-phenyl)-4-methyl-heptanoic acid; 2-Aminomethyl-7—(3,5-dichloro-phenyl)-4-methyl-heptanoic acid; 2-Aminomethyl-4—methyl-7-(2,3,4-trichloro-phenyl)-heptanoic acid; 2-Aminomethyl-4—methyl-7-(2,3,5-trichloro-phenyl)-heptanoic acid; 2-Aminomethyl-4—methyl-7-(2,3,6-trichloro-phenyl)-heptanoic acid;

2-Aminomethyl-4—methyl-7-(2,4,6-trichloro-phenyl)-heptanoic acid; 2-Aminomethyl-4 -methyl-7-(2,3,4,5-tetrachloro-phenyl)-heptanoic acid; 2-Aminomethyl-4--methyl-7-(2,3,4,6-tetrachloro-phenyl)-heptanoic acid; 2-Aminomethyl-4--methyl-7-(2,3,5,6-tetrachloro-phenyl)-heptanoic acid; 2-Aminomethyi-4&.-methyl-7-pentachlorophenyl-heptanoic acid;

2-Aminomethyl-7"~(2-chloro-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(3-chioro-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7~(4-chloro-phenyl)-4-ethyl-heptanoic acid;

—_—21—

2.Aminomethyl-7-(2,3-dichioro-phenyl}--4-ethyl-heptanoic acid; 2-Aminomethyl-7-(2,4-dichloro-phenyl)s-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(2,5-dichloro-phenyl-4-ethyl-heptancic acid; 2-Aminomethyl-7-(2,6-dichloro-phenyl)-4-ethyl-heptanoic acid; © 2-Aminomethy}-7-(3,4-dichloro-phenyl_)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(3,5-dichloro-phenyl-)-4-ethyl-heptanoic acid; 2-Aminomethyl-4-ethyl-7-(2,3,4-trichicaro-phenyl)-heptanoic acid; 2-Aminomethyi-4-ethyl-7-(2,3,5-trichlcaro-phenyl)-heptanoic acid; 2-Aminomethyl-4-ethyl-7-(2,3,6-trichioro-phenyl)-heptanoic acid; 2-Aminomethyi-4-ethyl-7-(2,4,6-trichioro-phenyl)-heptanoic acid; o-Aminomethyi-4-ethyl-7-(2,3,4,5-tetraachloro-phenyl)-heptanoic acid; 2-Aminomethyl-4-ethyl-7-(2,3,4,6-tetr achloro-phenyl)-heptanoic acid; 2-Aminomethyl-4-ethyl-7-(2,3,5,6-tetrachloro-phenyl)-heptanoic acid; 2-Aminomethyl-4-ethyl-7-pentachlorcaphenyl-heptanoic acid; 2-Aminomethyi~4-(2-methoxy-phenylD)-pentanoic acid; 2-Aminomethyl-4-(3-methoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4-(4-methoxy-phenyl )-pentanoic acid; : 2-Aminomethyl-4-(2,3-dimethoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,4-dimethoxy-pheenyl)-pentanoic acid; 2-Aminomethyl-4-(2,5-dimethoxy-pheenyl)-pentanoic acid; 2-Aminomethyi-4-(2,6-dimethoxy-pheenyl)-pentanoic acid; 2-Aminomethyi-4-(3,4-dimethoxy-ph enyl)-pentanoic acid; 2-Aminomethyk4-(3,5-dimethoxy-phsenyl)-pentanoic acid; 2-Aminomethyl-4-(2,3,4-trimethoxy-gphenyl)-pentanoic acid; 2-Aminomethyl-4-(2,3,5-trimethoxy-gphenyl)-pentanoic acid; 2-Aminomethyi-4-(2,3,6-trimethoxy--phenyl)-pentanoic acid; : 2-Aminomethyl-4-(2,4,6-trimethoxy--phenyl)-pentanoic acid; : 2-Aminomethyl-4-(2-methoxy-phenwyl)-hexanoic acid; 2-Aminomethyi-4-(3-methoxy-phenwyi)-hexanoic acid; 2-Aminomethyi-4-(4-methoxy-phenvyl)-hexanoic acid; 2-Aminomethyl-4-(2,3-dimethoxy-plhenyl)-hexanoic acid; 2-Aminomethyl-4-(2,4-dimethoxy-phhenyl)-hexanoic acid;

J, 7,

2. Aminomethyl-4-(2,5-dimethoxy-ph-enyl)-hexanoic acid; 2-Aminomethyl-4-(2,6-dimethoxy-ph=enyl)-hexanoic acid; 2-Aminomethyl-4-(3,4-dimethoxy-phaenyl)-hexanoic acid;

2. Aminomethyl-4-(3,5-dimethoxy-phaenyl)-hexanoic acid;

2-Aminomethyl-4-(2,3,4-trimethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4-(2,3,5-trimethoxy- phenyl)-hexanoic acid; 2-Aminomethyl-4-(2,3,6-trimethoxy- phenyl)-hexanoic acid; 2-Aminomethyl-4-(2,4,6-trimethoxy—phenyl)-hexanoic acid; 2-Aminomethyl-5-(2-methoxy-phenwi)-4-methyl-pentanoic acid;

2.Aminomethyl-5-(3-methoxy-phenwyi)-4-methyl-pentanaic acid; 2-Aminomethyl-5-(4-methoxy-phen=yi)-4-methyl-pentanoic acid; 2-Aminomethyl-5-(2,3-dimethoxy-phenyl)-4-methyi-pentanoic acid; 2-Aminomethyl-5-(2,4-dimethoxy-p Bhenyl)-4-methyl-pentanoic acid; 2-Aminomethyl-5-(2,5-dimethoxy-p henyl)-4-methyl-pentanoic acid;

2-Aminomethyl-5-(2,6-dimethoxy-p henyl)-4-methyi-pentanoic acid; 2-Aminomethyl-5+(3,4-dimethoxy-pehenyl)-4-methyl-pentanoic acid; 2-Aminomethyl-5-(3,5-dimethoxy-pshenyi}-4-methyl-pentanoic acid; 2-Aminomethyl-4-methyl-5-(2,3,4-t_rimethoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4-methyl-5-(2,3,5-trimethoxy-phenyl)-pentanoic acid;

2-Aminomethyl-4-methyl-6-(2,3,6-trimethoxy-phenyl)-pentanoic acicd;

© 2.Aminomethyl-4-methyl-5-(2,4,6-&rimethoxy-phenyl)-pentancic acicH; 2.Aminomethyl-5-(2-methoxy-pheryl)-4-methyl-hexanoic acid; 2.Aminomethyl-5-(3-methoxy-phemyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(4-methoxy-phemnyl)-4-methyl-hexanoic acid;

2-Aminomethyl-5-(2,3-dimethoxy-gohenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(2,4-dimethoxy--phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(2,5-dimethoxy- phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(2,6-dimethoxy—phenyl)-4-methyi-hexanoic acid; 2-Aminomethyl-5-(3,4-dimethoxy—phenyl)-4-methyl-hexanoic acid;

2-Aminomethyl-5-(3,5-dimethoxy—phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-4-methyl-5-(2,3,4—trimethoxy-phenyl)-hexanoic aci=d; 2-Aminomethyl-4-methyl-5-(2,3,5—~trimethoxy-phenyl)-hexanoic aci d,

2-Aminomethyl-4-methyl-5-(2,3,6-trimethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4-methyi-5-(2,4,6-trimethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-6-(2-mesthoxy-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-6-(3-mesthoxy-phenyl)-4-methyl-hexanoic acid;

2-Aminomethyl-6-(4-methoxy-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-6-(2,3-edimethoxy-phenyl)-4-methyl-hexanoic acid;

: 2-Aminomethyl-6-(2 4-«dimethoxy-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-6-(2,5-dimethoxy-phenyl)-4-methyi-hexanoic acid; 2-Aminomethyl-6-(2,6-«dimethoxy-phenyl)-4-methyl-hexanoic acid;

2-Aminomethyl-6-(3,4-adimethoxy-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-6-(3,5-adimethoxy-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-4-methuyl-6-(2,3,4-trimethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4-methayl-6-(2,3,5-trimethoxy-phenyi)-hexanoic acid; 2-Aminomethyl-4-mettmy-6-(2,3,6-trimethoxy-phenyl)-hexanoic acid;

2-Aminomethyl-4-metteyl-6-(2,4,6-trimethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-5-(2-m ethoxy-phenyl)-4-ethyl-pentanoic acid; 2-Aminomethyl-5-(3-m ethoxy-phenyl)-4-ethyl-pentanoic acid; 2-Aminomethyl-5-(4-m ethoxy-phenyl)-4-ethyl-pentanoic acid; : 2-Aminomethyl-5-(2,3- dimethoxy-phenyl)-4-ethyl-pentanoic acid;

2-Aminomethyl-5-(2,4—dimethoxy-pheny!)-4-ethyl-pentanoic acid; 2-Aminomethyl-5-(2,5—dimethoxy-phenyl)-4-ethyl-pentanoic acid; 2-Aminomethyl-5-(2,6—dimethoxy-phenyl)-4-ethyl-pentanoic acid; 2-Aminomethyl-5-(3,4—dimethoxy-phenyl)-4-ethyl-pentanoic acid; 2-Aminomethyl-5-(3,5—dimethoxy-phenyl)-4-ethyl-pentanoic acid;

2-Aminomethyl-4-ethy I-5-(2,3,4-trimethoxy-phenyl)-pentanoic acid;

. 2-Aminomethyl-4-ethy-1-5-(2,3,5-trimethoxy-phenyl)-pentanoic acid;

2-Aminomethyl-4-ethy-I-5-(2,3,6-trimethoxy-phenyl)-pentanoic acid;

2-Aminomethyl-4-ethy-1-5-(2,4,6-trimathoxy-phenyl)-pentanoic acid; 2-Aminomethyi-4-ethy~1-5-(2,3,4,5-tetramethoxy-phenyl)-pentanoic aacid;

2-Aminomethyl-4-ethy»l-5-(2,3,4,6-tetramethoxy-phenyl)-pentanoic aacid; 2-Aminomethyl-4-ethyl-5-(2,3,5,6-tetramethoxy-phenyl)-pentanoic acid;

2-Aminomethyl-4-ethy»1-5-pentamethoxyphenyl-pentanoic acid; —D4—

2-Amineomethy}-6-(2-methoxy-phenyl)-4-ethyl—hexanoic acid; 2-Amin=omethyl-6-(3-methoxy-phenyi)-4-ethyl—hexanoic acid; 2-Amin omethyl-6-(4-methoxy-phenyl)-4-ethyl -hexanoic acid; 2.Amineomethyl-6-(2,3-dimethoxy-phenyl)-4-eathyl-hexanoic acid;

2-Amirmomethyl-6-(2,4-dimethoxy-phenyl)-4-ethyi-hexanoic acid; 2-Amirmomethyl-6-(2,5-dimethoxy-phenyl)-4-ethyl-hexanoic acid; 2-Amirmomethyl-6-(2,6-dimethoxy-phenyl)-4-ethyl-hexanoic acid; 2.Amirmomethyl-6-(3,4-dimethoxy-phenyl)-4-ethyl-hexanoic acid; 2-Amirmomethyi-6-(3,5-dimethoxy-pheny!)-4-ethyl-hexanoic acid,

2-Amiraomethyl-4-ethyl-6-(2,3,4-trimethoxy-pehenyl)-hexanoic acid;

. 2-Amiromethyl-4-ethyl-6-(2,3,5-trimethoxy-phenyl)-hexanoic acid; 2-Amiromethyl-4-ethyl-6-(2,3,6-trimethoxy-phenyl)-hexanoic acid; 2-Amiromethyl-4-ethyl-6-(2,4,6-trimethoxy-phenyl)-hexanocic acid; 2-Amiromethyl-7-(2-methoxy-phenyl)-4-metthyl-heptanoic acid;

2-Amiromethyl-7-(3-methoxy-phenyl)-4-mefthyl-heptanoic acid; 2-Amiromethyl-7-(4-methoxy-phenyl)-4-metthyl-heptanoic acid; 2-Amirwomethyl-7-(2,3-dimethoxy-phenyl)-4—methyl-heptanoic acid; 2-Amiromethyl-7-(2,4-dimethoxy-phenyl)-4—methyl-heptanoic acid; 2-Amimomethyl-7-(2,5-dimethoxy-phenyl)-4—methyl-heptanoic acid; 2-Amimomethyl-7-(2,6-dimethaxy-phenyl)-4—methyl-heptanoic acid; 2-Amimnomethyl-7-(3,4-dimethoxy-phenyl)-4--methyi-heptanoic acid; 2-Ami nomethyl-7-(3,5-dimethoxy-phenyl)-4--methyi-heptanoic acid; 2-Ami nomethyl-4-methyl-7-(2,3,4-trimetho><y-phenyl)-heptanoic acid; 2-AmE nomethyl-4-methyl-7-(2,3,5-trimethoxy-phenyl)-heptanoic acid; 2-Amiinomethyl-4-methyl-7-(2,3,6-tfrimethoxxy-phenyl)-heptanoic acid; 2-Amanomethyl-4-methyl-7-(2,4,6-trimethoaxy-phenyl)-heptanoic acid; 2-Amanomethyl-7-(2-methoxy-phenyl)-4-etthyl-heptanoic acid; 2-Am inomethyl-7-(3-methoxy-phenyl)-4-et hyl-heptanoic acid; 2-Am inomethyl-7-(4-methoxy-phenyl)-4-et hyl-heptanoic acid; 2-Am inomsthyl-7-(2,3-dimethoxy-phenyl)--4-ethyi-heptanoic acid; 2-Amsinomethyl-7-(2,4-dimsthoxy-phenyl)--4-ethyl-heptanoic acid; } 2-Amminomethyl-7-(2,5-dimethoxy-phenyl)-4-ethyl-heptanoic acid;

2-Aminomethyl-7-(2,6-dimethaexy-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(3,4-dimethoxy-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(3,5-dimethoxy-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-4-ethyl-7-(2,3,4-trimethoxy-phenyl)-heptanoic acid;

2-Aminomethyl-4-ethyl-7-(2,3, 5-trimethoxy-phenyl)-heptanoic acid; 2-Aminomethyl-4-ethyl-7-(2,3.. 6-trimethoxy-phenyl)-heptanoic acid; 2-Aminomethyl-4-ethyl-7-(2,4 . 6-trimethoxy-phenyl)-heptanoic acid; 2-Aminomethyl-4-(2-trifluoromethyl-phenyl)-pentanoic acid; 2-Aminomethyl-4-(3-trifluoromethyl-phenyl)-pentanoic acid;

10 . 2-Aminomethyl-4-(4-trifluoronethyl-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,3-di-triflu oromethyl-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,4-di-triflus oromethyl-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,5-di-triflumoromethyi-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,6-di-trifumoromethyl-phenyl)-pentanoic acid;

2-Aminomethyl-4-(3,4-di-triflacromethyl-phenyl)-pentanoic acid; 2-Aminomethyl4-(3,5-di-trifiLsoromethyl-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,3,4-tri-trifluoromethyl-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,3,5-tri-triéfluoromethyl-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,3,6-tri-tr ifluoromethyl-phenyl)-pentanoic acid;

2-Aminomethyl-4-(2,4,6-tri-trifluoromethyl-phenyl)-pentanoic acid;

) 2-Aminomethyl-4-(2-trifluoro methyl-phenyt)-hexanoic acid; 2-Aminomethyl-4-(3-trifluoro methyl-phenyl)-hexanoic acid; 2-Aminomethyl-4-(4-trifluorosmethyl-phenyl)-hexancic acid; 2-Aminomethyl-4-(2,3-di-trifRuoromethyl-phenyl)-hexanoic acid; :

2-Aminomethyi-4-(2,4-di-trif Buoromethyl-phenyl)-hexanoic acid; 2-Aminomethyl-4-(2,5-di-trif Juoromethyl-phenyl)-hexanoic acid; 2-Aminomethyl-4-(2,6-di-trif luoromethyl-phenyl)-hexanoic acid; 2-Aminomethyl-4-(3,4-di-trifFluoromethyl-phenyl)-hexanoic acid; 2-Aminomethyl-4-(3,5-di-irifluoromethyl-phenyl)-hexanoic acid;

2-Aminomethyl-4-(2,3,4-tri-Rrifluoromethyl-phenyl)-hexanoic acid; 2-Aminomethyl-4-(2,3,5-tri--trifluoromethyl-phenyl)-hexanoic acid; 2-Aminomethyl-4-(2,3,6-tri--trifluoromethyi-phenyl)-hexanoic acid;

2-A minomethyl-4-(2,4,6-tri-trifluoromethyl--phenyl)-hexanoic acid; 2-A_minomethyi-5-(2-trifluoromethyi-phenyl)-4-methyi-pentanoic acid; 2-A_minomethyl-5-(3-trifluoromethyi-pheny 1)-4-methyl-pentanoic acid; 2-A.minomethyl-5-(4-trifluoromethyl-pheny~1)-4-methyl-pentanoic acid; 2-Aaminomethyl-5-(2,3-di-trifluoromethyl-plihenyl)-4-methyl-pentanoic acid; 2-paminomethyl-5-(2,4-di-triflucromethyi-p henyl)-4-methyl-pentanoic acid; 2-Mminomethyl-5-(2,5-di-trifluoromethyl-pe henyl)-4-methyt-pentanoic aci d, 2-Aminomethyl-5-(2,6-di-trifluoromethyl-pohenyl)-4-methyl-pentanoic acid, 2-Aminomethyi-5-(3,4-di-trifluoromethyl-pohenyl)-4-methyl-pentanoic ’ acd, 2-mminomethyl-5-(3,5-di-trifluoromethyl-fohenyl)-4-methyi-pentanoic : ac id; 2-sAminomethyl-4-methyl-5-(2,3,4-tri-trifliaoromethyl-phenyl)-pentanoic ~~ acid; 2-.Aminomethyl-4-methyl-5-(2,3,5-tri-trifiioromethyl-phenyl)-pentanoic acsid; 2- Aminomethyl-4-methyl-5-(2,3,6-tri-triflmuoromethyl-phenyl)-pentanoic acid, 2—Aminomethyl-4-methyl-5-(2,4,6-tri-trifl uoromethyl-phenyl)-pentanoic acid; 2—Aminomethyl-5-(2-trifluoromethyl-phe= nyl)-4-methyl-hexanoic acid; 2—Aminomethyl-5-(3-trifluoromethyl-phe=nyl)-4-methy--hexanoic acid; 2-—Aminomethyl-5-(4-trifluoromethyl-phe=nyl)-4-methyi-hexanoic acid; 2 -Aminomethyl-5-(2,3-di-triflucromethyfi-phenyi)-4-methyl-hexanoic a_cid; 2=-Aminomethyl-5-(2,4-di-trifluoromethy~{-phenyl)-4-methyl-hexanoic aacid;

2-Ami yomethyl-5-(2,5-di-trifluoromethyl-phenyl)-4-methyi-h-exanoic acid; 2.Aminomethyl-5-(2,6-di-tritluoromethyl-phenyl)-4-methyl-rmexanoic acid;

2-Am inomethyl-5-(3,4-di-trifluoromethyl-phenyl)-4-methyl-Imiexanoic acid; 2-Am_inomethyl-5-(3,5-di-trifluoromethyl-phenyi)-4-methyl-Ehexanoic acid; 2-Arrminomethyl-4-methyl-5-(2,3,4-tri-trifluoromethyl-pheny~l)-hexanoic acid; 2.Aminomethyl-4-methyl-5-(2,3,5-tri-trifluoromethyl-phenywi)-hexanoic acid; 2-Aminomethyl-4-methyl-5-(2,3,6-tri-triflucromethyl-phenwyl)-hexanoic acidz

2. Arminomethyl-4-methyl-5-(2,4,6-tri-triflucromethyl-phenyl)-hexanoic acids 2. Arninomethyl-6-(2-triflucromethyl-phenyl)-4-methyl-hex=anoic acid; 2-Arninomethyl-6-(3-trifluoromethyl-phenyl)-4-methyl-hexxanoic acid; o-Arninomethyl-6-{4-trifluoromethyl-phenyl)-4-methyl-he=xanoic acid; :

2-Awminomethyl-6-(2,3-di-trifluoromethyl-phenyi)-4-methyy/I-hexanoic acicy; So :

2-A-minomethyl-6-(2,4-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid; 2-A_minomethyl-6-(2,5-di-trifluoromethyi-phenyl)-4-methayl-hexanoic acicd;

2. Aaminomethyi-6-(2,6-di-trifluoromethyl-phenyl)-4-metiyl-hexanoic acird; 2. minomethyl-6-(3,4-di-triflucromethyl-phenyl)-4-metlinyl-hexanoic acid,

2-mminomethyl-6-(3,5-di-trifluoromethyi-phenyl)-4-met hyl-hexanoic ac:id;

2-Armninomethyl-4-methyl-6-(2,3,4-tri-trifluoromeethyl-phenyl)-hexanoic

: acidz 2-Arninomethyl-4-methyl-6-(2,3,5-tri-trifluorom ethyl-phenyl)-hexanoic acid ;

2-Arninomethyl-4-methyl-6-(2,3,6-tri-trifluorommethyl-phenyl)-hexanoic acid ; 2-Arninomethyl-4-methyi-6-(2,4,6-tri-triflucronethyl-phenyl)-hexanoic acid; 2.Arninomethyk5-(2-trifluoromethyl-phenyl)-4—ethyl-pentanoic acid;

2-Arminomethyl-5-(3-trifluoromethyl-phenyl)-4—ethyl-pentanoic acid; 2.Amminomethyi-5-(4-trifluoromethyl-phenyl)-4—ethyl-pentanoic acid; 2-Amminomethyl-5-(2,3-di-trifluoromethyl-phen-yl)-4-ethyl-pentanoic acid;

: 2.Amminomethyl-5-(2,4-di-trifluoromethyl-phensyl)-4-ethyl-pentanoic acid; 2-Asminomethyk5-(2,5-di-trifluoromethyl-phermyl)~4-ethyi-pentanoic acid;

2-Amminomethyl-5-(2,6-di-trifluoromethyl-phermyl)-4-ethyl-pentanoic acid; : 2.A-minomethyl-5-(3,4-di-trifluoromethyl-pheryl)-4-ethyl-pentanoic acid;

. 2-A minomethyl-5-(3,5-di-trifluoromethyl-pheryl)-4-ethyl-pentanocic acid; 2-A_minomethyl-4-ethyl-5-(2,3,4-tri-trifluoromesthyl-phenyl)-pentancic acid;

2-A.minomethyl-4-ethyl-5-(2,3,5-tri-trifluoromaesthyl-phenyt)-pentanoic acic; 2-Aaminomethyl-4-ethyl-5-(2,3,6-tri-trifluorom ethyl-phenyl}-pentanoic acid;

2-paminomethyl-4-ethyl-5-(2,4,6-tri-trifluorormethyl-phenyl)-pentanoic aci d,

2-A minomethyl-4-ethyl-5-(2,3,4,5-tetra-triflusoromethyl-phenyt)- pemntanoic acid;

2-Aminomethyl-4-ethyl-5-(2,3,4,6-tetra-triflu oromethyl-phenyl)- pemntanoic acid; .

2-mminomethyl-4-ethyl-5-(2,3,5,6-tetra-trifltmoromethyl-phenyl)- pe -ntanoic acid; 2-a\minomethyl-4-ethyl-5-penta-trifluorometihylphenyl-pentanoic acid;

2.Aminomethyl-6-(2-trifluoromethyl-phenyl)-4-ethyl-hexanoic aci-d; 2.Aminomethyl-6-(3-trifluoromethyl-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(&-trifluioromethyl-phenyl)-4-ethyl-hexanoic acld;, 2-Aminomethyl-6-(2,3-di-trifluoromethyl-phenyl)-4-ethyl-hexanoiic acid;

2-Aminomethyl-6-(2 4-di-trifluoromethyl-phenyl)-4-ethyl-hexanoiic acid; 2-Aminomethyl-6-(2,5-di-trifluoromethyl-phenyl)-4-ethyl-hexano ic acid; 2-Aminomethyl-6-(2,6-di-trifluoromethyl-phenyl)-4-ethyl-hexano -ic acid;

2-Aminomethyl-6-(3,4-di-trifluoromethyl-phenyl)-4-ethyl-hexano-ic acid; 2-Aminomethyl-6-(3,5-di-trifluoromethyl-phenyl)-4-ethyl-hexanomwic acid; 2-Aminomethyl-4-ethyl-6-(2,3,4-tri-trifluoromethyl-phenyl)-hexamnoic acid; : 2-Aminomethyl-4-ethyl-6-(2,3,5-tri-trifluoromethyl-phenyl)-hexamnoic acid; 2-Aminomethyl-4-ethyl-6-(2,3,6-tri-trifluoromethyl-phenyl)-hexa_noic acid; : o_-Aminomethyl-4-ethyl-6-(2,4,6-tri-trifluoromethyl-phenyl)-hexaanoic acid; 2-Aminomethyi-7-(2-trifluoromethyl-phenyl)-4-methyl-heptanoiec acid; 2-Aminomethyl-7-(3-trifluoromethyl-phenyl)-4-methyl-heptanoiec acid;

2-Aminomethyl-7-(<4-trifluoromethyl-phenyl)-4-methyi-heptanoisc acid; 2-Aminomethyl-7-(2,3-di-trifluoromethyl-phenyl)-4-methyl-heptzanoic acid;

2-Aminomethyl-7-( 2,4-di-trifluoromethyl-phenyl)-4-methyl-hep®anoic acid; :

2-Aminomethyl-7-(2,5-di-trifluoromethyi-phenyl)-4-methyl-hep-tanoic acid; : 2-Aminomethyl-7-(2,6-di-trifluoromethyl-phenyl)-4-methyl-hepmtanoic acid; 2-Aminomethyl-7-(3,4-di-trifluoromethyl-phenyl)-4-methyl-hefotanoic acid; 2-Aminomethyl-7-¢3,5-di-trifluoromethyl-phenyl)-4-methyl-heoitanoic acid;

2-Aminomethyi-4-methyl-7-(2,3,4-tri-trifluoromethyl-phenyl)-heptanoic acid; 2-Aminomethyi-4-methyl-7-(2,3,5-tri-trifluoreomethyl-phenyl)-heptanoic acid;

2-Aminomethyl~4-methyl-7-(2,3,6-tri-trifluor-omethyl-phenyl)-heptanoic acid; 2-Aminomethyl-4-methyi-7-(2,4,6-tri-trifluor-omethyl-phenyl)-heptanoic acid; 2-Aminomethyl-7-(2-trifluoromethyi-phenyl)-4-ethyl-heptanoic acid;

2-Aminomethyl-7-(3-trifluoromethyt-phenyi)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(4-trifluoromethyl-phenyl)-4-ethyl-heptanoic acid;

- 2-Aminomethyl-7-(2,3-di-triflucromethyl-plaenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(2,4-di-trifluoromethyl-phaenyl)4-sthyl-heptanoic acid; 2-Aminomethyl-7-(2,5-di-trifluoromethyl-ptmenyl)-4-ethyl-heptanoic acid;

2-Aminomethyl-7-(2,6-di-trifluoromethyl-ptenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(3,4-di-trifluoromethyl-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(3,5-di-trifluoromethyl-penyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-4-ethyl-7-(2,3,4-tri-trifluorcamethyl-phenyl)-heptanoic acid;

2-Aminomethyl-4-ethyl-7-(2,3,5-tri-trifluorcomethyl-phenyt)-heptanoic acid; : 2-Aminomethyl-4-ethyl-7-(2,3,6-tri-trifluorcomethyl-phenyl)-heptanoic acid, 2-Aminomethyl-4-ethyl-7-(2,4,6-tri-trifluorcomethyl-phenyl)-heptanoic acid; 2-Aminomethyl-4-(2-trifluoromethoxy-phesnyl)-pentanoic acid; 2-Aminomethyl-4-(3-triftuocromethoxy-phe=nyl)-pentanoic acid; 2-Aminomethyl-4-(4-trifluoromethoxy-pheanyl)-pentanoic acid; 2-Aminomethyl-4-(2,3-di-trifluoromethoxyw-phenyl)-pentanoic acid;

2-Aminomethyl-4-(2,4-di-trifluoromethoxyy-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,5-di-trifluoromethoxyy/-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,6-di-trifluocromethoxyy-phenyi)-pentanoic acid;

—_—3

2-Aminome-thyl-4-(3,4-di-trifluoromethoxy-phenyl)-penianoic acid; 2-Aminomethyl-4-(3,5-di-trifluoromethoxy-phenyl)-pen=tanoic acid; 2-Aminome-thyl-4-(2,3,4-tri-trifluoromethoxy-phenyl)-peantanoic acid; 2-Aminome thyl-4-(2,3,5-tri-trifluoromethoxy-phenyl)-pesntanoic acid;

2-Aminome thyl-4-(2,83,6-tri-trifluoromethoxy-phenyl)-peantanoic acid; 2-Aminome thyl-4-(2,4,6-tri-trifuoromethoxy-phenyl)-peantanoic acid; 2-Aminome thyl-4-(2-trifluoromethoxy-phenyl)-hexanoi-c acid; 2-Aminome thyl-4-(3-trifluoromethoxy-phenyl)-hexanoi c acid;

- 2-Aminome thyi-4-(4-trifluoromethoxy-phenyl)-hexanoi c acid;

2-Aminome thyl-4-(2,3-di-trifluoromethoxy-phenyl)-hexcanoic acid; 2-Aminome thyl-4-(2,4-di-trifluoromethoxy-phenyl)-hexzanoic acid; 2-Aminome-thyl-4-(2,5-di-trifluoromethoxy-phenyl)-hexxanoic acid; 2-Aminome-thyi-4-(2,6-di-trifluoromethoxy-phenyl)-hexxanoic acid;: 2-Aminome thyl-4-(3,4-di-trifluoromethoxy-phenyl)-hexxanoic acid;

2-Aminome>thyl-4-(3,5-di-triflucromethoxy-phenyl)-he>xanoic acid; 2-Aminomerthyl-4-(2,3,4-tri-trifluoromethoxy-phenyl)-h: exanoic acid; 2-Aminomesthyl-4-(2,3,5-tri-trifluoromethoxy-phenyi)-hmexanoic acid; 2-Aminome=thyl-4-(2,3,6-tri-trifluoromethoxy-phenyl)-hmexanoic acid; 2-Aminome=thyl-4-(2,4,6-tri-trifluoromethoxy-phenyl)-tmexanoic acid; :

2-Aminome=thyl-5-(2-trifluoromethoxy-phenyl)-4-methwyl-pentanocic acid; 2-Aminome=thyl-5-(3-trifluoromethoxy-phenyl)-4-meth=yl-pentanoic acid; 2-Aminome=thyl-5-(4-trifluoromethoxy-phenyl)-4-methzyl-pentanoic acid; 2-Aminomeathyi-5-(2,3-di-trifluoromethoxy-phenyl)-4-rmethyi-pentanoic acid; :

2-Aminomezthyl-5-(2,4-di-trifluoromethoxy-phenyl)-4-rmethyl-pentanoic acid; 2-Aminomethyl-5-(2,5-di-trifluoromethoxy-phenyl)-4-emethyi-pentanoic acid; 2-Aminomethyi-5-(2,6-di-trifluoromethoxy-phenyl)-4-mmethyi-pentanoic acid; 2-Aminomethyl-5-(3,4-di-trifluoromethoxy-phenyl)-4-smethyl-pentanoic acid;

V0 2005/030700 EPCT/TB2004/002985 2-Aminomethyl-5-(3,5-di-trifluoromethoxy-phenyl)-4-methyl-pentanoic acid; 2-Aminomethyl-4-methyl-5-(2,3 4-tri-trifluoromethoxy—phenyl)-pentanoic acid;

2-Aminomethyl-4-methyl-5-(2,3,5-tri-trifluoromethoxy~-phenyl)-pentanoic acid; 2-Aminomethyl-4-methyl-5-(2,3,6-tri-trifluoromethoxys-phenyl)-pentanoic acid; 2-Aminomethyl-4-methyl-5-(2,4,6-tri-trifluoromethoxy/-phenyl)-pentanoic acid; 2-Aminomethyl-5-(2-trifluoromethoxy-phenyl)-4-ethy=l-pentanoic acid; 2-Aminomethyl-5-(3-trifiuoromethoxy-phenyl)-4-ethyri-pentanoic acid; 2-Aminomethyl-5-(4-trifluoromethoxy-phenyl)-4-ethyl-pentanoic acid;

2-Aminomethyl-5-(2,3-di-trifluoromethoxy-phenylf)-4—ethyl-pentanoic acid; 2-Aminomethyl-5-(2,4-di-trifluoromethoxy-phenyl)-4--ethyl-pentanoic acid; 2-Aminomethyl-5-(2,5-di-trifluoromethoxy-phenyl)-&-ethyi-pentanoic acid;

2-Aminomethyl-5-(2,6-di-trifluoromethoxy-phenyl)-=1-ethyl-pentanoic acid; 2-Aminomethyl-5-(3,4-di-trifluoromethoxy-phenyl)--4-ethyl-pentanoic acid; 2-Aminomethyl-5-(3,5-di-trifluoromethoxy-phenyl)- 4-ethyl-pentanoic acid; : 2-Aminomethyl-4-ethyl-5-(2,3,4-tri-trifluoromethoxsy-phenyi)-pentanoic acid; 2-Aminomethyl-4-ethyl-5-(2,3,5-tri-trifluoromethoxcy-phenyl)-pentanoic acid;

308 2-Aminomethyl-4-ethyl-5-(2,3,6-tri-trifluoromethoxxy-phenyl)-pentanoic acid;

2-Aminomethyl-4-ethyl-5-(2,4,6-tri-trifluoromethoxy-phenyl)-pe mtanoic acid;

- 2-Aminomethyl—4-ethyl-5-(2,3,4,5-tetra-trifluoromethoxy-pheny-1)- pentanoic acid;

2-Aminomethyi—4-ethyl-5-(2,3,4,6-tetra-trifluoromethoxy-phenyl)- pentanoic acid; 2-Aminomethyl—4-ethyl-5-(2,3,5,6-tetra-trifluoromethoxy-phenyel)- pentanoic acid; 2-Aminomethyl—4-ethyl-5-penta-trifluoromethoxyphenyl-pentaroic acid; 2-Aminomethyl-5-(2-trifluoromethoxy-phenyl)-4-methyl-hexanic acid; 2-Aminomethyl—5-(3-trifluoromethoxy-phenyi)-4-methyl-hexan®ic acid; 2-Aminomethyl—5-(4-trifluoromethoxy-phenyl)-4-methyl-hexan«oic acid; 2-Aminomethyl-5-(2,3-di-trifluoromethoxy-phenyi)~4-methyl-hexanoic acid; :

2-Aminomethyl-5-(2,4-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(2,5-di-trifluoromethoxy-phenyl)-4-methyi-hexanoic acid; 2-Aminomethyl-5-(2,6-di-trifluoromethoxy-phenyl)-4-methyl-hesxanoic acid;

: 2-Aminomethyl -5-(3,4-di-trifluoromethoxy-phenyl)-4-methyl-h-exanoic - acid; 2-Aminomethyf-5-(3,5-di-triftuoromethoxy-phenyl)-4-methyl-twexanoic acid;

2-Aminomethyl-4-methyl-5-(2,3,4-tri-trifluoromethoxy-phenyl-hexanoic acid; 2-Aminomethy ¥-4-methyl-5-(2,3,5-tri-trifluoromethoxy-phenyl)-hexanoic acid; 2-Aminomethy I-4-methyl-5-(2,3,6-tri-trifluoromethoxy-phenyl)-hexanoic acid; 2-Aminomethy I-4-methyl-5-(2,4,6-tri-trifluoromethoxy-phenyl )-hexanoic acid;

2-Aminomethyl-6-(2—triflucromethoxy-phenyl)-4-methyl-hexanoiec acid; 2-Aminomethyl-6-(3—trifluoromethoxy-phenyl)-4-methyl-hexanoisc acid; 2-Aminomethyl-6-(4—trifluoromethoxy-phenyl)-4-methyi-hexanoiec acid; 2-Aminomethyl-6-(2, 3-di-trifluoromethoxy-phenyl)-4-methyl-hex anoic acid; 2-Aminomethyl-6-(2, 4-di-trifluoromethoxy-phenyl)-4-methyl-hex anoic acid; 2-Aminomethyl-6-(2, 5-di-trifluoromethoxy-phenyl)-4-methyi-hex anoic acid; 2-Aminomethyl-6-(2, ©-di-trifluoromethoxy-phenyl)-4-methyl-hex anoic acid; . 2-Aminomethyl-6-(3,<4-di-trifluorométhoxy-phenyl)-4-methyl-hex_ anoic acid; 2-Aminomethyl-6-(3, 5-di-trifluoromethoxy-phenyl)-4-methyi-hexcanoic acid; 2-Aminomethyl-4-meathyl-6-(2,3,4-tri-trifluoromethoxy-phenyl)-heexanoic acid; 2-Aminomethyl-4-mesthyl-6-(2,3,5-tri-trifluoromethoxy-phenyl)-heexanoic acid; ‘ 2-Aminomethyl-4-mesthyi-6-(2,3,6-tri-trifluoromethoxy-phenyl)-heexanoic acid; 2-Aminomethyl-4-mesthyl-6-(2,4,6-tri-trifluoromethoxy-phenyl)-heexanoic acid; : 2-Aminomethyl-6-(2-trifluoromethoxy-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(3-2rifluoromethoxy-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(4-trifluoromethoxy-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(2, 3-di-trifluoromethoxy-phenyl)-4-ethyl-hexamoic acid; 2-Aminomethyl-6-(2,«-di-trifluoromethoxy-phenyl)-4-ethyl-hexaanoic acid; 2-Aminomethyi-6-(2,5-di-triflucromethoxy-phenyl)-4-ethyl-hexaanoic acid;

=22-Aminomethyl-6-(2,6-di-trifluoromethoxy-phenyl)-4-ethhyl-hexanoic acid; =2-Aminomethyl-6-(3,4-di-trifluoromethoxy-phenyl)-4-ethhyl-hexanoic acid;

=2-Aminomethyl-6-(3,5-di-trifluoromethoxy-phenyl)-4-ethhyl-hexanoic acid; 2-Aminomethyl-4-ethyl-6-(2,3,4-tri-trifluoromethoxy-phesnyl)-hexanoic acid; : 2-Aminomethyl-4-ethyl-6-(2,3,5-tri-trifluoromethoxy-pheenyl)-hexanoic acid; 2-Aminomethyl-4-ethyl-6-(2,3,6-tri-triflucromethoxy-pheenyl)-hexanoic acid; 22-Aminomethyl-4-ethyl-6-(2,4,6-tri-trifluoromethoxy-phesnyl)-hexanoic acid;

2-Aminomethyl-7-(2-trifluoromethoxy-phenyl)-4-methyL -heptanoic acid; 2-Aminomethyl-7-(3-trifluoromethoxy-phenyl)-4-methyl_-heptanoic acid; 2-Aminomethyl-7-(4-trifluoromethoxy-phenyl)-4-methyk: -heptanoic acid;

2-Aminomethyl-7-(2,3-di-trifluoromethoxy-phenyl)-4-meathyl-heptanoic acid;

2=-Aminomethyi-7-(2,4-di-trifluoromethoxy-phenyl)~4-meethyl-heptanoic acid; 2-Aminomethyl-7-(2,5-di-trifluoromethoxy-phenyl)-4-meethyl-heptanoic amcid; 2=-Aminomethyl-7-(2,6-di-triflucromethoxy-phenyl)-4-meethyi-heptanoic amcid; 2=-Aminomethyl-7-(3,4-di-trifluoromethoxy-phenyl)-4-meethyl-heptanoic acid; 2=-Aminomethyl-7-(3,5-di-trifluoromethoxy-phenyl)-4-meethyi-heptanoic acid;

2 -Aminomethyl-4-methyl-7-(2,3,4-tri-trifluoromethoxy-fohenyl)-heptanoic a cid;

2-Aminomethyl-4-methyl-7-(2,3,5-tri-trifluoromethoxy-phenyl)-heptanoic acid; 2.Aminomethyl-4-methyl-7-(2,3,6-tri-&rifluoromethoxy-phenyl)-heptanaic acid;

2. Aminomethyl-4-methyl-7-(2,4,6-tri-Rrifluoromethoxy-phenyl)-heptanoic. acid; 2.Aminomethyl-7-(2-trifluoromethoxy—phenyl)-4-ethyi-heptanoic acid; 2-Aminomethyi-7-(3-trifluoromethoxy—phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(4-trifluoromethoxy—phenyl)-4-ethyl-heptanoic acid;

2-Aminomethyl-7-(2,3-di-trifluorometioxy-phenyl)-4-ethyl-heptanoic

: acid; 2-Aminomethyl-7-(2,4-di-trifluorometinoxy-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(2,5-di-trifluorometiEoxy-phenyl)-4-ethyl-heptancic acid; 2-Aminomethyl-7-(2,6-di-triflucrometEnoxy-phenyi)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(3,4-di-trifluorometEnoxy-phenyl)-4-ethyl-heptanoic acid;

2. Aminomethyl-7-(3,5-di-trifluorometlhoxy-phenyl)-4-ethyl-heptanoic acid; 2.Aminomethyl-4-ethyl-7-(2,3,4-tri-tritffluoromethoxy-phenyl)-heptanoic acid; 2-Aminomethyl-4-ethyl-7-(2,3,5-tri-tri-fluoromethoxy-phenyl)-heptanoic acid; 2-Aminomethyl-4-ethyl-7-(2,3,6-tri-tri-fluoromethoxy-phenyl)-heptanoic acid; 2-Aminomethyl-4-ethyl-7-(2,4,6-tri-tri-fluoromethoxy-phenyl)-heptanoic acid;

2.Arninomethyl-4-(2-ethoxy-phenyl)-gpentanoic acid; 2-Aminomethyl-4-(3-ethoxy-phenyl)-gpentancic acid; } 2-Aminomethyl-4-(4-ethoxy-phenyl)-goentanoic acid;

2-Aminomethyl-4-€2,3-diethoxy-phenyl)-pentanoic acid ; 2-Aminomethyi-4-&2,4-diethoxy-phenyl)-pentanoic acidll; 2-Aminomethyl-4-«2,5-diethoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4- (2,6-diethoxy-phenyl)-pentanoic acicx;

2-Aminomethyl-4- (3,4-diethoxy-phenyl)-pentanoic acicl; 2-Aminomaethyl-4- (3,5-diethoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4- (2,3,4-triethoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4- (2,3,5-triethoxy-phenyl)-pentanoic aecid; 2-Aminomethyl-4—(2,3,6-triethoxy-phenyl)-pentanoic a=cid; ~*~

2-Aminomethyi-4—(2,4,6-triethoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4—(2-ethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4—(3-ethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4—(4-ethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4~—(2,3-diethoxy-phenyl)-hexanoic acicl;

2-Aminomethyl-4—(2,4-diethoxy-phenyl)-hexanoic acicl; 2-Aminomethyl-4—(2,5-diethoxy-phenyl)-hexanoic acicl; 2-Aminomethyl-4—(2,6-diethoxy-phenyl)-hexanoic acict; 2-Aminomethyl-4—(3,4-diethoxy-phenyl)-hexanoic acid, 2-Aminomethyi-4—(3,5-diethoxy-phenyl)-hexanoic acicd;

2-Aminomethyl-4—(2,3,4-triethoxy-phenyl)-hexanoic a-cid;

: 2-Aminomethyl-4—(2,3 5-tristhoxy-phenyl)-hexanoic a_cid; 2-Aminomethyl-4~(2,3,6-triethoxy-phenyi)-hexanoic a.cid; 2-Aminomethyl-4—(2,4,6-triethoxy-phenyi)-hexanoic aacid; 2-Aminomethyl-5 -(2-ethoxy-phenyf)-4-methyl-pentarmaic acid;

2-Aminomethyl-5--(3-ethoxy-phenyl)-4-methyl-pentarmcic acid, 2-Aminomethyl-5--(4-ethoxy-phenyl)-4-methyl-pentarmoic acid; 2-Aminomethyl-5-(2,3-diethoxy-phenyl)-4-methyl-pesntanoic acid; 2-Aminomethyl-5-(2,4-diethoxy-phenyl)-4-methyl-pemntanoic acid;

2-Aminomethyl-5-(2,5-diethoxy-phenyl)-4-methyi-pesntanoic acid;

2-Aminomethyl-5-(2,6-diethoxy-phenyl)-4-methyl-pemntanoic acid; 2-Aminomethyl-5-(3,4-diethoxy-phenyl)-4-methyl-pe-ntanoic acid; 2-Aminomethyl-55-(3,5-diethoxy-phenyl)-4-methyl-pe ntanoic acid;

2-Aminomethyl-4-me-thyl-5-(2,3,4-triethoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4-me-thyl-5-(2,3,5-triethoxy-phenyl)-pentanoic acid; 2-Aminomethyi-4-me-thyl-5-(2,3,6-triethoxy-phenyl)-pentanoic acicH; 2-Aminomethyl-4-me—thyl-5-(2,4,6-triethoxy-phenyl)-pentanoic acict;

2-Aminomethyl-5-(2-ethoxy-phenyl)-4-ethyl-pentanoic acid; 2-Aminomethyl-5-(3-esthoxy-phenyl)-4-ethyl-pentanoic acid; 2-Aminomethyl-5-(4-esthoxy-phenyl)-4-ethyl-pentanoic acid; 2-Aminomethyl-5-(2, 3-disthoxy-phenyl)-4-ethyl-pentanoic acid; 2-Aminomethyi-5-(2,48-diethoxy-phenyl)-4-ethyl-pentanoic acid;

2-Aminomethyl-5-(2,5-diethoxy-phenyl)-4-ethyl-pentanoic acid; 2-Aminomethy}-5-(2,E-diethoxy-phenyl)-d-ethyi-pentancic acid; 2-Aminomethyi-5-(3,48-diethoxy-phenyl)-4-ethyl-pentanoic acid; ~ 2-Aminomethyl-5-(3,5-diethoxy-phenyl)-4-ethyl-pentanoic acid; 2-Aminomethyl-4-ethwyl-5-(2,3,4-triethoxy-phenyl)-pentanoic acid;

2-Aminomethyi-4-ethwyl-5-(2,3,5-triethoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4-ethwyl-5-(2,3,6-triethoxy-phenyl)-pentanoic acid; 2-Aminomethyi-4-ethwyl-5-(2,4,6-triethoxy-phenyl)-pentancic acid;

2-Aminomethyi-4-ethwy}-5-(2,3,4,5-tetraethoxy-phenyl)-pentanoic aacid; 2-Aminomethyl-4-ethwyl-5-(2,3,4,6-tetraethoxy-phenyl)-pentanoic acid;

2-Aminomethyl-4-ethwy}-5-(2,3,5,6-tetraethoxy-phenyl)-pentanoic axcid; 2-Aminomethyi-4-ethwyl-5-pentaethoxyphenyl-pentanoic acid; 2-Aminomethyl-5-(2-eathoxy-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(3-eathoxy-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5~(4-eathoxy-phenyl)-4-methyl-hexanoic acid;

2-Aminomethy!-5-(2,3-diethoxy-phenyl)-4-methyl-hexanoic acid;

2-Aminomethyl-5-(2,48-diethoxy-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(2,58-diethoxy-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(2,6-diethoxy-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(3, 8 -diethoxy-phenyl)-4-methyl-hexanoic acid;

2-Aminomethyl-5-(3,5s-diethoxy-phenyl)-4-methyl-hexanoic acid; : 2-Aminomethyl-4-met:hyl-5-(2,3,4-triethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4-met-hyl-5-(2,3,5-triethoxy-phenyl)-hexanoic acid;

2-Aminomethyl-4-methyl-5-(2,3,6-triethoxy-phenyl)-hexanoic acid;. 2-Aminomethyi-4-methyl-5-(22,4,6-triethoxy-phenyl)-hexanoic acids 2-Aminomethyl-6-(2-ethoxy-gohenyl)}-4-methyl-hexanoic acid; 2-Aminomethy!-6-(3-ethoxy-gohenyl)-4-methyl-hexanoic acid;

2-Aminomethyl-6-(4-ethoxy-gphenyi)-4-methyl-hexanoic acid; 2-Aminomethyl-6-(2,3-diethoxy-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyi-6-(2,4-diethoxy-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-6-(2,5-diethoxy-phenyl)-4-methyl-hexanoic acid; : 2-Aminomethyl-6-(2,6-diethoxy-phenyl)-4-msthyl-hexanoic acid;

2-Aminomethyl-6-(3,4-diethoxy-phenyl)-4-methyl-hexanoic acid;

2.Aminomethyl-6-(3,5-diethoxy-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-d4-methyl-6-(2,3,4-triethoxy-phenyl)-hexanoic acid;

2-Aminomethyl-4-methyl-6-{2,3,5-triethoxy-phenyl)-hexanoic acicy;

2-Aminomethyl-4-methyl-6-€2,3,6-triethoxy-phenyl)-hexanoic acid;

2-Aminomethyl-4-methyl-6-€2,4,6-triethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-6-(2-ethoxy—phenyl)-4-ethyl-hexanoic acid; 2-Aminomethy!-6-(3-ethoxy—phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(4-ethoxy—phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(2,3-dieth oxy-phenyl)-4-ethyl-hexanoic acid;

2-Aminomethyl-6-(2,4-dieths oxy-phenyl)~4-ethyl-hexanoic acid; 2-Aminomethyl-6-(2,5-dietrmoxy-phenyl)-4-ethyl-hexanoic acid; : 2-Aminomethyl-6-(2,6-diethuoxy-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyi-6-(3,4-diethaoxy-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(3,5-diethoxy-phenyl)-4-ethyl-hexanoic acid;

2-Aminomethyl-4-ethyl-6~(2,3,4-triethoxy-phenyl)-hexanoic acidz 2-Aminomethyl-4-ethyl-6-(2,3,5-triethoxy-phenyl)-hexanoic acids 2-Aminomethyi-4-ethyl-6-(2,3,6-triethoxy-phenyl)-hexanoic acids 5. Aminomethyl-4-ethyl-6-(2,4,6-triethoxy-phenyl)-hexanoic acid 2-Aminomethyl-7-(2-ethoxy/-phenyl)-4-methyl-heptanoic acid;

2-Aminomethyl-7-(3-ethoxy/-phenyl)-4-methyl-heptanoic acid; 2-Aminomethyl-7-(4-ethoxy-phenyl)-4-methyl-heptanoic acid; 2-Aminomethyl-7-(2,3-diethoxy-phenyf)-4-methyl-heptanoic acid;

2-A.minomethy}-7-(2,4-diethoxy-phenyl}-4-methyl-heptanoic= acid; 2.A_minomethyl-7-(2,5-diethoxy-phenyl)-4-methyl-heptanoic acid; 2-A_minomethyl-7-(2,6-diethoxy-phenyl)-4-methyl-heptanoic= acid; 2-A minomethyl-7-(3,4-diethoxy-phenyl)-4-methyl-heptanoics acid;

2-A minomethyl-7-(3,5-diethoxy-phenyl)-4-methyl-heptanoic= acid; . 2-Amninomethyl-4-methyl-7-(2,3,4-triethoxy-phenyl)-heptanoic acid; 2-Ammninomethyl-4-methyl-7-(2,3,5-triethoxy-phenyl)-heptancic acid; 2-Aeminomsthyl-4-methyl-7-(2,3,6-triethoxy-phenyl)-heptancic acid; 2-Arminomethyl-4-methyl-7-(2,4,6-triethoxy-phenyl)-heptanceic acid;

2-Arninomethyl-7-(2-ethoxy-phenyl)-4-ethyl-heptanoic acid; 2-Arninomethyl-7-(3-ethoxy-phenyl)-4-ethyl-heptanoic acid; 2-Arninomethyl-7-(4-ethoxy-phenyl)-4-ethyl-heptanoic acid; Co

. 2-Arminomethyl-7-(2,3-disthoxy-phenyl)-4-ethyl-heptanoic acid; 2-Arminomethyl-7-(2,4-diethoxy-phenyl)-4-ethyl-heptanoic aecid;

2-Armninomethyl-7-(2,5-diethoxy-phenyl)-4-ethyl-heptanoic acid; } 2-Armninomethyl-7-(2,6-diethoxy-phenyl)-4-ethyi-heptanoic acid;

- 2-Armninomethyl-7-(3,4-diethoxy-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(3,5-diethoxy-phenyi)-4-ethyi-heptanoic acid; 2-Aminomethyl-4-ethyl-7-(2,3,4-triethoxy-phenyl)-heptanoic acid,

2-Aminomethyl-4-ethyl-7-(2,3,5-triethoxy-phenyl)-heptanoic acid; 2-Aminomethyi-4-ethyl-7-(2,3,6-triethoxy-phenyl)-heptanocic acid;

: 2-Amiinomethyl-4-ethyl-7-(2,4,6-triethoxy-phenyl)-heptanoic acid; 2-Amiinomethyl-4-(2-methyl-phenyl)-pentanoic acid; 2-Amiinomethyl-4-(3-methyl-phenyl)-pentanoic acid;

2-Amainomethyl-4-(4-methyl-phenyl)-pentanoic acid;

2-Amminomethyl-4-(2,3-dimethyl-phenyl)-pentanoic acid; 2-Amainomethyl-4-(2,4-dimethyl-phenyl)-pentanoic acid; 2-Amminomethyl-4-(2,5-dimethyl-phenyl)-pentanoic acid; 2-Am inomethyi-4-(2, 6-dimethyl-phenyl)-pentanoic acid;

2-Am inomethyl-4-(3,4-dimethyl-phenyl)-pentanoic acid; 2-Aminomethyl-4-(3,5-dimethyl-phenyl)-pentanoic acid; 2-Amiinomethyl-4-(2,3,4-trimethyl-phenyl)-pentanoic acid;

2-Ammninomethyl-4-(2,3,5-trimethyl-phenyl)-penteanoic acid; 2-Amminomethyl-4-(2,3,6-trimethyphenyl)-pentzanoic acid; 2-Aaminomethyl-4-(2,4 8-trimethyl-phenyl)-pentaanoic acid;

2-A rninomethyl-4-(2-methyl-phenyl)-hexanoic amcid; 2-A minomethyl-4-(3-methyl-phenyl)-hexanoic emcid;

2-A minomethyl-4-(4-methyl-phenyl)-hexanoic aacid; : 2-A minomethyl-4-(2,3-dimethyl-phenyl)-hexancoic acid; 2-A minomethyl-4-(2,4-dimethyl-phenyl)-hexanoic acid; 2-A minomethyl-4-(2,5-dimethyl-phenyl)-hexanoic acid;

2-A minomethyl-4-(2,6-dimethyl-phenyl)-hexanoic acid; 2-A minomethyl-4-(3,4-dimethyl-phenyl)-hexancic acid; 2-A minomethyl-4-(3,5-dimethyl-phenyl)-hexancic acid; 2-A_minomethyl-4-(2,3,4-trimethyl-phenyl)-hexamnoic acid; 2-A minomethyl-4-(2,3,5-trimethyl-phenyl)-hexamnoic acid;

2-A_minomethyl-4-(2,3,6-trimethyl-phenyl)-hexaanoic acid; 2-A_minomethyl-4-(2,4,6-trimethyl-phenyl)-hexaanoic acid; 2-A_minomethyi-5-(2-methyl-phenyl)-4-methyl-foentanoic acid, 2-A_minomethyl-5-(3-methyl-phenyl)-4-methyl-poentanoic acid; 2-A_minomethyi-5-(4-methyl-phenyl)-4-methyl-oentanoic acid;

2-A.minomethyl-5-(2,3-dimethyl-phenyl)-4-metiyi-pentanoic acid; 2-A.minomethyl-5-(2,4-dimethyi-phenyl)-4-metiyl-pentanoic acid; 2-Aaminomethyl-5-(2,5-dimethyl-phenyl)-4-metEnyl-pentanoic acid;

. 2-Aaminomethyl-5-(2,6-dimethyi-phenyl)-4-methhyl-pentanoic acid; 2-Aaminomethyl-5-(3,4-dimethyl-phenyl)-4-metihyl-pentanoic acid;

2-paminomethyl-5-(3,5-dimethyl-phenyl)-4-metfhyl-pentanoic acid; 2-Aaminomethyl-4-methyl-5-(2,3,4-trimethyl-pheenyl)-pentanoic acid; 2-Aa minomethyl-4-methyi-5-(2,3,5-trimethyl-ph enyl)-pentanoic acid; 2. minomethyl-4-methyl-5-(2,3,6-trimethyl-ph enyl)-pentanoic acid; 2-mminomethyl-4-methyl-5-(2,4,6-trimethyl-pheenyl)-pentanoic acid;

2-Mminomethyl-5-(2-methyl-phenyl)-4-ethyl-peantanoic acid; 2-Aaminomethyl-5-(3-methyl-phenyl)-4-ethyl-pe=ntanoic acid; 2-mminomethyl-5-(4-methyl-phenyl)-4-ethyl-pentanoic acid;

2-Aminomethyl-5-(2,3-dimethyl-p henyl)-4-ethyl-pentanoic &xcid; 2-Aminomethyl-5-(2,4-dimethyl-p-henyl)-4-ethyl-pentanoic &cid; 2-Aminomethyl-5-(2,5-dimethyl-pshenyi)-4-ethyl-pentanoic &cid; 2-Aminomethyl-5-(2,6-dimethyl-pshenyl)-4-ethyl-pentanoic =acid;

" 2-Aminomethyl-5-(3,4-dimethyl-pehenyl)-4-ethyl-pentanoic =acid; 2-Aminomethyl-5-(3,5-dimethyl-pehenyl)-4-ethyl-pentanoic «acid; 2-Aminomethyl-4-ethyl-5-(2,3,4-t rimethyl-phenyl)-pentanoilic acid; 2-Aminomethyi-4-ethyl-5-(2,3,5-t rimethyl-phenyi)-pentanoilic acid;

2-Aminomethyl-4-ethyl-5-(2,3,6-t rimethyl-phenyl)-pentanosic acid;

2-Aminomethyl-4-ethyl-5-(2,4,6-t rimethyl-phenyl)-pentanofic acid; 2-Aminomethyl-4-ethyi-5-(2,3,4,5-tetramethyl-phenyl)-pen—tanoic acid; 2-Aminomethyl-4-ethyl-5-(2,3,4,65-tetramethyl-phenyl)-pen tanoic acid; 2-Aminomethyl-4-ethyl-5-(2,3,5,65-tetramethyl-phenyl)-pen tanoic acid; 2-Aminomethyl-4-ethyi-5-pentammethylphenyl-pentanoic acid;

2-Aminomethyl-5-(2-methyl-pheryi)-4-methyl-hexanoic acid; 2-Aminomethyi-5-(3-methyl-pheryl)-4-methyl-hexanoic aczid; 2-Aminomethyl-5-(4-methyl-pheryl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(2,3-dimethyl-pohenyl)-4-methyl-hexanoiec acid; 2-Aminomethyl-5-(2,4-dimethyi-phenyl)-4-methyl-hexanoiec acid;

2-Aminomethyl-5-(2,5-dimethyl-phenyl)-4-methyl-hexanoi-c acid; 2-Aminomethyl-5-(2,6-dimethyl-pohenyl)-4-methyl-hexanoi c acid;

~ 2-Aminomethyl-5-(3,4-dimethyl-pohenyl)-4-methyl-hexanoi.c acid; 2-Aminomethyl-5-(3,5-dimethyl-pohenyl)-4-methyl-hexanolc acid; 2-Aminomethyl-4-methyl-5-(2,3,<4-trimethyl-phenyl)-hexaroic acid;

2-Aminomethyl-4-methyl-5-(2,3, %5-trimethyl-phenyl)-hexaroic acid; 2-Aminomethyl-4-methyl-5-(2,3,&5-trimethyi-phenyl)-hexaroic acid; o.Aminomethyl-4-methyl-5-(2,4, 8 trimethyl-phenyl)-hexaroic acid; 2-Aminomethyl-6-(2-methyl-phemnyl)-4-methyl-hexanolc a=cid;, 2-Aminomethyl-6-(3-methyl-phemnyl)-4-methyl-hexanoic a-cid;

2-Aminomethyl-6-(4-methyl-phemnyl)-4-methyl-hexanoic a_cid; 2-Aminomethyi-6-(2,3-dimethyl-gohenyl)-4-methyl-hexanosic acid; 2-Aminomethyl-6-(2,4-dimethyl-gohenyl)-4-methyl-hexanosic acid;

—R3—

2-Amminomethyl-6-(2,5-dimethyl-phenyl)-4-methyl-hexanoic acid; 2-Amminomethyl-6-(2,6-dimethyl-phenyl)-4-methyl-hexanoic acid; 2-Amminomethyl-6-(3,4-dimethyl-phenyl)-4-methyl-hexanoic acid; 2-Amminomethyl-6-(3,5-dimethyl-phenyl)-4-methyl-hexanoic acid;

2-Amminomethyl-4-methyl-6-(2,3,4-trimethyl-phenyl)-hexanoic acid; 2-Amminomethyl-4-methyl-6-(2,3,5-trimethyl-phenyl)-hexanoic acid; : 2-Amminomethyi-4-methyl-6-(2,3,6-trimethyl-phenyl)-hexanoic acid; 2-Amminomethyl-4-methyl-6-(2,4,6-trimethyl-phenyl)-hexanoic acid; 2-Amminomethyl-6-(2-methyl-phenyl)-4-sthyl-hexanoic acid;

2-Ammninomethy}-6-(3-methyl-phenyl)-4-ethyl-hexanoic acid; 2-Amminomethyl-6-(4-methyl-phenyl)-4-ethyl-hexanoic acid; 2.Amminomethyi-6-(2,3-dimethyl-phenyl)-4-ethyl-hexanoic acid; : 2-Amminomethyl-6-(2,4-dimethyl-phenyl)-4-ethyl-hexanoic acid; 2-Ammninomethyl-6-(2,5-dimethyl-phenyl)-4-ethyl-hexanoic acid;

2-Amminomethyl-6-(2,6-dimethyl-phenyl)-4-ethyl-hexanoic acid; 2-Amninomethyl-6-(3,4-dimethyl-phenyl)-4-ethyl-hexanoic acid; 2-Amminomethyl-6-(3,5-dimethyl-phenyl)-4-ethyl-hexanoic acid; : 2_Amninomethyl-4-ethyl-6-(2,3,4-trimethyl-phenyl)-hexanoic acid; 2-Amminomethyl-4-ethyl-6-(2,3,5-trimethyi-phenyl)-hexanoic acid;

2-Aninomethyl-4-ethyl-6-(2,3,6-trimethyl-phenyl)-hexanoic acid;

: 2-A minomethyl-4-ethyl-6-(2,4,6-trimethyl-phenyl)-hexanoic acid; 2-A minomethyl-7-(2-methyl-phenyl)-4-methyl-heptanoic acid; 2-A_minomethyl-7-(3-methyl-phenyl)-4-methyi-heptanoic acid; 2_A_minomethyt-7-(4-methyl-phenyl)-4-methyi-heptanoic acid;

2-A.minomethyl-7-(2,3-dimethykphenyl)-4-methyl-heptanoic acid;

2-A.minomethyl-7-(2,4-dimethyl-phenyl)-4-methyl-heptanoic acid; 2-A.minomethyl-7-(2,5-dimethyk-phenyl)-4-methyl-heptanoic acid; : 2-A.minomethyl-7-(2,6-dimethyl-phenyl)-4-methyl-heptanoic acid; 2-A.minomethyl-7-(3,4-dimethyl-phenyl)-4-methyl-heptanoic acid;

2-A.minomethyl-7-(3,5-dimethyl-phenyl)-4-methyl-heptanoic acid; 2-Aaminomethyl-4-methyl-7-(2,3,4-trimethyl-phenyl)-heptanoic acid; 2-A.minomethyl-4-methyl-7-(2,3,5-trimethyl-phenyl)-heptanoic acid;

2-Armsinomethyi-4-methyl-7-(2,3,6-trimethyl-pherayl)-heptanoic acid; 2-Armminomethyl-4-methyl-7-(2,4,6-trimethyl-pheryl)-heptanoic acid; o-Armainomethyl-7-(2-methyl-phenyl)-d-sthyl-hep-tanoic acid; 2-Amainomethyl-7-(3-methyl-phenyl)-4-ethyl-hepstanoic acid;

2-Aminomethyl-7-(4-methyl-phenyl)-4-ethyl-hepstanoic acid; 2-Amiinomethyl-7-(2,3-dimethyi-phenyl)-4-ethyl—heptanaic acid; 2-Aminomethyl-7-(2 4-dimethyi-phenyl)-4-ethyl—heptanoic acid; 2-Aminomethyl-7-(2,5-dimethyi-phenyl)-4-ethyl—heptanoic acid; 2-Aminomethyl-7-(2,6-dimethyl-phenyl)-4-ethyl—heptanoic acid;

2-Aminomethyl-7-(3,4-dimethyl-phenyl)-4-ethyl—heptanoic acid; 2-Aminomethyl-7-(3,5-dimethyl-phenyl)-4-ethyl—heptanoic acid; 2-Aminomethyl-4-ethyl-7-(2,3,4-trimethyl-phenyyi)-heptanoic acid; 2-Aminomethyl-4-ethyl-7-(2,3,5-frimethyl-phenyyl)-heptanoic acid; 2-Aminomethyl-4-ethyl-7-(2,3,6-trimethyl-phenwyl)-heptanoic acid;

2-Anninomethyt-4-ethyl-7-(2,4 ,6-trimethyl-phenwyl}-heptanoic acid; 2-Amninomethyl-4-(2-hydroxy-phenyl)-pentanoicc acid; 2-Armninomethyl-4-(3-hydroxy-phenyi)-pentanoiec acid; 2-Armninomethyl-4-(4-hydroxy-phenyl)-pentanoiec acid; : 2-Arminomethyl-4-(2,3-dihydroxy-phenyl)-pent=xnoic acid; :

2-Armninomethyl-4-(2,4-dihydroxy-phenyl)-pentaanoic acid;

: 2-Arninomethyl-4-(2,5-dihydroxy-phenyl)-pentaanoic acid; 2_Arninomethyl-4-(2,6-dihydroxy-phenyl)-penteanoic acid; : 2-Arminomethyi-4-(3,4-dihydroxy-phenyl)-pentaanoic acid; - 2-Arninomethyl-4-(3,5-dihydroxy-phenyl)-pent=anoic acid;

2-Arninomethyl-4-(2,3,4-trihydroxy-phenyl)-pe- ntanoic acid; 2-Arninomethyl-4-(2,3,5-trihydroxy-phenyl)-pesntanoic acid; 2-Amminomethyl-4-(2,3,6-trihydroxy-phenyl)-pe=ntanoic acid; 2-Amminomethyl-4-(2,4,6-trihydroxy-phenyl)-peentanoic acid; 2.Ammninomethyl-4-(2-hydroxy-phenyi)-hexanoiic acid;

2.A minomethyl-4-(3-hydroxy-phenyl)-hexanoiic acid;

2-A minomethyl-4-(4-hydroxy-phenyl)-hexanoiic acid; 2-A minomethyl-4-(2,3-dihydroxy-phenyl)-hex=anoic acid;

2-Aminomethyl-4-(2,4-dihydroxy-phenyl)-hexansoic acid; 2-Aminomethyl-4-(2,5-dihydroxy-phenyl)-hexammoic acid; 2-Aminomethyl-4-(2,6-dihydroxy-phenyl)-hexammaic acid; 2-Aminomethyl-4-(3,4-dihydroxy-phenyl)-hexarmoic acid;

2-Aminomethyi-4-(3,5-dihydroxy-phenyl)-hexans cic acid; 2-Aminomethyl-4-(2,3,4-trihydroxy-phenyl)-hexaanoic acid; 2-Aminomethyl-4-(2,3,5-trihydroxy-phenyl)-hexaanoic acid; 2-Aminomethyl-4-(2,3,6-trihydroxy-phenyl)-hexaanoic acid; - 2-Aminomethyl-4-(2,4,6-trihydroxy-phenyl)-hexaanoic acid;

~ 2-Aminomethyl-5-(2-hydroxy-phenyl)-4-methyl-poentanoic acid; 2-Aminomethyi-5-(3-hydroxy-phenyl)-4-methyl-poentanoic acid; 2-Aminomethyl-5-(4-hydroxy-phenyl)-4-methyi-poentanoic acid; 2-Aminomethyl-5-(2,3-dihydroxy-phenyl)-4-metyl-pentanoic acid; 2-Aminomethyl-5-(2,4-dihydroxy-phenyl)-4-metiyl-pentanoic acid;

2-Aminomethyl-5-(2,5-dihydroxy-phenyl)-4-metiyl-pentanoic acid; 2-Aminomethyi-5-(2,6-dihydroxy-phenyl)-4-metiyl-pentanoic acid; 2-Aminomethyl-5-(3,4-dihydroxy-phenyl)-4-metiyl-pentanoic acid; 2-Aminomethyi-5-(3,5-dihydroxy-phenyl)-4-metimyl-pentanoic acid; 2-Aminomethyl-4-methyl-5-(2,3,4-trihydroxy-pheenyl)-pentanoic acid;

2-Aminomethyl-4-methyl-5-(2,3,5-trihyd roxy-pheanyl)-pentanoic acid;

: 2-Aminomethyl-4-methyl-5-(2,3,6-trihydroxy-pheanyl)-pentanoic acid; 2-Aminomethyl-4-methyl-5-(2,4,6-trihydroxy-pheanyl)-pentanoic acid; 2-Aminomethyl-5-(2-hydroxy-phenyl)-4-methyi-imexanoic acid; 2-Aminomethyl-5-(3-hydroxy-phenyl)-4-methyl-miexanoic acid;

2-Aminomethyl-5-(4-hydroxy-phenyl)-4-methyl-lexanoic acid; 2-Aminomethyl-5-(2,3-dihydroxy-phenyl)-4-metiyl-hexanoic acid; 2-Aminomethyi-5-(2,4-dihydroxy-phenyl)-4-mettyl-hexanoic acid; 2-Aminomethyl-5-(2,5-dihydroxy-phenyl)-4-metiyl-hexanoic acid; 2-Aminomethyl-5-(2,6-dihydroxy-phenyl)-4-metiyl-hexanoic acid;

2-Aminomethyl-5-(3,4-dihydroxy-phenyl)-4-mettyl-hexanoic acid; 2-Aminomethyl-5-(3,5-dihydroxy-phenyl)-4-metinyl-hexanoic acid; 2-Aminomethyl-4-methyl-5-(2,3,4-trihydroxy-pheanyl)-hexanoic acid;

2-Aminomethyl-4-methyl-5-(2,3,5-trihydroxy-phenyl)-hexanoweic acid; 2-Aminomethyl-4-msthyl-5-(2,3,6-trihydroxy-phenyl)-hexanomic acid; 2-Aminomethyl-4-methyl-5-(2 4,6-trihydroxy-phenyl)-hexanosic acid; 2-Aminomethyl-6-(2-hydroxy-phenyl)-4-methyl-hexanoic acied;

2.Aminomethyl-6-(3-hydroxy-phenyl)-4-methyl-hexanoic aci«d;

: 2-Aminomethyl-6-(4-hydroxy-phenyl)-4-methyl-hexanoic aci d, 2-Aminomethyl-6-(2,3-dihydroxy-phenyl)-4-methyl-hexanoic= acid; 2-Aminomethyf-6-(2,4-dihydroxy-phenyl)-4-methyl-hexanoic= acid, 2-Aminomethyl-6-(2,5-dihydroxy-phenyl)-4-methyl-hexanoic= acid;

_ 2-Aminomethyl-6-(2,6-dihydroxy-phenyl)-4-methyl-hexanoic= acid; 2-Aminomethyl-6-(3,4-dihydroxy-phenyl)-4-methyl-hexanoic= acid; 2-Aminomethy}-6-(3,5-dihydroxy-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-4-methyl-6-(2,3,4-trihydroxy-phenyl)-hexanoic acid; 2-Aminomethyl -4-methyl-6-(2,3,5-trihydroxy-phenyl)-hexancic acid;

2-Aminomethyl-4-methyl-6-(2,3,6-trihydroxy-phenyl)-hexaneic acid;

. 2-Aminomethyl-4-methyi-6-(2,4,6-trihydroxy-phenyl)-hexaneoic acid; 2-Aminomethyl-5-(2-hydroxy-phenyl)-4-ethyl-pentanoic acid; 2-Aminomethyl-5-(3-hydroxy-phenyl)-4-ethyl-pentanoic acid; 2-Aminomethyl-5-(4-hydroxy-phenyl)-4-ethyl-pentanoic acicl;

2-Aminomethyl-5-(2,3-dihydroxy-phenyl)-4-ethyl-pentanoic acid; 2-Aminomethyl-5-(2,4-dihydroxy-phenyl)-4-ethyl-pentanoic acid; 2-Aminomethyl-§-(2,5-dihydroxy-phenyf)-4-ethyl-pentanoic acid; 2-Aminomethyl-5-(2,6-dihydroxy-phenyl)-4-ethyl-pentanocic acid; 2-Aminomethyll-5-(3,4-dihydroxy-phenyl)-4-ethyl-pentanoic- acid;

2-Aminomethyl-5-(3,5-dihydroxy-phenyl)-4-ethyl-pentanoic= acid; 2-Aminomethyl-4-ethyl-5-(2,3,4-trihydroxy-phenyl)-pentanOic acid; 2-Aminomethyl-4-ethyl-5-(2,3,5-trihydroxy-phenyl)-pentanOic acid; 2-Aminomethy1-4-ethyl-5-(2,3,6-trihydroxy-phenyi)-pentanoic acid; 2-Aminomethy1-4-ethyl-5-(2,4,6-trihydroxy-phenyl)-pentancic acid;

2-Aminomethy3-4-ethyl-5-(2,3,4,5-tetrahydroxy-pheny!)-pemntanoic acid; 2-Aminomethy §-4-ethyl-5-(2,3,4,6-tetrahydroxy-phenyl)-pemntanoic acid; 2-Aminomethy 1-4-ethyl-5-(2,3,5,6-tetrahydroxy-phenyl)-pemntanoic acid;

: 2-Aminomethyl-4-ethyl-5-pentahydroxyphenyl-peratanoic acid; 2-Aminomethyl-6-(2-hydroxy-phenyl)-4-sthyl-hexa_noic acid; 2-Aminomethyl-6-(3-hydroxy-phenyl)-4-ethyl-hexamnoic acid; 2-Arninomethyl-6-(4-hydroxy-phenyl)-4-ethyl-hexaanoic acid;

2-Aminomethyi-6-(2,3-dihydroxy-phenyl)-4-ethyl-iniexanoic acid; 2.Aminomethyl-6-(2,4-dihydroxy-phenyl)-4-sthyl-Miexanoic acid; 2-Aminomethyl-6-(2,5-dihydroxy-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(2,6-dihydroxy-phenyl)-4-ethyl-Mexanoic acid; 2_Aminomethyl-6-(3,4-dihydroxy-phenyl)-4-ethyl-iexanoic acid;

2.Aminomethyl-6~(3,5-dihydroxy-phenyl)-4-ethyl-Fexanoic acid; 2-Aminomethyl-4-athyl-6-(2,3,4-trihydroxy-phenyl )-hexanoic acid; 2-Aminomethyl-4-ethyl-6-(2,3,5-trihydroxy-phenyll)-hexanoic acid;

2-Aminomethyl-4-ethyl-6-(2,3,6-trihydroxy-phenyl)-hexanoic acid, 2-Aminomethyl-4-sthyl-6-(2,4,6-trihydroxy-phenyl)-hexanoic acid;

2-Aminomethyl-7-(2-hydroxy-phenyl)-4-methyl-heptanoic acid; 2-Aminomethyl-7-(3-hydroxy-phenyl)-4-methyl-heaptanoic acid; 2-Aminomethyl-7-(4-hydroxy-phenyl)-4-methyl-heaptanoic acid; 2-Aminomethyl-7-(2,3-dihydroxy-phenyl)-4-methwyi-heptanoic acid; : 2-Aminomethyl-7-(2,4-dihydroxy-phenyl)-4-meth=yl-heptanoic acid;

2-Aminomethyl-7-(2,5-dihydroxy-phenyi)-4-meth-yl-heptanoic acid; 2-Aminomethyl-7-(2,6-dihydroxy-phenyl)-4-meth yl-heptanoic acid; 2-Aminomethyl-7-(3,4-dihydroxy-phenyl)-4-mettayi-heptanoic acid;

2.Aminomethyl-7-(3,5-dihydroxy-phenyl)-4-methayi-heptanoic acid; 2-Aminomethyl-4-methyl-7-(2,3,4-trihydroxy-phenyl)-heptanoic acid;

2-Aminomethyl-4-methyl-7-(2,3,5-trihydroxy-phenyl)-heptanoic acid;

: 2-Aminomethyl-4-methyl-7-(2,3,8-trihydroxy-pheanyl)-heptanoic acid; 2-Aminomethyl-4-methyl-7-(2,4,6-trihydroxy-phesnyl)-heptanoic acid; 2-Aminomethyl-7-(2-hydroxy-phenyl)-4-ethyl-he=ptanoic acid; 2-Aminomethyl-7-(3-hydroxy-phenyl)-4-ethyl-hesptanoic acid;

2-Aminomethyl-7-(4-hydroxy-phenyl)-4-ethyl-hesptanoic acid; 2-Aminomethyl-7-(2,3-dihydroxy-phenyl)-4-ethy=i-heptanoic acid;

2-Aminomethyi-7-(2,4-dihydroxy-phenyl)-4-ethywl-heptanoic acid;

2-Aminomethyl-7-(2,5-dihydroxy-phe nyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(2,6-dihydroxy-phe nyl)~4-ethyl-heptanoic acid; 2-Aminomethyl-7-(3,4-dihydroxy-phe nyl)-4-ethyl-heptanoic acid; 2.Aminomethyl-7-(3,5-dihydroxy-phe=nyi)-4-ethyl-heptanoic acid;

2-Aminomethyl-4-ethyl-7-(2,3,4-trihycdroxy-phenyl)-heptanoic acid; 2-Aminomethyl-4-ethyl-7-(2,3,5-trihycdroxy-phenyl)-heptanoic acid; 2-Aminomethyl-4-ethyl-7-(2,3,6-trihycdroxy-phenyl)-heptanoic acid; 2-Aminomethyl-4-ethyl-7-(2,4,6-trihycdroxy-phenyl)-heptanoic acid; 2-Aminomethyi-4-ethyl-7-(2,3,4,5-tetarahydroxy-phenyl)-heptanoic acilid;

2-Aminomethyl-4-ethyl-7-(2,3,4,6-tetmrahydroxy-phenyl)-heptanoic acilid; 2-Aminomethyl-4-ethyl-7-(2,3,5,6-tetmrahydroxy-phenyl)-heptanoic acid; 2-Aminomethyl-4-ethyl-7-pentahydrasxyphenyi-heptanoic acid; (2R,4R)-2-Aminomethyl-4-(2,4-difluoe=ro-benzyl)-hexanoic acid; (2S,4R)-2-Aminomethyl-4-~(2,4-difluo ro-benzyl)-hexanoic acid;

(2R,4S)-2-Aminomethyl-7-(2,4-difluo-ro-phenyl)-4-ethyl-heptanoic acid; (2S,4S)-2-Aminomethyl-7-(2,4-difluo ro-phenyl)-4-ethyl-heptanoic acd;

: (2R,4S)-2-Aminomethyl-4-(2,4-difluo~ro-benzyl)-hexanoic acid; (2S,4S)-2-Aminomethyl-4-(2,4-difluo ro-benzyl)-hexanoic acid; (2S,4S)-2-Aminomethyl-4-(3,5-difluo ro-benzyl)-hexanoic acid; :

(2S,45)-2-Aminomethyl-4-(2-fluoro-taenzyl)-hexanoic acid; (2S,4S)-2-Aminomethyl-5-(2,4-difluo- ro-phenyl)-4-methyl-pentanoic acid;

(2S)-2-Aminomethyl-5-(2,4-difluoro-pohenyl)-pentanoic acid; (2S,4S)-2-Aminomethyl-4-(2,6-difluosro-benzyl)-hexanoic acid;

(2S,45)-2-Aminomethyl-4-(4-fluoro-toenzyl)-hexanoic acid; (2S,4S)-2-Aminomethyl-4~(2,5-difluosro-benzyl)-hexanoic acid; (2S,4S)-2-Aminomethyl-4-(3-fluoro-toenzyl)-hexanoic acid; : (2S,45)-2-Aminomethyl-4-pentafluorrophenylimethyl-hexanoic acid; (25,4R)-2-Aminomethyl-7-(2,4-diflucoro-phenyl)-4-ethyk-heptanoic acid;

(2S,4S)-2-Aminomethyl-4-(4-trifluorcomethyi-benzyl)-hexanoic acid; 2-Aminomethyl-4-(4-methoxy-2-methhyl-benzyl)-hexanoic acid;

2-Aminomethyl-5-(4-methoxy-2-methyl-phenyl)-4-methyl-p entanoic acid; : 2.Aminomethyl-4-(4-methoxy-3-methyl-benzyl)-hexanoic eacid; and 2-Aminomethyl-5-(4-methoxy-3-methyl-phenyl)-4-methyl-prentanoic acid.

Other compoounds of formula V include the following compounds, and their pharmaceutically acceptable salts: 2-Aminomethyl-~4-ethyl-5-methyi-hexanoic acid; 2-Aminomethyl-4-ethyi-3-methyl-hexanoic acid; Ce - 2-Aminomethyl-3,4-dimethyl-hexanoic acid; 2-Aminomethyl-3-ethyl-4-methyl-hexanoic acid; 2-Aminomethyl-4-ethyl-3-methyl-heptanoic acid; 2-Aminomethyl-3,4-dimethyl-octanoic acid; 2-Aminomethyl-3-methyl-pentanoic acid; 2-.Aminomethyl-3-methyl-hexanoic acid; 2.Aminomethyl-3-methyl-heptanoic acid; 2-Aminomesthyl-3,4-dimethyl-pentanoic acid; 2-Aminomesthyl-3,5-dimethyi-hexanoic acid; ‘. 2-Aminomethyl-3,6-dimethyi-heptanoic acid; 2.Aminomethyi-3,5, 5-trimethyl-hexanoic acid; 2-Aminomethyl-3-cyclopropyl-butyric acid; : : 2-Aminomethyl-3-cyclopentyl-butyric acid; 2.Aminomethyl-3-cyclohexyl-butyric acid; 2-Aminomethyl-4-cyclohexyl-3-methyl-butyric acid; 2_Aminomethy!-5-cyclohexyl-3-methyl-pentanoic acid; 2-Aminomethy}-3-methyl-4-(4-methyl-cyclohexyl)-butyric acid; 2-Aminomethyl-3-ethyl-pentanoic acid, 2-Aminomethyl-3-ethyl-hexanoic acid; 2-Aminomsethyl-3-ethyl-heptanoic acid; : 2-Aminomethyl-3-ethyl-4-methyl-pentanaic acid; : 2-Aminomethyl-3-cyclohexylmethyl-pentanoic acid; 2-Aminomethyl-5-(4-methoxy-cyclohexyl)-3-methyl-pentaanoic acid;

2-Aminomethyl-5-(4-me®hoxy-phenyl)-3-methyl-pentanoic acid; 2-Aminomethyl-4-(2-me-thoxy-phenyl)-3-methyl-butyric acid; 2-Aminomethyl-4-(4-me-thoxy-phenyl)-3-methyl-butyric acid; 2-Aminomethyl-3-phenysl-butyric acid; 2-Aminomethyi-3-methywi-4-phenyi-butyric acid; 2-Aminomethyl-3-methywI-5-phenyl-pentanoic acid; E 2-Aminomethyl-3-methyl-4-(3-trifluoromethyl-phenyl)-butyric acid; 2-Aminomethyl-3-(4-ethayl-phenyl)-butyric acid; 2-Aminomethyl-3-(2,5-dlimethyl-phenyl)-butyric acid; 10 . 2-Aminomethyl-3-methyyI-4-p-tolyl-butyric acid; 2-Aminomethyl-3-m-tolyyI-butyric acid; 2-Aminomethyl-3-benzyyl-pentanoic acid; and 2-Aminomethyl-4-(4-fiusoro-phenyl)-3-methyl-butyric acid.

This invention also prowides compounds of formula Vi

HN

ON

Rs Fo vi and their pharmaceutically ac ceptable salts, wherein Rs, Rs, and Rs are ass defined above in formula |, wi th the proviso that Rs, Rs, and Rs are not simultaneously hydrogen atorms.

Specific compounds of formula VI include the following compounds and their pharmaceutically acceptable salts: " o.Aminomethyl-5-cyclopropyl-hexanoic acid; 2-Aminomethyl-5-cycleobutyl-hexanoic acid; 2-Aminomethyl-5-cycleopentyl-hexanoic acid; 2-Aminomethyl-5-cycleohexyl-hexanoic acid; 2-Aminomethyl-5-phemnyl-hexanoic acid; 2-Aminomethyl-5-(3-c hioro-phenyl)-hexanoic acid; 2. Aminomethyl-5-(3-tr-ifluoromethyl-pheny)-hexanoic acid;

2-Aminomethy!-5-(4-trifluoromeRhyl-phenyl)-hexanoic acid; 2-Aminomethyl-5-cyclopropyl-heeptanoic acid; o_Aminomethyl-5-cyclobutyl-hegptanoic acid; 2-Aminomethyl-5-cyclopentyl-heeptanoic acid;

2-Aminomethyl-5-cyclohexyi-hezptanoic acid; 2-Aminomethyl-5-phenyl-heptamoic acid; 2-Aminomethyl-5-(3-chloro-phe=nyl)-heptanoic acid; 2-Aminomethyl-5-(3-trifluorome=thyi-phenyl)-heptanoic acid; 2-Aminomethyl-5-(4-trifluorome=thyl-phenyl)-heptanoic acid;

2-Aminomethyl-5-methyi-6-phe-nyl-hexanoic acid; 2-Aminomethyl-6-(3-chloro-phe2nyi)-5-methyl-hexanoic acid; 2-Aminomethyl-5-methyl-6-(3-tmrifluoromethyl-phenyl)-hexanoic acid;

2-Aminomethyl-5-methyl-6-(4-tarifluoromethyi-phenyl)-hexanoic acicl; 2-Aminomethyl-5-cyclopropyimaethyl-heptanoic acid;

2-Aminomethyl-5-cyclobutylme=thyl-heptanoic acid; 2-Aminomethyl-5-cyclopentylmaethyi-heptanoic acid; 2.Aminomethyl-5-cyclohexyimesthyl-heptanoic acid; 2-Aminomethyl-5-benzyl-heptamnoic acid; 2-Aminomethyl-5-(3-chloro-berzyl)-heptanoic acid;

2-Aminomethyl-5-(3-trifluoromethyl-benzyl)-heptanoic acid; 2.Aminomethyl-5-(4-triflucromesthyl-benzyl)-heptanoic acid; 2.Aminomethyl-5-methyl-7-pheanyl-heptanoic acid; 2-Aminomethyl-7-(3-chloro-pheenyl)-5-methyi-heptanoic acid; 2.Aminomethyl-5-methyl-7-(3-Rrifluoromethyl-phenyl)-heptanoic acid;

2-Aminomethyl-5-methyl-7-(4-trifluoromethyl-phenyl)-heptanoic acid; 2.Aminomethyl-7-cyclopropyl-%5-ethyl-heptanoic acid; 2-Aminomethyl-7-cyclobutyl-5—ethy!-heptanoic acid; 2-Aminomethyl-7-cyclopentyl-5-ethyl-heptanoic acid; 2-Aminomethyl-7-cyclohexyl-5S-sthyl-heptanoic acid;

2-Aminomethyl-5-ethyl-7-pheryl-heptanoic acid; 2-Aminomethyl-7-(3-chioro-pheenyl)-5-ethyl-heptanoic acid; 2-Aminomethyl-5-ethyl-7-(3-tr@fluoromethyl-phenyl)-heptanoic acid;

—_—52—

2-Aminomethyl-5-ethyl-7-(4-trifluoro methyl-pheny!)-heptancic accid; 2-Aminomethyl-5,5-dimethyl-heptane cic acid; 2-Aminomethyl-5,5-dimethyi-octano-ic acid; and 2-Aminomethyl-5,5-dimethyi-nonancic acid.

This invention also provides pharmaceutical compositions comgorising a therapeutically effective amount of a comp ound of formula I, Hl, HI, IV, ™V or Vi, or a pharmaceutically acceptable salt thereaof, and a pharmaceutically acceptable carrier.

This invention also provides a methsod of treating a disorder or condition in a mammal, including a human , the disorder or condition selected from epilepsy, faintness attacks, fibromyalgia, hypokinesia, cranial diseorders, hot flashes, essential tremor, chemical dependencies and addictions, #(e.g., dependencies on or addictions to alcohol, samphetamines (or amphetaamine- like substances), caffeine, cannabis, cocaimne, heroin, hallucinogens, tcobacco, inhalants and aerosol propellants, nicotine , opioids, phenylglycidine derivatives, sedatives, hypnotics, benzodiazepines and other anxiolytiecs), and withdrawal symptoms associated with suck dependencies or addictiors, addictive behaviors such as gambling; miggraine, spasticity including muscle spasticity and hypotonia with paralysis, art: hritis, irritable bowel syndro -me (IBS), chronic pain, acute pain, neuropathisc pain, post herpetic neuralegia, lower back pain, surgical pain, vascular heeadache, chronic headache, sinus : headache, inflammatory disorders (e.g., rrmeumatoid arthritis, osteoartlhuiitis, disease modification of osteoarthritis diseamse, psoriasis), diuresis, premenstrual syndrome, premenstrual dyssphoric disorder, tinnitus, anasd gastric damage. The method comprises administsering to a mammal in need of such treatment a therapeutically effective amoumnt of a compound of formula |, I, Ill,

IV, V or VI, or a pharmaceutically acceptalole salt thereof.

The present invention also providess a method of treating neurodegenerative disorders termed acute brain injury. These include but are not limited to stroke, head trauma, and aspohyxia. Stroke refers to a ceerebral vascular disease and may also be referrecd to as a cerebral vascular imncident (CVA) and includes acute thromboembolics stroke. Stroke includes bcoth focal and global ischemia. Also, included are transient cemrebral ischemic attacks and other cerebral vascular problems accompanied boy cerebral ischemia, such as those that occur in patients undergoing carotid endarterectomy or other cerebrovascular or vascular surgical procedures, or diagnostic vascular procedures including cerebral angiography and the like.

Compounds of formula [, I, ill, IV, V or VI, area also useful in the treatment of head trauma, spinal cord trauma, or injLary from general anoxia, hypoxia, hypoglycemia, hypotension as well as similar injuries seen during proceciures from embole, hyperfusion, and hypoxia. They are also useful in preveriting neuronal damage that occurs during cardiac bypass surgery, in ~ incidemnts of intracranial hemorrhage, in perinatal asphyxia, in cardiac arrest, and status epilepticus.

This invention also provides. a method of treating a disorder or condit ion in a mammal, including a human, the disorder or condition selected from tlhe group consisting of delirium, dementia, and. amnestic and other cognit ive or neurodegenerative disorders, such as P*arkinson’s disease (PD),

Huntimgton’s disease (HD), Alzheimer's disease, serie dementia, dementia of the Al=heimer's type, memory disorder, vascular dermentia, and other dementias, for example, due to HIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's disease, Creu*tzfeldt-Jakob disease, or due toe multiple aetiologies; movement disorders such as akinesias, - dyskiresias, including familial paroxysmal dyskinesi. as, spasticities, Tourette's syndrome, Scott syndrome, PALSYS and akinetic-ri gid syndrome; extra- pyramidal movement disorders such as medication—induced movement disorders, for example, neuroleptic-induced Parkins- onism, neuroleptic maligrant syndrome, neuroleptic-induced acute dysztonia, neuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskine=sia and medication- inducezd postural tremour; Down's syndrome; demyelinating diseases such as multipele sclerosis (MS) and amylolateral sclerosis (AALS), peripheral neuro pathy, for example diabetic and chemotherapwy-induced-neuropathy, and postheemetic neuralgia, trigeminal neuralgia, segme ntal or intercostal neura.lgia and other neuralgias; and cerebral vasculiar disorders due to acute or chronic cerebrovascular damage such as cerebral infarction, subarach noid haemorrhage or cerebral oedema. Thre method comprises administering toa mammal in need of such treatment a therapeutically effective amount of = compound of formula |, II, Hl, IV, V or WI, or a pharmaceutically acceptabl.e salt thereof.

This invention also provides for- improving cognition in mammals, - including humans, having AD, PD, and fibromyalgia by enhancing the arrount and the quality of sieep. The method comprises administering to 8 mamamal in need of improved cognition a therapeutically effective amount of a compound of formula |, Il, lll, IV, V or VI, or a pharmaceutically acceptab’le salt thereof. .

This invention also provides a rmethod of treating pain in a mamme-al, including a human, the method comprising administering to a mammal ir need of such treatment a therapeutically effective amount of a compouned of formula I, 11, 111, IV, V or VI, or a pharmaceutically acceptable salt thereof.

Pain refers to acute as well as chronic pain. Acute pain-is.usually short- lived and is associated with hyperactivity of the sympathetic nervous system.

Examples are postoperative pain and allodynia. Chronic pain is usually defined as pain persisting from three Ro six months and includes somatosgenic pain and psychogenic pain. Other pa in is nociceptive. : Examples of the types of pain &hat can be treated with the compoeunds of formula I, If, lll, IV, V or VI, and the ir pharmaceutically acceptable salfts, include pain resulting from soft tissue and peripheral damage, such as eacute trauma, pain associated with osteoarthritis and rheumatoid arthritis, mussculo- skeletal pain, such as pain experienced after trauma; spinal pain, denta_| pain, : myofascial pain syndromes, episiotormy pain, and pain resulting from bums; deep and visceral pain, such as hear? pain, muscle pain, eye pain, orofacial pain, for example, odontaigia, abdominal pain, gynaecological pain, for example, dysmenorrhoea, labour pais and pain associated with endometriosis; pain associated with Merve and root damage, such as paain associated with peripheral nerve disorders, for example, nerve entrapment and brachial plexus avulsions, amputation, peripheral neuropathies, tic douloureux, atypical facial pain, nerve root damage, trigeminal neuralgia, neuropathic lower back pain, HIV related neuropathic pain, cancer related neuropathic pain, diabetic neuropathic pain, and arachnoiditis; neuropathic and non-neuropathic pain associated with carcinoma, often referred to as cancer pain; central nervous sysstem pain, such as pain due to spinal cord or brain stem damage; lower back pain; sciatica; phantom limb pain, headache, including migraine and other vasscular headaches, acute or chronic tension headache, cluster headache, termperomandibular pain and maxillary sinus : pain; pain resulting from ankylossing spondylitis and gout; pain caused by increased bladder contractions; post operative pain; scar pain; and chronic non-neuropathic pain such as pain associated with fibromyalgia, HIV, rheumatoid and osteoarthritis, amnthralgia and myalgia, sprains, strains and trauma such as broken bones; a_nd post surgical pain. Co : Still other pain is caused Iby injury or infection of peripheral sensory nerves. It includes, but is not limited to pain from peripheral nerve trauma, herpes virus infection, diabetes rmellitus, fibromyalgia, causalgia, plexus avulsion, neuroma, limb amputation, and vasculitis. Neuropathic pain is also caused by nerve damage from ¢ hronic alcoholism, human immunodeficiency virus infection, hypothyroidism, umremia, or vitamin deficiencies. Neuropathic pain includes, but is not limited tc pain caused by nerve injury such as, for . example, the pain diabetics suffer from.

Psychogenic pain is that wvhich occurs without an organic origin such as low back pain, atypical facial goain, and chronic headache.

Other types of pain include inflammatory pain, osteoarthritic pain, trigeminal neuralgia, cancer pairm, diabetic neuropathy, restless leg syndrome, acute herpetic and postherpetic mneuralgia, causalgia, brachial plexus avulsion, occipital neuralgia, gout, phantorm limb, bum, and other forms of neuralgia, neuropathic and idiopathic pain syndrome.

This invention also providees a method of treating depression, which comprises administering to a ma-mmal, including a human, in need of such treatment a therapeutically effectzive amount of a compound of formula |, II, Il,

IV, V or VI, or a pharmaceutically acceptable salt thereof. Depression can be the result of organic disease, secondary to stress associated with personal loss, or idiopathic in origin. There is a strong tendency for familial occurrencee of some forms of depression suggesting a mechanistic cause for at least some forms of depression. The diagnosis of depression is made primarily bw quantification of alterations in patients’ mood- These evaluations of mood ar-e generally performed by a physician or quantified by a neuropsychologist usirng validated rating scales, such as the Hamilton Depression Rating Scale or thea

Brief Psychiatric Rating Scale. Numerous other scales have been developed to quantify and measure the degree of mood alterations in patients with depression, such as insomnia, difficulty with concentration, lack of energy, feelings of worthlessness, and guilt. The stardards for diagnosis of depression as well as all psychiatric diagnoses are collected in Diagnostic amnd

Statistical Manual of Mental Disorders (4th ec., 1994), which is referred to ass the DSM-IV-R Manual, and is published by tree American Psychiatric

Association.

This invention also provides a method of treating a disorder or : condition in a mammal, including a human, the disorder or condition selectecd from the group consisting of mood disorders, such as depression, or more particularly, depressive disorders, for exampl e, single episodic or recurrent major depressive disorders, dysthymic disorcders, depressive neurosis and neurotic depression, melancholic depression, including anorexia, weight losss, including weight loss associated with anorexi a, cancer, old age and/or frailty, insomnia, early morning waking and psychormnotor retardation, atypical depression (or reactive depression), including increased appetite, hypersomnia, psychomotor agitation or irritability, seasonal affective disorde=r and pediatric depression; or bipolar disorderss or manic depression, for example, bipolar | disorder, bipolar Il disorde r and cyclothymic disorder; conduct disorder and disruptive behavior disorder; anxiety disorders, such aus panic disorder with or without agoraphobia, amgoraphobia without history of panic disorder, specific phobias, for example , specific animal phobias, sociaal anxiety disorder, social phobia, fear of flying, obsessive-compulsive disorder, stress disorders, including post-traumatic streass disorder and acute stress disorder, and generalized anxiety disorders; borderline personality disorder; schizophrenia and other psychotic disorders, for example, schizophrenifor m disorders, schizoaffective disorders, delusional disorders, brief psychotic disorders, shared psychotic disorders, psychotic disorders with delusions sor hallucinations, psychotic episodes off anxiety, anxiety associated with psychosis, psychotic mood disorderss such as severe major depressive disorder; mood disorders associated with psychotic disorders such as acuste mania and depression associated wiith bipolar disorder, mood disorders associated with schizophrenia; behavioral disturbances associated with mental retardation, autistic disorder, and conduct disorder. The method comprises administering to a mammal in need of such treatment a therapeutically effective amount of a. compound of formula I, Il, ll, IV, V omr VI, or a pharmaceutically acceptable sa It thereof.

The compounds of the invention are also useful in the treatment of sleep disorders. Sleep disorders are disturbances that affect the ability to fall and/or stay asleep, that involve sleegping too much, or that result in abnorsmal behavior associated with sleep. The disorders include, for example, insomnia, drug-associated sleeplessness, hypersomnia, narcolepsy, slee=p apnea syndromes, parasomnias, restless leg syndrome, jet lag, periodic Bimb movement disorder, and altered sleep architecture.

This invention also provides & method of treating a disorder or condition in a mammal, including a human, the disorder or condition selected from the group consisting of sleep d isorders (e.g., insomnia, drug-associated sleeplessness, REM sleep disorders, hypersomnia, narcolepsy, sleep-wake cycle disorders, sleep apnea syndrcmes, parasomnias, and sleep disord ers associated with shift work and irregular work hours). The method compr ises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of ormula |, I, Il, IV, Vor Vi, ora pharmaceutically acceptable salt theareof.

Compounds of formulas 1, 11, lil, IV, V or VI contain at least one stereogenic (chiral) center and therefore may exist in different enantiomeric and diastereomeric forms. This inveantion includes all stereoisomers, incsluding optical isomers, of the compounds of formula , li, Ill, IV, V or VI. Saemples of the compounds.r nay exist as racemic mixtures, as individual enantiomers and diasterecisomerss, and as mixtures thereof. The invention also inclu-des ali pharmaceutical compositions and methods of treatment defined above that contain or emplowy stereoisomers of the compounds of formula |, 1l, BI, IV, V or

Vi. :

Compournds with one stereogenic center may exist as a race=mic (equimolar) mixture, as a non-equimolar mixture of isomers, and ass pure enantiomers hawing S- or R-stereoconfiguration. Compounds with “two stereogenic centers may exist as a racemic mixture, as & non-equirmolar mixture of isomears, and as pure enantiomers having SS, RR, SR or RS stereoconfiguration. Compounds with three stereogenic centers may exist as a racemic mixtume, as a non-equimolar mixture of isomers, and as goure enantiomers hawing RRR, SSS, SRR, RSS, ASR, SRS, RRS or SSR stereoconfigurattion. Individual isomers may be obtained by knowra methods, such as optical wesolution, optically selective reaction, or chromato graphic separation in the preparation of the final product or its intermediate. Individual enantiomers of fhe compounds of this invention may have advantamges, as compared with &acemic mixtures of these compounds, in the treatrment of various disordews or conditions.

The pressent invention also includes isotopically labeled cormnpounds, which are identical to those recited in formula 1, Il, 11, IV, V, or VI Hut for the fact that one or more atoms are replaced by an atom having an at-omic mass or mass numbear different from the atomic mass or mass number Lisually found in nature . Examples of isotopes that can be incorporated irito compounds of &he present invention include isotopes of hydrogen , carbon, nitrogen, oxyge=n, phosphorous, sulfur, fluorine and chlorine, such as H, 3H, 13, 1G, MC, "=N, 80, 70, ¥'P, 32P, ¥S, "°F, and *C|, respectively.

Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or of said prodrugs which co ntain the aforementioned isotopes and/or other isotopes of other atoms aree within the scope of this invention. Certain isotopically labeled compounds: ©f the present invention, for example those into which radioactive isotopes such as *H armd

CS are incorporated, are useful in drugg and/or substrate tissue distributiora asssays. Tritiated, i.e., °H, and carbon-"14, i.e., '“C, isotopes are particulari=y preaferred for their ease of preparation and detectability. Further, substituti on 5. wit-h heavier isotopes such as deuterium, i.e., *H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labeled compounds of formmula i, Il, Ili, IV, V, or VI of this invention and prodrugs thereof can gernerally be prepared by carrying out the procedures disclosed in the

Schemes and/or in the Examples and Preparations below, by substituting a reamdily available isotopically labeled reagent for a non-isotopically labeled reamgent. : :

Unless otherwise indicated, this disclosure uses definitions provided bel ow. Some of the definitions and forrnulae may include a “-” (dash) to ind icate a bond between atoms or-a po int of attachment to a named or unramed atom or group of atoms. Other definitions and formulae may include an “=” (equal sign) or “=” (identity sign) to indicate a double bond cara trip $e bond, respectively. Certain fonmualae may also include an “** (asterisk) to imdicate a stereogenic (chiral) center. Such formulae may refer to the rac=emate or to individual enantiomers, which may or may not be substantially pur-e.

The term “substituted” when used in connection with a compound, substituent, or moiety, indicates that one or more hydrogen atoms have been rep laced with one or more non-hydroge=n atoms or groups, provided that valeance requirements are met and that a chemically stable compound resauits frorm the substitution.

The term “alkyl” refers to straight chain and branched saturated hydrocarbon groups, generally having & specified number of carbon atomss; i.e.» (Ci-Ce)alkyl refers to an alkyl group having 1, 2, 3, 4, 5, or 6 carbon atomms. Examples of alkyl groups include, without limitation, methyl, ethyl, n- prozpyl, i-propyl, n-butyl, s-butyl, i-butyl, t-butyl, pent-1-yl, pent-2-yl, pent-3—yi,

3-methylbut-1-yl, 3-methyibut-2-yl, 2-methylbut-2-yl, 2,2,2~trimethyleth-1-yl, n- hexyl, 3-ethyibutyl, and the like.

The term “cycloalkyl® refers to saturated monocyclic and bicyclic hydrocarbon rings, generally having a specified number off carbon atoms that comprise the ring; i.e., (Ca-Cs)cycloalkyl refers to a cycloalkyl group having 3, 4, 5, or 6 carbon atoms as ring members. The cycloalkyl ¥nay be attached to a parent group or to a substrate at any ring atom, unless such attachment would violate valence requirements. Likewise, the cycloa tkyl groups may include one or more non-hydrogen substituents unless susch substitution would violate valence requirements. Useful substituents @include, without limitation, alkyl, as defined above, and hydroxy, mercapto, nitro, halogen, and amino.

Examples of monocyclic cycloalkyl groups include , without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. Examples of bicyclic cycloalkyl groups include, without limitation, bicycio[1.1.0Jbutyl, bicyclo[1.1.1]pentyl, bicyclo[2.1.0]pentyl, bicyclo[2.1.1]he=xyl, bicyclo[3.1.0]hexyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.0}hepotyl, bicyclo[3.1.1]heptyl, bicyclof4.1.0Jheptyl, bicyclof2.2.2]oc=tyl, bicyclo[3.2.1]octyl, bicyclof4.1.1}octyl, bicyclo[3.3.0Joctyl , bicycio[4.2.0Joctyl, bicyclo]3.3.1]nonyl, bicyclo[4.2.1]nonyl, bicyclo[4.3.0jnorwyl, bicyclo[3.3.2]decyl, bicyclo[4.2.2]decyl, bicyclo[4.3.1]decyi, bicyclo[4.4.0]decyl, bicyciof3.3.3Jundecyl, bicyclo[4.3.2]uindecyi, bicyclo[4.3.3]dodecyl, and the like.

The term “alkoxy” refers to alkyl-O-, where alkyl iss defined above.

Examples of alkoxy groups include, without limitation, nmethoxy, ethoxy, n- propoxy, i-propoxy, n-butoxy, s-butoxy, 1-butoxy, n-pent oxy, s-pentoxy, and the like. 5

The term “treating” refers to reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or preventing one or more symptoms of such c=ondition or disorder.

The term “treatment,” as used herein, refers to the act ef treating, as “treating” is defined immediately above.

The phrase “leaving group” refers ®o any group that leaves a molecule dumring a fragmentation process, includings substitution reactions, elimirmation resactions, and addition-elimination reactions. Leaving groups may be numcleofugal, in which the group leaves wih a pair of electrons that forrmnerly

SE - se=rved as the bond between the leaving group and the molecule, or m ay be elexctrofugal, in which the group leaves without the pair of electrons. T he abmility of a nucleofugal leaving group to lesave depends on its base stremngth, willth the strongest bases being the pooresst leaving groups. Common numcleofugal leaving groups include nitroge=n (e.g., from diazonium salts), 10 . su Honates (including tosylates, brosylatess, nosylates, and mesylates),- : triflates, nonaflates, tresylates, halide ionss, carboxylate anions, phenol ate iors, and alkoxides. Some stronger base-s, such as NH;- and OH- car be made better leaving groups by treatment wwith an acid. Common electrofugal - leaving groups include the proton, CO,, amd metals. So

The phrase “enantiomeric excess” or “ee” is a measure, for a gi-ven sa mple, of the excess of one enantiomer «over a racemic sample of a chiral co.mpound and is expressed as a percentaage. Enantiomeric excess Iss defined as 100 x (er-1)/ (er + 1), where “er” is th e ratio of the more abundant: "en antiomer to the less abundant enantioner.

The term “enantioselectivity” refers to a given reaction (e.g., - hysdrogenation) that yields more of one ermantiomer than another. :

The phrase “high level of enantiosealectivity” refers to a given reaaction thaat yields product with an ee of at least a_bout 80 %.

The phrase “enantiomerically enric hed” refers to a sample of a =chiral co mpound, which has more of one enantieomer than another. The deggree of : en richment is measured by er or ee. :

The phrase “substantially pure ena_ntiomer” or “substantialty en_antiopure” refers to a sample of an ena ntiomer having an ee of abowmut 90 % or greater.

The phrase “enantiomerically pure™ or “enantiopure” refers toa sample of an enantiomer having an ee of about 99 % or greater.

The phrase “opposite enantiomer” reefers to a molecule that is a nor- superimposable mirror image of a reference molecule, which may be obtained : by inverting all of the stereogenic centers o=f the reference molecule. For example, if the reference molecule has S a_bsolute stereochemical configuration, then the opposite enantiome r has R absolute stereochemical configuration. Likewise, if the reference molecule has S,S absolute stereochemical configuration, then the oppeosite enantiomer has R,R stereochemical configuration, and so on. :

The phrase “pharmaceutically acceptable salts, esters, amides, an d prodrugs” refers to acid or base addition salts, esters, amides, zwitterionic forms, where possible, and prodrugs of claimed and disclosed compounds, which are within the scope of sound medical judgment, suitable for use irm : - -contact with the tissues of patients without undue toxicity, irritation, allergic response, and the like, commensurate withe a reasonable benefit/risk ratic, and effective for their intended use.

Because amino acids are amphoteric, pharmacologically compatibele salts can be salts of appropriate inorganic er organic acids, for example, hydrochloric, sulfuric, phosphoric, acetic, oxalic, lactic, citric, malic, salicylic, malonic, maleic, succinic, and ascorbic. S&arting from corresponding hydroxides or carbonates, salts with alkali smetals or alkaline earth metalss, for example, sodium, potassium, magnesium, or calcium are formed. Salts with - quaternary ammonium ions can also be prespared with, for example, the tetramethyl-ammonium ion.

The effectiveness of an orally admiristered drug is dependent upon the drug's efficient transport across the mucos.al epithelium and its stability ir entero-hepatic circulation. Drugs that are effective after parenteral administration but less effective orally, or whose plasma half-life is consieiered too short, may be chemically modified into a prodrug form.

A prodrug is a drug that has been chemically modified and may be biologically inactive at its site of action, but: which may be degraded or modified by one or more enzymatic or other in vivo processes to the parent bioactive form.

A

This chemically modified drug, or pmrodrug, should have a different pharmacokinetic profile than the parent drug, enabling easier absorption across the mucosal epithelium, better salt formulation, improved solubility, enhanced systemic stability (for an increasse in plasma half-life, for example), and the like. These chemical modificatiorss include, but are not limited to (1) ester or amide derivatives which may be cleaved by, for example, esterases or lipases; (2) peptides, which may be rec-ognized by specific or nonspecific proteinases; (3) derivatives that accumula_te at a site of action through membrane selection of a prodrug form or modified prodrug form; and (4) any combination of (1) to (3). The ester or am ides prodrugs may be derived from the carboxylic acid moiety of the parent drug molecule or from the carboxylic acid moiety or the amine moiety of the par-ent drug molecule, respectively, by known means. In addition, the peptide prodrug may be coupled to the parent drug molecule via amide bond formation wwith the amine or carboxylic acid 16 moiety of the parent drug molecule using lknown techniques.

Current research in animal experimaents has shown that the oral absorption of certain drugs may be increassed by the preparation of “soft” quatemary salts. The quaternary salt is termed a “soft” quaternary salt since, unlike normal quaternary salts, e.g., R-N*@CHa)s, it can release the active drug upon hydrolysis.

Soft quaternary salts have useful p hysical properties compared with . the basic drug or its salts. Water solubility may be increased compared with other salts, such as the hydrochloride, bul more important there may be an increased absorption of the drug from the intestine. Increased absorption is probably due to the fact that the soft quatemary salt has surfactant properties and is capable of forming micelles and un ionized ion pairs with bile acids, etc., which are able to penetrate the intestinal epithelium more effectively. The prodrug, after absorption, is rapidly hydrolyzed with release of the active parent drug. :

Prodrugs of compounds of formula. 1, il, lll, IV, V or VI are included within the scope of this invention. For a dliscussion of prodrugs and soft drugs, see E. Palomino, Drugs of the Futcire 15(4):361-68 (1990). See also,

T. Higuchi and V. Stella, “Pro-drugs as Novel Delivery» Systems,” ACS

Symposi®um Series 14 (1975); E.B. Roche (ed.), Bioreaversible Canmiers in Drug

Design (- 1987); and H. Bundgaar, Design of Prodrugss (1985).

Ceertain of the compounds of the present invertion can exist in unsolvateed forms as well as solvated forms, includingy hydrated forms. In general, the solvated forms, including hydrated formss, are equivalent to unsolvateed forms and are intended to be encompass ed within the scope of the prese=nt invention.

DETAILED DESCRIPTION

The compounds of this invention can be prepared as described below.

In the reaction schemes and discussion that follow, sstructural formulas |, II, Ill,

IV,V, or Vi, and the radicals Ri, Ra, Rs Rs, Rs and Res, unless otherwise indicatecd, are as defined above.

In. some of the reaction schemes and examples below, certain compourds can be prepared using protecting groupss, which prevent undesira_ble chemical reaction at otherwise reactive ssites. Protecting groups may als be used to enhance solubility or otherwise modify physical properties of a compound. For a discussion of prote cting group strategies, a descriptieon of materials and methods for instalfing ard removing protecting - groups, eand a compilation of useful protecting group=s for common functional groups, Encluding amines, carboxylic acids, alcohols, ketones, aldehydes, and } the like, =see T. W. Greene and P.G. Wuts, Protectineg Groups in Organic

Chemistry (1999) and P. Kocienski, Protective Grougpos (2000).

Ina addition, some of the schemes and examples below may omit details of comrmaon reactions, including oxidations, reductiors, and so on, which are known to persons of ordinary skill in the art of organtic chemistry. The details of such rreactions can be found in a number of treatises, including Richard

Larock, aComprehensive Organic Transformations (1 999), and the multi- volume series edited by Michael B. Smith and otherss, Compendium of

Organic Synthetic Methods (1974-2003). Generally, starting materials and reagentss may be obtained from commercial sourcess.

Generally, the chemical transformations described throughout the specification may be carried out usimng substantially stoichiometric amourmts of reactants, though certain reactions mmay benefit from using an excess of ene or more of the reactants. Additionally, many of the reactions disclosed throughout the specification may be- carried out at about RT, but particular reactions may require the use of higgher or lower temperatures, dependin.g on reaction kinetics, yields, and the likee. Furthermore, many of the chemicamli transformations may employ one or more compatible solvents, which depending on the nature of the reac=tants, may be polar protic solvents, [olar aprotic solvents, non-polar solvents, or some combination. Although the- choice of solvent or solvents may influence the reaction rate and yield, smuch solvents are generally considered to be inert (unreactive). Any referencess in the disclosure to a concentration rarnge, a temperature range, a pH ranges, a catalyst loading range, and so on, warhether expressly using the word “rarage” ‘ or not, includes the indicated endpo ints.

Diverse methods exist for the= preparation of chiral and racemic — amino acids. Such methods can be found in Eusebio Juaristi (editor),

Enantioselective Synthesis of g-Amaino Acids (1997).

The methods described below are illustrative of methods that can: be utilized for the preparation of such compounds but are not limiting in scospe.

Method A

TQ

P. O.PG

Roo (AKO) NAC: Ry Ro flo meee J x CC0,PG

Rs R4 R4

Re Rs Rs 1 2 : Aen

H

Ph iv AJ

R,—R. Hydrogenolysis PRC * Np

Rs NH, ~~ Ry CO.PG *\"Rg *

Rj Rs R

CO,PG Rs 3 4 3

Hydrolysis

R

Rg Re Po nm, 5 .

CO,H = chiral center l

The use of chiral amine additions to o,f-unsaturated systems ass a 5 synthetic approach to B-amino acids, as illustrated in Method A above, has been described previously. See, e.q., S. G. Davies et al, J. Chem. Soe.

Chem. Commun. 1153 (1993); S. G. Davies, Synlett 117 (1994); Ishikawa et al, Synlett 1291 (1998); and Hawkims, J. Org. Chem. 51:2820 (1985).

Referring to Method A above, compounds of formula | can be prepared from the corresponding compounds of formula 4, wherein PG represents a suitable ester protecting group that can be wemoved by hydrolysis or hydrogenolysis, using conditions well known to thosse of skill in the art. See T. W. Greene and

P. G. M. Wuts, Protective groups ir organic synthesis (1991) for a detailed description for the formation and reemoval of suitable protecting groups). For example, this reaction can be conducted under hydrolytic conditions by treatment with an appropriate acid, such as hydrochloric acid or sutfuric acid, at a temperature from about room ®&emperature to about the reflux temperature of the reaction mixture, preferably at the reflux temperature, or by treatment with an appropriate inorganic base, such as sodium hydroxide, potassium hydroxide, or lithium hydroxide, preaferably sodium hydroxide, at a temperature from about room temperature to abmout the reflux temperature, preferably at about room temperature. This reaction is preferably carried out using hydrochloric acid at the reflux tempeerature. When PG is t-butyl, however, the reaction is preferably camied out In trifluoroacetic acid (TFA). When PG Is a } basic group, the hydrolysis can be «carried out under basic conditions, using methods well known to those of ski {lin the art, for example, using sodium or potassium hydroxide. _ Compounds of formula 4 cam be prepared from the corresponding . compounds of formula 3 using hydmrogenolysis conditions that are well known to those of skill in the art. For example, this reaction can be carried out by : treating the compounds of formula 3 with a palladium metal catalyst, such as, for example, paliadium hydroxide aen carbon, or palladium on carbon, or with

Raney Nickel, in a solvent such as, for example, methanol, ethanol or tetrahydrofuran, under an atmosph ere of hydrogen (between about 1 and 5 atmospheres of pressure) to give the desired compound of formula 4.

Preferably, the reaction is carried aeut using palladium on carbon in ethanol under about 1 atmosphere of hydrogen.

Compounds of formula 3 cam be prepared by treating the corresponding compounds of formula 2 with an appropriate amine such as

(R)-(+)-N-beanzyl-a-methylbenzylamine, (S)-(-)-N-benzyl— o—methylbe nzylamine after treatment with an appropriate base such as lithium diiso propylamide, n-butyl lithium, or lithium or potassium bis(trimethyBsilyl)amide, in a solvent such as ethyl ether, or, preferably,

tetrahydrofur ran (THF), at a temperature from about —-80=>C to about 25°C, and then adding the appropriate compound of formula 2. Tie stereochemistry about the nitrogen of the amine will determine the stereochemistry about the nitrogen of the final product.

Preferably, this reaction is =carried out using either (R)-(+)-N-benzyl- o-methylbenzylamine, (S)-(-)-N- benzyl- a-

methylbenzyrlamine, after deprotonation with n-butyl-lithimum in tetrahydrofuran, at a temperature of about -78 °C, according to method described by S.

D.

Bull etal, J.

Chem.

Soc., Perkin Trans. 122:2931-38 (2001)». Preferably, this reaction is carried out using either (R)-(+)-N-benzyl- a-rrmethylbenzylamine, or (S)-(-)-N-berazyl- a-methylbenzylamine, after deprotonation with n-butyl-lithium in tetrahydrofuran, at a temperature of about -78 °C, according to method described by” S.

D.

Bull et al., J.

Chem.

Soc., Perkin Trams. 122:2931-38 (2001).

: Comprounds of formula 2 can be prepared from ttme corresponding compounds of formula 1 by treating them with an appropriate phosphonate ester in the peresence of a suitable base such as sodium hydride, lithium diisopropylarnide, or tristhyl amine and either lithium chieoride or lithium bromide, in aa solvent such as ether or THF.

Preferably, the compound of formula 1 is reacted with a phosphonate ester (ALK = mesthyl, ethyl, isopropyl, benzyl or the like) in the presence of lithium bromide and triethylamine in tetrahydrofuran at about room temperature.

Compoundss of formula 1 can be prepared frormn commercially available materials using m-ethods well known to those of skill inthe art.

It will be appreciated that compawunds of formula | may possess one or more stereogenic centers.

Using the ab=ove-described method, com pounds with specific stereochemical configmurations can be : prepared.

Compounds that can be made by this me ethod include, but are not limited to the following: 3-Amino-4,5-dimethyl-hexanoic acid; 3-Amino-4,5-dimethyl-heptanoic acid;

3-Amino-4,5-dimethyl-octanoic acid; 3-Amino-4,5-dimethyl-nonanoic acid; 3-Amino-4-ethyl-5-methyl-heptanoic acid; 3-Amino-4-ethyl-5-methyl-octanoic acidz : 3-Amino-4-ethyl-5-methyi-nonanoic acicl;

3-Amino-4-ethyl-5,6-dimethyl-heptanoic acid; 3-Amino-4-ethyl-5,7-dimethyl-octanoic acid; 3-Amino-4-ethyl-5,8-dimethyl-nonanoic acid; (3R,4R)-3-Amino-4,5-dimethyl-hexanoic acid; (3R.4R,5R)-3-Amino-4,5-dimethyl-heptaanoic acid; ’

(3R,4R,5R)-3-Amino-4,5-dimethyl-octaroic acid; (3R,4R,5R)-3-Amino-4,5-dimethyl-nona noic acid; (3R,4R,5R)-3-Amino-4,5-dimethyt- decaanoic acid; 3-Amino-4,6-dimethyl-heptanoic acid; 3-Amino-4,6-dimethyl-octanoic acid;

3-Amino-4,6-dimethyl-nonanoic acid;

~ 3-Amino-4,6-dimethyl-decanoic acid;

oo 3-Amino-4,6,7-trimethyl-octanoic acid; 3-Amino-4,6,8-trimethyl-nonanoic acid; 3-Amino-4,6,9-trimethyl-decanoic acid,

3-Amino-6-cyclopropyl-4-methyl-heptarsoic acid; } 3-Amino-6-cyclobutyl-4-methyl-heptanaeic acid; 3-Amino-8-cyclopentyi-4-methyl-heptarmoic acid; 3-Amino-6-cyciohexyl-4-methyl-heptanoic acid; 3-Amino-7-cyclopropyl-4,6-dimethyl-hegptanoic acid;

3-Amino-7-cyclobutyl-4,6-dimethyl-hep&anoic acid; 3-Amino-7-cyclopentyl-4,6-dimethyl-hepotanoic acid; 3-Amino-7-cyclohexyi-4,6-dimethyl-hep-~tanoic acid;

3-_Amino-8-cyclopropyl-4,6-dimethyl-oct-anoic acid; 3—Amino-8-cyclobutyl-4,6-dimethyl-octa noic acid; 3—Amino-8-cyclopentyl-4,6-dimethyl-oct-anoic acid;

3—Amino-8-cyclohexyl-4,6-dimethyl-octeanoic acid; 5 . 3—Amino-6-(3-chioro-phenyl)-4-methyl-ieptanoic acid; 3— Amino-6-(3,4-dichioro-phenyl)-4-metiyi-heptanoic acid; 3— Amino-4-methyl-6-(3-trifluoromethyl-phenyl)-heptanoic acid; 3— Amino-4-methyl-6-(4-trifluoromethyl-ohenyl)-heptanoic acid; 3—Amino-7-(3-chioro-phenyl)-4,6-dimetiyl-heptanoic acid;

“3—Amino-7-(3,4-dichloro-phenyl)-4,6-dirnethyl-heptanoic acid; 3—Amino-4,6-dimethyl-7-(3-trifluorometiyl-phenyl)-heptancic acid; . , 3~— Amino-4,6-dimethyl-7-(4-trifluorometiyl-phenyl)-heptanoic acid;

. : 3—Amino-8-(3-chloro-phenyl)-4,6-dimetlhyl-octanoic acid; 3—Amino-8-(3,4-dichloro-phenyl)-4,6-diamethyl-octanoic acid; 3—Amino-4,6-dimethyl-8-(3-trifluorometiihyl-phenyl)-octancic acid; 3—Amino-4,6-dimethyl-8-(4-trifluorometiinyl-phenyl)-octanoic acid; 3—Amino-4-ethyl-6-methyl-octanoic acicl; 3—Amino-4-ethyl-6-methyi-nonanoic acid; 3—Amino-4-ethyl-6-methyl-decanocic acid;

3—Amino-4-ethyl-6,7-dimethyl-octanoic acid; 3—Amino-4-ethyl-6,8-dimethyl-nonanoics acid; 3—Amino-4-ethyl-6,9-dimethyl-decanoic acid;

: 3—Amino-6-cyclopropyl-4-ethyl-heptanoic acid; 3—Amino-6-cyclobutyl-4-ethyl-heptanoiec acid;

3 -Amino-6-cyclopentyl-4-ethyl-heptanOic acid;

3 -Amino-6-cyclohexyl-4-ethyl-heptano-ic acid; : 3.-Amino-7-cyclopropyl-4-ethyl-6-meth=yl-heptanoic acid; 3s-Amino-7-cyclobutyl-4-ethyl-6-methyli-heptanoic acid; 3s-Amino-7-cyclopentyl-4-ethyl-6-meth=yl-heptanoic acid;

3=-Amino-7-cyclohexyl-4-ethyl-6-methywi-heptanoic acid;

33 -Amino-8-cyclopropyl-4-ethyl-6-meth yl-octanoic acid; -Amino-8-cyclobutyi-4-ethyl-6-methyl-octanoic acid;

3-Amino-8-cyclopertyl-4-ethyl-6-methyl-octanoic acid; 3-Amino-8-cyclohexxyl-4-ethyl-6-methyl-octanoic acid; 3-Amino-6-(3-chloro-phenyl)-4-ethyl-heptancic acid; 3-Amino-6-(3,4-dichloro-phenyl)-4-ethyl-heptanoic acid;

: 3-Amino-4-ethyl-6-( 3-trifluoromethyl-phenyl)-heptanoic acidz 3-Amino-4-ethyl-6-( 4-trifluoromethyl-phenyl)-heptanoic acidg 3-Amino-7-(3-chloro-phenyl)-4-ethyl-6-methyi-heptanoic acied; 3-Amino-7-(3,4-dictloro-phenyl)-4-ethyl-6-methyl-heptanoic acid; 3-Amino-4-ethyl-6-rmethyl-7-(3-trifluoromethyl-phenyl)-hepta_noic acid;

3-Amino-4-ethyl-6-rnethyl-7-(4-trifluoromethyl-phenyl)-hepta. noic acid; 3-Amino-8-(3-chloro-phenyl)-4-ethyl-6-methyl-octanoic acidz 3-Amino-8-(3,4-dicheloro-phenyl)-4-ethyl-6-methyl-octanoic aacid;

3-Amino-4-ethyl-6-rmethyl-8-(3-trifluoromethyi-phenyl)-octan cic acid; and

3-Amino-4-ethyl-6-nnethyl-8-(4-trifluoromethyl-phenyl)-octan cic acid.

—7 2

Method B

Ray >< Z00sH

R R

2 "Re

X

HN™ © | : =

Ph 6 oO 0 oO O

R R R R

—_—

Rf Ai Re * * Co Rs Ry Rs, * / PGO,C” ;

Ph P*h 7 8 oe

R R R

Row ><e-NHCO.R; ~~ DPPA, al cohol Roe >< 15COH

R:™ Ri| Rs ) R:™ "Ry | Rs :

CO.PG CO,PG 9 ee

Rs Ry Rs NH, * = chiral center *

Rz R, Re

CO,H

The diastereoselective alkylatior of imides such as those of formula 7 to afford chiral succinate analogs such as those of formula 8 has been previously described as an approach to preparing f-amino acids. See. e.g.,

Evans et al, J. Org. Chem. 64.6411 (12399); Sibi and Deshpande, J. Clmem. :

Soc. Perkin Trans 1 1461 (2000); and sArvanitis et al, J. Chem. Soc. Perkin

Trans 1521 (1998).

Compounds of formula 8 can be= prepared from compounds of fcomula 7 in the presence of a suitably derived -ester (PG as defined above, LG: =Bror 1 or CI) such as, for example, t-butyl brcomoacetate, benzyl bromoaceta.te with an organometallic base such as, for example, lithium diisopropylamide or lithium bis(trimethylsilyl)amide or sodiu mn bis(trimethyisilyl)amide and the like in a solvent such as, for example, tetra hydrofuran, ether, and the like. The reaction can be carried out using sodiu m bis(trimethylsilyl)amide in tetrahydrofuran at -78°C and treatment: of the resultant anion intermediate with t-butyl bromoacetate at -78°C to -30°C.

Compounds of formula 9 can be= prepared by hydrolyzing the corresponding compounds of formula 8 in the presence of lithium hydreoxide and hydrogen peroxide in a solvent such as water or THF, at a temper=ature from about 0°C to about room temperature. Preferably, this reaction iss carried out using hydrogen peroxide and lithiurn hydroxide in aqueous tetrahydrofuran at about 0°C according to the method described in the literature. See P.-

W. Yuen et al., Bioorganic and Medicirmal Chem. Left. 4(6):823-26 (1994).

Treatment of the compound of fomula 9 with diphenylphosphor-ylazide - (DPPA) followed by treatment with a suitable alcohol such as t-butanoll, benzyl alcohol or p-methoxybenzyl alcohol, in a suitable solvent such as tolueane, benzene, MTBE, or THF, at a temperafture from about 50°C to about the reflux temperature of the reaction mixture yie ids the corresponding compourad of formula 10, wherein Ry is methyl, ethyl, t-butyl, benzyl, or p-methoxybeanzy!.

R; is dependent on the choice of the akicohol used. Preferably, this reaction is carried out using a toluene solvent in the presence of p-methoxybenzye! alcoho! under refluxing conditions.

Compounds of formula 10 can be conve=rted into the desired compounds of formula | by hydrolysis or hydroggenolysis, using conditions well known to those of skill in the art. See T. W. Greene and P. G. M. Wuts,

Protective groups in organic synthesis (1991) feor a detailed description for the formation and removal of suitable protecting greoups. For example, this reaction can be conducted under hydrolytic corditions by treatment with an appropriate acid, such as hydrochloric acid or sulfuric acid, at a‘temperature from about room temperature to about the refit x temperature of the reaction mixture, preferably at the reflux temperature, ow by treatment with an appropriate inorganic base, such as sodium hyedroxide, potassium hydroxide, or lithium hydroxide, preferably sodium hydroxide, at a temperature from about room temperature to about the reflux tenmperature, preferably at about room temperature. This reaction is preferably carried out using hydrochloric : acid at the reflux temperature. When PG is t-butyl, however, the reaction is preferably carried out in trifluoroacetic acid (TF#A). When PG is a basic group, the hydrolysis can be carried out under basic conditions, using methods well known to those of skill in the art, for example, u sing sodium or potassium hydroxide.

Compounds of formula 7 can be preparesd by treating the corresponding compounds of formula 5 with an amine base such as } triethylamine, in the presence of trimethylacetyl«chloride, in an ethereal solvent such as THF, and then treating the intermediateas formed by this reaction (in situ) with a chiral oxazolidinone of formula 6. E xamples of other oxazolidinones that can be used in this method are: (4S)-(-)-4-isopropyl-2- oxazolidinone; (S)-(-}-4-benzyl-2-oxazolidinone 5 (4S,5R)-(-)-4-methyl-5- phenyl-2-oxazolidinone; (R)-(+)~4-benzyl-2-oxazzclidinone, (S)-(+)-4-phenyl-2- oxazolidinone; (R)-(-)-4-phenyl-2-oxazolidinone-; (R)-4-isopropyl-2- oxazolidinone; and (4R,5S)-(+)-4-methyl-5-phernyl-2-oxazolidinone)) and lithium chloride. Preferably, this reaction is carried out by treating an acid of formula 5 with trimethylacetylchloride and triethylamine in tetrahydrofuran at about -20°C, followed by treatment of the intermediate formed in such reaction with an oxazolidinone of formula 6 and lithium chloride at about room temperature- according to literature procedures. See G.-J. Ho and

D. J. Mathre=, J. Org. Chem. 60:2271-73 (19957).

Altermatively, compounds of formula 7 c=an be prepared by treating the correspondirg compounds of formula 6 with arn acid chloride derived from treatment of the corresponding compound of fcarmula 5 with oxalyl chloride, in a solvent suczh as dichloromethane, in the pressence of dimethylformamide (DMF). Acid s of formula 5 can be prepared fromm commercially available ) materials usi ng methods well known to those o»f skill in the art. These acids may possesss one or more stereogenic centers _

Alternatively, referring to Method C below, compounds of formula 8 can be treated wilth an appropriate acid (for exampl e, trifluoroacetic acid (TFA) when the t-butyl ester is used) to yield the corresponding compounds of } formula 12, which can then be subjected to a CSurtius rearrangement (where . Ryis defined aas above) to yield the corresponding compounds of formula 13.

See Arvanitis et al, J. Chem. Soc. Perkin Transs 1521 (1998) for a description of this approa_ch. Further hydrolysis of the imid e group yields the corresponding compound of formula 14; hydrolwysis of the resulting carbamate group in formula 14 gives the desired B-amino acids of formula V.

Composunds of formula 13 may be conveerted to compounds of formula 14 in @& manner similar to the method fosr converting compounds of formula 8 into compounds of formula 8 (Method® B). Furthermore, compounds of formula 14 Emay be converted to compounds =of formula Il through treatment S with a strong &acid, such as hydrochloric acid or the like, or a strong bass, such as sodiurm or potassium hydroxide or, if R= is benzyl or p-methoxybenzyl, through hygrocgenolytic conditions, using palladi um on carbon in ethanol or

THF under a h ydrogen atmosphere. This apprcaach; which preserves the stereochemistry about the stereogenic center in the compounds of formula 8 and formula ll, is utilized in Example 4 below.

Method C

Ry. Rs J hi : Ry Rs 1

Rs “no Hydrolysis Ra Ks N —_—

Rs R, + Rs R4 > 8 12 . DPPA, R;OH

Oo O

R R Rs Rs

Ra~ >< ~CO-H Hydrolysis Rs . Ro ————————

Rs Ry : ’ Rs R;

NHCO,R VARY

OaR, R;O0,CHN y e 14 13

Hydrolysis * = chiral center

Ra Ras, Fs CO,H : Rs R;, - :

NH, v

Other alternative approaches to synthesizing a-substituted f-amino acids that can be utilized for prep aring the compounds of this invention. See, e.g., Juaristi et al., Tetrahedron Ausymm. 7(8):2233 (1996); Seebach et al.,

Eur. J. Org. Chem. 335 (1999); N agula et al., Org, Lett, 2:3527 (2000);

Arvanitis et al., J. Chem. Soc. Pearkin Trans 1 521 (1998); and Hintermann et al., Helv. Chim. Acta 81:2093 (1998), as shown in Method D below.

Method D o O o O

Re~ Ps TiCl, / IPrNEY Re Rs

Rg 4 2 . * 0 — 0

Rs Ry +H: A H : R3 Ry ya : Ph On “CO,PG PGOCHN Ph 7 13 1. LIOOH 2.H,, Pd/C & Ps co.H

RS Py

NH

\'

T he use of chiral sulfimines to afford B-am ino acids, as illustrated in

Method E below, has been described previously. See, e.g., T. P. Tang and

J. A. Ellman, J. Org. Chem. 64:12-13 (1999); Dawis and McCoull, J. Org.

Chem. 654:3396-97 (1999), and Davis et al., J. Org. Chem. 64:1403-06 (1999).

Method E 0 0

Ry Rs HN pg Re Rs Arr ot § 2Me

Ron XO 16 Ai PNA « Re 18 Sn

R2 Ry Re Ry “RRs O base Ra S—Re oO 15 17 19 acid hydrolysis

Rs Rs

Ra NH,

The final step in the above scheme (Rs = t-butyl or p-tolyl, Rg =a suitably derived ester such as nmethyl, ethyl or t-butyl) is a hydrolysis of both the sulfonamide and ester groupos of a compound of formula 19 to give a compound of formula |. This reaaction is generally carried out using a sitrong acid such as trifluoroacetic acid, hydrochloric acid, hydrobromic acid or- sulfuric acid, in a solvent such aus water or dioxane or a mixture of watesr and dioxane, at a temperature from zabout 20°C to about 100°C, preferably -at about room temperature. The reeaction may be carried out by treating compounds of formula 19 with aan acid such as TFA in a solvent such eas methanol then treating the product with TFA in a solvent such as dichloromethane to give a compeound of formula I.

Compounds that can be nade by this method include, but are nost limited to the following: 3-Amino-4,5-dimethyi-hex anoic acid; 3-Amino-4,5-dimethyl-hep=tanoic acid; 3-Amino-4,5-dimethyl-octaanoic acid; 3-Amino-4,5-dimethyl-non anoic acid; 3-Amino-4-ethyl-5-methyl—heptanoic acid; 3-Amino-4-ethyl-5-methyl—octanoic acid;

3-Amino-4-ethyl-5-methyl-norianoic acid; 3-Amino-4-ethyl-5-methyl- de=canoic acid; 3-Amino-4-ethyl-5,6-dimethyl—heptanoic acid; 3-Amino-4-ethyl-5,7-dimethyl—octanoic acid;

3-Amino-4,5-diethyl-nonanoic= acid; 3-Amino-5-ethyl-4,7-dimethyl—octanoic acid; : 3-Amino-5-ethyl-4,8-dimethyl—nonanoic acid; 3-Amino-4,5-diethyl-6-methyl—heptanoic acid; 3-Amino-4,5-diethyl-7-methyl—octanoic acid;

3-Amino-4,5-diethyl-8-methyl—nonanoic acid;

3-Amino-4,5,6-trimethyl-heptamnoic acid; 3-Amino-4,5,7-trimethyl-octarmoic acid,” 3-Amino-4,5,8-trimethyl-nonamnoic acid; 3-Amino-4-ethyl-5-methyl-hexcanoic acid;

20. 3-Amino-5-ethyl-4-methyl-octaanoic acid; 3-Amino-5-ethyl-4-methyl-hepetanoic acid; 3-Amino-4-methyl-5-propyl-oc=tanoic acid;

3-Amino-6-cyclopentyi-4,5-dirmnethyl-hexanoic acid; 3-Amino-7-cyclopentyl-4,5-dinmethyl-heptanoic acid;

3-Amino-5-ethyl-4,6-dimethyl--heptanoic acid; 3-Amino-5-ethyi-4,7-dimethyl- octanoic acid; 3-Amino-5-ethyl-4,8-dimethyl- nonanoic acid; (3R,4R)-3-Amino-4,5-dimethy J-hexanoic acid;

(3R,4R,5R)-3-Amino-4,5-dimesthyl-heptanoic acid;

(3R.4R,5R)-3-Amino-4,5-dimeathyl-octanoic acid;

(3R4R 5R)-3-Amina-4,5-dime=thyl-nonanoic acid; (3R,4R,5R)-3-Amino-4,5-dime=thyi- decanoic acid;

3-Amino-5-cyclopropyl-4-ethyl-hexarsoic acid; 3-Amino-6-cyciopropyl-4-ethyl-5-met hyl-hexanoic acid; 3-Amino-5-cyclobutyl-4-ethyl-hexanoeic acid; 3-Amino-6-cyclobutyl-4-sthyl-5-methyl-hexanoic acid;

3-Amino-5-cyclopentyl-4-methyl-hexaanoic acid; 3-Amino-6-cyclopentyl-4-ethyl-5-metlhyl-hexanoic acid; 3-Amino-5-cyclohexyl-4-ethyl-hexanoic acid; 3-Amino-6-cyciohexyl-4-ethyl-5-meth yl-hexanoic acid; 3-Amino-5-cyclopropyl-4-methyl-hexanoic acid;

: 3-Amino-8-cyclopropyi-4,5-dimethyl-exanoic acid;

} 3-Amino-5-cyclobutyl-4-methyl-hexaroic acid;

3-Amino-6-cyclobutyl-4,5-dimethyl-hexanoic acid; . 8-Amino-5-cyciopentyl-4-methyl-hexaanoic acid; 3-Amino-6-cyclopentyi-4,5-dimethyi-taexanoic acid;

3-Amino-5-cyclohexyl-4-methyl-hexaroic acid; 3-Amino-6-cyciohexyl-4,5-dimethyl-hexanoic acid; 3-Amino-8-cyclohexyl-4,5-dimethyl-octanoic acid; 3-Amino-8-cyclohexyl-4,5-dimethyl-octanoic acid;

3-Amino~4,6-dimethyl-heptanoic acids

3-Amino-~4,6-dimethyl-octanoic acid;

3-Amino-4,6-dimethyl-nonanoic acid; 3-Amino-4,6-dimethyl-decanoic acid; 3-Amino-4,6,7-trimethyl-octanoic acid ; 3-Amino-4,6,8-trimethyl-nonanoic acicl;

3-Amino-4.6,9-trimethyl-decanoic acid; 3-Amino-6-cyclopropyl-4-methyl-heptaanoic acid; 3-Amino-6-cyclobutyl-4-methyl-heptaroic acid; 3-Amino-6-cyclopentyi-4-methyl-heptaanoic acid; 3-Amino-6-cyclohexyl-4-methyl-hepta noic acid;

3-Amino-7-cyclopropyl-4,6-dimethyl-h eptanoic acid; 3-Amino-7-cyclobutyl-4,6-dimethyi-hegotanoic acid; 3-Amino-7-cyclopentyl-4,6-dimethyl-heptanoic acid;

WOCD 2005/030700 PCT/1B2004/002985 3-Amino-7-cyclohexyl-4,6-dimethyl -heptanoic acid; 3-Amino-8-cyclopropyl-4,6-dimethywl-octanoic acid; 3-Amino-8-cyclobutyl4,6-dimethyl—octanoic acid; 3-Amino-8-cyclopentyl-4,6-dimethyel-octanoic acid;

3-Amino-8-cyclohexyl-4,6-dimethyl -octanoic acid; 3-Amino-6-(3-chloro-phenyl)-4-methyl-heptanoic acid; 3-Amino-6-(3,4-dichloro-phenyl)-4- methyl-heptanoic acid; 3-Amino-4-methyl-6-(3-trifluoromet-hyl-phenyl)-heptanoic acid; 3-Amino-4-methyl-6-(4-trifluorometlhyl-phenyl)-heptanoic acid;

10 .. . 3-Amino-7-(3-chloro-phenyl)-4,6-dimmethyi-heptanoic acid; 3-Amino-7-(3,4-dichloro-phenyl)-4,&-dimethyl-heptanoic acid; 3-Amino-4,6-dimethyl-7-(3-trifluorommethyl-phenyl)-heptanoic acid; 3-Amino-4,6-dimethyi-7-(4-trifluorommethyi-phenyl)-heptanoic acid; 3-Amino-8-(3-chloro-phenyl)-4,6-dimmethyl-octanoic acid;

3-Amino-8-(3,4-dichloro-phenyl)-4, E-dimethyl-octanoic acid; 3-Amino-4,6-dimethyl-8-(3-trifluorornethyl-phenyl)-octanoic acid; 3-Amino-4,6-dimsthyl-8-(4-trifluorormethyl-phenyl)-octanoic acid; 3-Amino-4-ethyl-6-methyl-octanoic acid, 3-Amino-4-sethyl-6-methyl-nonanoic= acid;

3-Amino-4-ethyl-6-methyl-decanoic= acid; 3-Amino-4-ethyl-6,7-dimethyl-octarmoic acid; 3-Amino-4-ethyl-6,8-dimethyl-nonamoic acid; 3-Amino-4-ethyl-6,9-dimethyl-decaroic acid; 3-Amino-6-cyclopropyl-4-ethyl-hept -anoic acid;

3-Amino-6-cyclobutyl-4-ethyl-heptamnoic acid; 3-Amino-6-cyclopentyi-4-ethyl-heptaanoic acid; 3-Amino-6-cyclohexyl-4-ethyl-heptaanoic acid; 3-Amino-7-cyclopropyl-4-ethyl-6-meathyl-heptanoic acid; 3-Amino-7-cyclobutyl-4-ethyl-6-met. hyl-heptanoic acid;

3-Amino-7-cyclopentyl-4-ethyi-6-mexthyl-heptanoic acid; 3-Amino-7-cyclohexyl-4-ethyl-6-me®hyl-heptanoic acid; 3-Amino-8-cyclopropyl-4-ethyl-6-meathyl-octanoic acid;

3-Amino-8-cyclobutyi-4-ethyl-6-methyl-octanoic acid; 3-Amino-8-cyclopentyl-4-ethyl-6-methyl-octanoic acid; 3-Amino-8-cyclohexyl-4-ethyl-6-methyl-octanoic acid; 3-Amino-6-(3-chloro-phenyl)-4-ethyl-heptanoic acid; 3-Amino-6-(3,4-dichlo ro-phenyi)-4-ethyi-heptanoic acid; 3-Amino-4-ethyl-6-(3-trifluoromethyl-phenyl)-heptanoic acid; 3-Amino-4-ethyl-6-(4-trifluoromethyl-phenyl)-heptanoic acid; 3-Amino-7-(3-chloro-phenyl)-4-ethyl-6-methyl-heptanoic acid; 3-Amino-7-(3,4-dichloro-phenyl)-4-ethyl-6-methyl-heptanoic acidF; =10 3-Amino-4-ethyl-6-methyl-7-(3-trifluoromethyl-phenyl)-heptanoic acid; 3-Amino-4-ethyl-6-methyl-7-(4-trifluoromethyl-phenyl)-heptanoic acid; 3-Amino-8-(3-chloro-phenyl)-4-ethyl-6-methyl-octanoic acid; 3-Amino-8-(3,4-dichloro-phenyi)-4-ethyl-6-methyl-octanoic acid; 3-Amino-4-ethyl-6-methyl-8-(3-triflucromethyl-phenyl)-octanoic a_cid; u5 and 3-Amino-4-ethyl-6-methyi-8-(4-trifluoromethyi-phenyl)-octanoic a_cid.

Method F 0

Ry ~ by " . Rs Rs

HAL SR base YK 1 Hydrolysis oa ak

Re Pw Rp Ps RZ Py

Ry Ps 0 A NH, 1) + 07 Ry v > 22 *=chiliral center

Prue 21 : 20 + The synthesis of B-amino acids of formula V via the enantioselec=tive alkylation of enantiopure 1-substituted-2-tert-butyl-3- methylperhydropyrimidine-4-one 21, as illustrated by Method F above, Fas been described previously. See, e.g., E. Juaristi, et al., Tetrahedron:

Asymmetry 7:2233 (1996) and references cited therein. Referring to

Method F above, compounds of formula 22 can be orepared from corresponding compounds of formula 20 (HAL = Br , |, Cl or another suitable leavring group), wherein Ry represents a phenyl or rmethoxy group, preferably a methoxy group. The hydrolysis can be conducted under acidic conditions in a sexaled tube, at reflux, or in a microwave. For insteance, the method utilizing 6N BHC in a sealed tube heated at 90-100°C for 8 hr— is described by E. Juaristi et all, Tetrahedron: Asymmetry 7:2233 (1996). Othesr preferred methods include heating a solution of compound 22 in a 1:1 ranixture of dioxane:6N HCI ina microwave for 1-3 hrs or at reflux for several days to give a compound of formmula V.

Compounds of formula 22 can be prepared freom the corresponding comppounds of formula 20 by treating them with an agppropriate perh-ydropyrimidine-4-one of formula 21 after deprotonation with an appr=cpriate base such as lithium diisopropylamide omr lithium or sodium bis(trrimethylsilyl)amide, in a solvent such as ethyl eter, or, preferably, tetrabhydrofuran (THF), at a temperature from about —80°C to about 0°C, and then adding the appropriate compound of formula 20=. The stereochemistry of the C5 center arises from approach of the electrophil e from the opposite face of the enolate from the sterically congested axial disposition of the tert-butyl group at C2. Preferably, the compound 22 is prepared by the reaction of electmrophiles 20 with compounds of formula 21, whickn have been deprotonated at —-78°C with sodium bis(trimethylsilyl)aamide in THF, at —=78°C to —1a0°C. The synthesis of enantiopure compound 2 1 (Ry, = Ph) from L- aspar—agine is described by E. Juaristi et al., Tetrahecdron: Asymmetry 7:2233 (19968).

Method G 1. (+)- or (-)-pseudoephedrine, . pd chloride; oH ad ot LEE HNP op : 2, HCl, MeOH, H,0 oO 23 24

Ry

HAL, Lop,

R{ Rg ° 20

LIHMDS, LiCl; :

THF :

HOC Pe le Rs oo HO, refiux A i --— RTRs, OH

Yeon wt Neen

HxN Oo \' 25 * = chiral center

In a like manner, Method G shows the synthesis of a-substitutted, §- amino acids of formula V via the enantioselective alkylation of enanti opure 3- amino-N-(2-hydroxy-1-methyi-2-phenyi-ethyl)-N-methyl-propionamide (formula 24). See, G. Nagwla et al., Organic Letters 2:3527-29 (2000). The method includes alkylation of compound 24 using an appropriate alkwlating agent 20, where HAL in formula 20 is Br, |, Cl or another suitable leawing group. The enolate alkylation is carried out in a polar aprotic solvent (THF) with excess LiCl at a temperature of about -5°C to about 0°C using a hindered base (e.g., lithium hexamethyldisilazide, lithium diisopropylamide, etc.) that is sufficiently strong to deprotonate the a-carbon of formula 24. Hydrolwsis of the resulting alkylated amidle 25 gives the desired B-amino acid of formula V.

The compound of formula 24 is prepared through N-acylation «of a chiral auxiliary, (+)- or (-)-psseudoephedrine, using a mixed anhydride. The mixed antydride is obtained by reacting an N-terminal protectec, 3-amino- propionic acid (e.g., 3-tert-butoxycarbonylamino-propionic acid 223) with trimethyla_cetyl chloride in the presence of tristhylamine in methylene chloride.

Following the coupling reaction, the protecting group is removec via known methods Ce.g., treatment of the resulting Boc-protected amide with HCl and

MeOH) to give the compound of formula 24. See A. Myers et al ., J. Am.

Chem. Somc. 119:656-73 (1997).

Cormnpounds of formula 20 shown in Method F and Metho-d G can be prepared rom commercially available materials using methods well known to those of skill in the art. It will be appreciated that compounds of formula 20 may possess one or more stereogenic centers. Using the above-described method, compounds with specific stereochemical configurations can be prepared.

The- preparation of compounds of this invention that are n ot specifically 15° described &n the foregoing experimental section can be accomplished using combinatiosns of the reactions described above that will be appar-ent to those skilled in the art. :

In each of the reactions discussed or illustrated above, preessure is not critical uniezss otherwise indicated. Pressures from about 0.5 atranospheres to about 5 atranospheres are generally acceptable, and ambient presssure, i.e., about 1 atrenosphere, is preferred as a matter of convenience.

The compounds of formula |, Il, lll, IV, V, and VI, and the Entermediates shown in thee above reaction schemes can be isolated and purified by conventionaal procedures, such as recrystallization or chromatogr-aphic separation.

The . ability of compounds of the present invention to bind ®&o the 026- subunit of aa calcium channel can be determined using the following binding assay. : . The wadioligand binding assay using [3H}-gabapentin and the o25- subunit deri ved from porcine brain tissue was used. See Nicolass S. Gee et al., “The novel anticonvulsant drug, gabapentin (Neurontin), binds to the c25 subunit of a calcium channel,” J. Biol. Chem. 271(10):5768-76 (1996).

Compounds of the invention bind with nanomolar to micromolar affinity for the 023 protein. For example, 2-aminomethyl-5-ethyl-nonanoic acid binds *with 75 nM affinity fo the o26 protein; (S)-3-amino-5-ethyl-3-methyl-heptanoiic acid binds with 149 nM affinity to the 23 protein; and (3S,5R)-3-amino-3,5- dimethyl-heptanoic acid binds with 236 nM affinity to the 028 protein.

The in vivo activity of compounds of this invention can be determined in animal models. For animal models related to hyperalgesia, see, e.g., kK. Sluka : et al., “Unilateral intramuscular injections of acidic saline produce a bila-teral, long-lasting hyperalgesia,” Muscle Nerve 24:37-46 (2001); W. Dixon, “Efficient analysis of experimental observatiosns,” Ann. Rev. Pharmacol. Toxicol. 20:441-62 (1980); L. O. Randall and J. J. Selitto, “A method for measuresment of analgesic activity on inflamed tissue,” Arch. Int. Pharmacodyn 4:409- 19 (1957); K. Hargreaves et al., “A nevv and sensitive method for measurin g thermal nociception in cutaneous hwperalgesia,” Pain 32:77-88 (1988). Fir animal models related to anxiety, see J. R. Vogel et al., “A simple and reliable conflict procedure for testing anti-arxiety agents,” Psychophammacologiaa 21:1- 7 (1971).

The compounds of the preseritinvention, and their pharmaceutica ly acceptable salts, can be administeread to mammals via either the oral, parenteral (such as subcutaneous, irtravenous, intramuscular, intrastemeal and infusion techniques), rectal, buccal o»r intranasal routes. -

The novel compounds of the goresent invention may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by any of the routes previously indicated, and such administration may be camied out in single or multiple doses. Moree particularly, the novel therapeutic acyents of this invention can be administered in a wide variety of different dosage forms; i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, suppositories, jellies, gels, pastes, oixntments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents= or fillers, sterile aqueous media and various non-toxic organic solvents, etc.

Moreover, oral pharmaceutical compositions can be suitably sweetened and/or flavored. In general, the weight ratio of the nov-el compounds of this invention to the pharmaceutically acceptable carrier will Ee in the range from about 1:6 to about 2:1, and preferably from about 1:4 to abosut 1:1.

For oral administration, tablets containirng various excipients such as microcrystalline cellulose, sodium citrate, calcisum carbonate, dicalcium phosphate and glycine may be employed alonag with various disintegrants such as starch (and preferably com, potato or -tapioca starch), alginic acid andit - certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and taic are often very useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules;: preferred materials in this connection also include lactose or milk sugar eas well as high molecular weigh® polyethylene glycols. When aqueous suspens ions and/or elixirs are desired for oral administration, the active ingredient ma&xy be combined with various sweetening or flavoring agents, coloring mattemr or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and \warious like combinations thereof. : : :

For parenteral administration, solutions of a compound of the present invention in either sesame or peanut oil or in asqueous propylene glycol may be employed. The aqueous solutions should koe suitably buffered (preferably pH greater than 8) if necessary and the liquid iluent first rendered isotonic.

These aqueous solutions are suitable for intrawenous injection purposes. Thea oily solutions are suitable for intra-articular, intara-muscular and subcutaneous injection purposes. The preparation of all thes e solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.

For intranasal administration or adminis-tration by inhalation, the novel compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressu rized container or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifiuoromethane, trichlorofluorormethane, dichiorotetrafluoroethan e, carbon dioxide or other suitable gas. In the case of a pressurized aeroso~{, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or n ebulizer may contain a solution o r suspension of the active compound. Ca psules and cartridges (made, for ~— example, from gelatin) for use in an inha ler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch. Formulations of the active —~ compounds of this invention for treatmerat of the conditions referred to above: : in the average adult human are preferably arranged so that each metered dose or “puff” of aerosol contains 20 1g t«<0 1000 xg of active compound. Whe overall daily dose with an aerosol will be within the range 100 ug to 10 mgs.

Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1, 2 or 3 doses each Rime.

The compounds of the present inveention can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, the compounds of the present invention can te administered by injection, that is, intravenously, intramuscularly, intracutanesously, subcutaneously, intraduodenally, or intraperitoneally. Alsos, the compounds of the present invention can be administered by inhalation, for example, intranasally.

Additionally, the compounds of the preset invention can be administered transdermally. It will be obvious to those sskilled in the art that the following dosage forms may comprise as the active component, either a compound «of formulas | to Vi or a corresponding pharm aceutically acceptable salt of such compound.

For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically accepetable carriers can be either solid or #iquid. Solid form preparations include powders, tablets, pills, capsules, «achets, suppositories, and dispersible granules. A solid carrier can be onee or more substances that may also act as diluents, flavoring agents, IDinders, preservatives, tablet disintegraating agents, or an encapsulating mate=rial. In powders, the carrier is a finely” divided solid, which is in a mixture wit h the finely divided active componemt. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable p roportions and compacted in the shape aand size desired.

The powders and tablefts preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magn esium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethyicellulose, alow - melting wax, cocoa butter, andl the like. The term “preparation” is inteended to include the formulation of the aactive compound with encapsulating material as a carrier providing a capsule ire which the active component with or without other carriers, is surrounded byy a carrier, which is thus in associatiors with it.

Similarly, cachets and lozenges are included. Tablets, powders, cap-sules, pills, cachets, and lozenges cam be used as solid dosage forms suita ble for oral administration.

For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa b utter, is first melted and the active cormnponent is dispersed homogeneously th erein, as by stirring. The molten homeogenous mixture is then poured into conwenient sized molds, allowed to cool, and : thereby to solidify.

Liquid form preparations include solutions, suspensions, and emulsions, for example, water ©r water propylene glycol solutions. Feor parenteral injection liquid prepa rations can be formulated in solution in : aqueous polyethylene glycol so lution. Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabi lizing and thickening agents as desire-d.

Aqueous suspensions suitable For oral use can be made by dispersing the finely divided active component in water with viscous material, such aas natural : or synthetic gums, resins, methylcellulose, sodium carboxymethylcelieilose, and other well-known suspendirag agents.

Also inclu«ded are solid form preparations that are intendec to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. Thesse preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

The pharnreaceutical preparation is preferably in unit dosag :e form. In such form the pre paration is subdivided into unit doses containingy appropriate quantities of the active component. The unit dosage form can be a packaged . 10 preparation, the package containing discrete quantities of preparaation, such as packeted tablelts, capsules, and powders in vials or ampoules. Also, the : unit dosage form can be a capsules, tablet, cachet, or lozenge itsea¥, or it can be the appropriate number of any of these in packaged form.

The quantity of active component in a unit dose preparatiorn may be varied or adjusted from 0.01 mg to 1 g according to the particular application and the potency of the active component. In medical use the drugs may be administered three times daily as, for example, capsules of 100 or 300 mg.

The composition caxn, if desired, also contain other compatible therrapeutic agents. : :

In therapeutFc use, the compounds utilized in the pharmaceutical - method of this invemtion are administered at the initial dosage of atoout 0.1 mg to about 1g daily. T he dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosagge for a particular situation iss within the skill of the art. Generally, treatment is initiated with smaller dosage-s that are less than the optimum dose of the coempound.

Thereafter, the dosage is increased by small increments until the ogplimum effect under the circumstances is reached. For convenience, the tootal daily dosage may be divicded and administered in portions during the day, if desired.

The following Examples illustrate the preparation of the compoounds of the present invention. They are not meant to be limiting in scope. Nefelting points are uncosrected. NMR data are reported in parts per million and are referenced to th-e deuterium lock signal from the sampsle solvent.

Example 1 : (4S;5R)-4-Methy/I-3-pentanoyl-5-phenyl-oxazolidin-2-0 -ne

Toa 0°C stirred solution of valeric acid (3.83 mi, 35.2 mmol) and Et;N (14.7 mL, 106 m mol) in dry THF (175 mL) was added ®rimethylacety! chloride : (5.29 mL, 42.3 nmimol) dropwise. The mixture was stirread at 0°C for 1 hour and ©. (4S,5R)-(-)-4-me-thyl-5-phenyl-2-oxazolidinone (7.50 g, 42.3 mmol) was added followed by LiCl €1.79 g, 42.3 mmol). The reaction wass warmed to room : temperature overnight with good stirring. The mixture was filtered and the filtrate was concentrated under reduced pressure. Et (75 mL) was added to the residue, which was washed with sat. NaHCO; (3 x «40 mL), 1N HCI (3 x 40 mL), and brine (2 x40 mL). The organic phase was dried over MgSO, filtered and concentrated under reduced pressure to give a quantitative yield 16 of crude product. (4S,5R)-3~((S)-2-Ethyl-pentanoyl)-4-methyl-5-phenyl-oxcazolidin-2-one

To a -78°C stirred solution of the (4S,5R)-4-Metyl-3-pentanoyl-5- phenyl-oxazolidin—2-one (8.20 g, 35.2 mmol) in dry THF * (150 mL) was added

NaHMDS (42.2 mL, 1.0 M in THF) dropwise. After 1 ho-ur, ethyl trifluoromethanesualfonate (5.93 mL, 45.7 mmol) was adeded dropwise and the reaction was stirre d at -78°C for an additional 2 hours. The reaction was warmed to —30°C For 30 minutes and quenched with sat . NH,Cl. The layers were separated aed the aqueous layer was extracted witth EtOAc (3 x 40 mL).

The organic extracts were combined and washed with b rine (2 x 40 mL). The organic phase was dried over MgSO, filtered, and conc-entrated under reduced pressure to yield 8.05 g of crude product. (S)-2-Ethyl-pentan-1-ol

To a room tesmperature solution of the (4S,5R)-3-C (S)-2-ethyl- pentanoyl)-4-methy-I-5-phenyl-oxazolidin-2-one (8.05 g, 227.8 mmol) in THF

(200 mL) was added a solastion of NaBH, (4.21 g, 111 mmol) in H2O (90 mL).

The reaction was allowed 1o stir overnight at room temperature, was quenched with 2N HCI (75 mL) and the layers were separated. The aqueous layer was extracted with EROAc (4 x 40 mL), and the organic extracts were : combined and washed with brine (2 x 30 mL). The organic phase was dried over MgSO;, fitered and concentrated under reduced pressure. The residue was triturated with n-hexarses (2 x 20 mL) to remove the oxazolidinone side product. After filtering off tFie oxazolidinone, the filtrate was concentrated under reduced pressure to yield 2.56 g of crude product. :

Methanesulfonic acid (S)-2—ethyl-pentyl ester

To a —10°C stirred solution of (S)-2-ethyl-pentan-1-of (1.30 g, 11.2 mmol) in dry CHzCl. (35 mL.) was added Et;N (2.33 mL, 16.8 mmol). The reaction was stirred at this temperature for 15 minutes and methansulfonyl chloride (0.952 mL, 12.3 mrnol) was added. The reaction was allowed to warm to room temperature overnight with good stirring. The reaction was washed with 1N HCI (3 x 30 mL), sat. NaHCO3; (3 x 30 mL), and brine (2 x 30 mL). The organic phase wa.s dried over MgSO, filtered and concentrated under reduced pressure to ggive a quantitative yield of crude product. .. (S)-3-lodomethyl-hexane }

To a stirred solution o»f methanesulfonic acid (S)-2-ethyl-pentyt ester : (2.18 g, 11.2 mmol) in acetome (35 mL) was added Nal (3.36 g, 22.4 mmol) and the reaction was heated to reflux overnight with good stirring. The reaction was allowed to cool to room temperature and the mixture was filtered. The salts were washed with acetone (3 x 15 mL) and H.O (60 mL) was added to the filtrate. Thee aqueous phase was extracted with hexanes (4 x 30 mL) and the organic extwacts were combined and washed with brine (2 x mL). The organic phase wwas dried over MgSO,, filtered and concentrated 30 under reduced pressure. The residue was purified by chromatography using hexanes (100%) to yield 1.24- g (49%) of pure product.

(2S,5R)-2-tert-Butyl-5-((S)-2-ethyl-pentyl)-3-methyl-4-oxo-tetrahydro- pyrimidine-1-carboxylic acid methyl ester

To a —78°C stirred solution of (S)-2-tert-butyl-3-methyl-4-oxo- tetrahydro-pyrimidine-1-carboxylic acid methyl ester (1.04 g, 4.57 mmol) in dry

THF (15 mL) was added NaHMDS (5.03 mL, 1.0 M in THF) dropwise. The reaction was stirred at —78°C for 1 hour and then a solution of (S)-3- lodomethyi-hexane (1.24g, 5.48 mmol) in dry THF (5 mL) was added dropwise. The reaction was stirred at this temperature for 2 hours and than was placed in a —10°C refrigerator owemight. The reaction was quenched with sat. NH,Cl (20 mL) and was allowed to warm to room temperature. The layers were separated and the aqueous layer was extracted with EtOAc (3 x mL). The organic extracts were combined and washed with brine (2 x 15 mL). The organic phase was dried over MgSQ,, filtered and concentrated under reduced pressure. The product was purified by chromatography using 15 hexanes/EtOAc (10->20%) to yield 0.185 g (12%) of pure product. 'H NMR (400 MHz, CDs0D) 3 ppm 0.9 (m, 6 H), 1.3 (m, 5 H), 1.4 (m, 3 H), 1.7 (m, 1

H), 2.5 (m, 1 H), 2.9 (d, J=6.6 Hz, 2 HI). MS: M+1 (328). (2R,4S)-2-Aminomethyl-4-ethyi-hepta noic acid

A stirred solution of (2S,5R)-2-tert-butyl-5-((S)-2-ethyi-pentyl)-3-methyi- 4-oxo-tetrahydro-pyrimidine-1-carboxylic acid methyl ester (0.185 g, 0.567 mmol) in a 1:1 mixture of 6N HCVdioxane (8 mL) was heated at 105°C for 6 days. The reaction was cooled to rooam temperature and concentrated under reduced pressure. The product was dissolved in 1:1 MeOH/H-O and loaded onto an ion exchange chromatography column (Varian SCX-Prepacked 10g, 60 mL) and eluted with 1:1 MeOH/H,O (95%) + NH;OH. The fractions containing product were collected and concentrated under reduced pressure to yield 0.06 g (57%) of product. 'H NMR (400 MHz, CDsOD) § ppm 0.9 (m, 6

H),1.83(m,5H), 1.4 (m,3H) 1.7 (m, 1 H), 2.5 (m, 1 H), 2.9 (d, J=6.6 Hz, 2 H).

MS: M+1 (188).

Using the above methodology the following compounds were also made: .

Compound Name | MS, H NMR, 400 MHz, 5, PPM, CD;0D

TE Jer | ATE (4R)-2-Aminomethyl-4- | 188 09(s,6H), 1 .3(m5H),1.4(m,3 ethyl-heptanoic acid (M+1) H), 1.7 (s, 1 FH), 25 (m, 1 H), 2.9 (d, em on [npn 202 0.9 (d, J66 Fiz, 6H), 0.9 (d, /=66 &2R,4S)-2- (M+1) Hz, 3 H), 1.2 Cm, 4 H), 1.2 (m, 1.H), m\minomethyl-4-7- 1.4(m, 1H), 8.5m, 2H),1.7(m, 1 climethyl-octanoic acid H),25(m, 1 H),29(d, 2H)

C2S,485)-2-Aminomethyl- | 230 2.93(d,2H), 2.-47(5-line

A1-othyl-8- (M+1) m,1H),1.72(m 1H), 1.54(7-line m, ranethylnonanoic acid | 1H), 1.42-1.11 (m,10H), 0.85(d,3H) | - (=2R/S,4S)2- 257 2.93(d,2H), 2.44(5-line m, 1H),

Mminomethyl-8-methyl- | (M+1) 1.72(m, 1H), 1. 55(7-line m,1H), 4--propyl-nonanoic acid 1.44(m,1H), 1.~40-1.10(m, 11H), 0.89(d,3H) (22S,4S)-2-Aminomethyl- | 202 2.93(d, 2H), 2.43 (mM, 1H), 1.71 (m, 4—ethyl-6-methyl- (M+1) 1H), 1.63 (m, 1 H), 1.42 (m, 1 H), © | heeptanoic acid. 1.36 (m, 2H), 1 .22 (m, 1 H), 1.06 (m, 2 H), 0.85 (Mm, S H) (2R,4S)-2- 202 2.89 (d, 2 H), 2.43 (m, 1 H), 1.62 (m,

Amminomethyl-d-ethyk6- | (M+1) | 2H), 1.44 (m, 1 H), 1.34 (m, 1 H), mmethyl-heptanoic acid 1.22 (m, 2 H), 3.12 (m, 1 H), 1.05 (m, 1H), 0.80 Cm, 9 H) (=R4R)-2- 202.1 2.90 (d, 2 H), 2 .43 (m, 1 H), 1.68 (m,

Arninomethyl-4-ethyl-6- | (M+1) 1H), 1.61 (m, B H), 1.42 (m, 1 H), meethyl-heptanoic acid 1.32 (m, 2 H), ®.21 (m, 1 H), 1.11 (m, 2 H), 0.80 (wm, 9 H)

Compeound Name MS, H NMR, 400 MHz, §, PPM, CD;0D

TT J

(2S,4R)-2~ 202 2.94 (d, 2H), 2.23 (m, 1 H), 1.62 (m,

Aminome®hyl-4-ethyl-6- | (M+1) 2 H), 1.44 (mm, 1 H), 1.42 (m, 1 H), methyl-he ptanoic acid 1.22 (m, 2 Hp, 1.13 (m, 1 H), 1.03

Ee

Example 2 (R)-3-((R)-3—~Methyl-hexanoyl)-4-phenyl-oxazolidin-2-cne

To th e copper (1) bromide dimethyisulfide commplex (13.34g, 64.87mmol) in dry THF (150ml) at -30°C under Nitrog en was added a 2M ether solutiosn of Propylmagnesiumchloride (64.87ml, 129.7mmol) and stirred ©. . for20min. (JR)-3-But-2-enoyl-4-phenyl-oxazolidin-2-ore (15.0g, 64.87mmol) in

THF (60m) was added over a 15 min period at -35°C and let slowly warm up to room tempoerature over 4hr. The mixture was coole=d to 0°C and quenched with saturate=d ammonium chloride solution. The suspension was extracted into ether, washed with 5% ammonium hydroxide solution and then with brine and dried oveer MgS04. The solution was concentratead under reduced pressure to amfford the titled compound (13.34g; 100 %-) as a white solid. 'H

NMR (400 MHz, CDCl3) ppm 0.8 (m, 6 H) 1.2 (m, 3H) 1.6 (s, 1 H) 2.0 (m, 1

H) 2.7 (dd, J==16.1, 8.5 Hz, 1 H) 3.0 (dd, &=15.9, 5.4 H=2, 1 H) 4.3 (dd, J=8.9, 3.8Hz, 1 H) 4.7 (t, /=8.9 Hz, 1 H) 5.4 (dd, J=8.8, 3.9 Hz, 1 H) 5.4 (dd, J8.8, 3.9 Hz, 1 H) 7.3 (m, 5 H). MS, m/z (relative intensity): 2276 M+1H, 100%]. (R)-3-((2R,3F®)-2,3-Dimethyl-hexanoyl)-4-phenyl-oxazolidin-2-one

To a 18M THF solution of Sodium hexamethyldis-ylamide (16.2g, 88.3mmol) at -78°C was added via canular a 0°C solut ion of (R)-3-((R)-3- methyl-hexane«oyl)-4-phenyl-oxazolidin-2-one (18.79, 67°.9mmof) in 70ml dry

THF. The ressulting solution was stirred at -78°C for 30- min. Methyl lodide (48.2g, 339.5rmmol) was added and stirring at -78°C waas continued for 4hr. It was quenched with saturated ammonium chloride solution, extracted into

CH.Cl, and waashed with 1M sodium Bisulfite. The solution was dr ied over

MgSO4, conc entrated and Chromatographed in 10% ethylacetate in hexane to give the titieed compound (11.1g, 56.5%) as an oil. MS, m/z (relative intensity): '"H BINMR (400 MHz, CDCls) 5 ppm 0.8 (t,-J=7.0 Hz, 3 H) 0.9 (d, . 5 J=6.6Hz,3H)1.0(d, /=6.8Hz,3H) 1.0 (d, =8.5Hz, 1H) 1.1 (m5 1H) 1.4 (m, 1 H) 1.7 (rn, 1 H) 3.7 (m, 1H) 4.2 (dd, /=8.8, 3.4 Hz, 1 H) 4.6 Ct, 8.7 Hz, 1 H) 5.4 (dd, 8.7, 3.3 Hz, 1 H) 7.2 (m, 2 H) 7.3 (m, 3 H). MS, m/z (relative intensity):290 [M+1H, 100%]. (2R,3R)-2,3-D _imethyl-hexan-1-ol

A 1M THHF solution of LAH (95.9ml, 95.9mmol) was added teo (R)-3- ((2R,3R)-2,3-dllimethyl-hexanoyl)-4-phenyl-oxazolidin-2-one (in THF (300ml) under nitrogens at -78°C and stirred for 3 hr at that temperature. W ater was added dropwisse to quench the excess LAH and then poured into a mixture of ice and ether. The mixture was extracted into ether, washed with wvater and dried over MgS 04. The solution was concentrated followed by the addition of excess hexane=. The resulting white precipitate was filtered and weashed with haxane. The filtrate was concentrated to afford the titled compouned (5.05g, 100%) as an ofl. 'H NMR (400 MHz, CDCl3) 3 ppm 0.8 (m, 9 H) 1.00 (d, J=6.8

Hz, 1 H) 1.1 (ma, 1H) 1.2(m, 3H) 1.6 (m, 2H) 3.4 (m, 1H) 3.6 (m, 1H). (2R,3R)-2,3-Dirnethyl-hexanal

Pyridiniusm chlorochromate (27.35g, 126.9mmol) and neutral alumina (96g, 3.5g per gram of pyridinium chlorochromate) in dry dichlorom=ethane (200ml) was stiared under nitrogen for 0.25hr. (2R,3R)-2,3-Dimethyy+-hexan-1- ol (5.0g, 38.46rmmol) in dichloromethane (60m) was added and thes resulting dark slurry was stirred at room temperature for 3hr. The slurry wass filtered through a short pad of silica eluting with excess dichloromethane.

Evaporation of fhe solvent afforded the titled compound (4.1, 84%) as an oil. 'H NMR (400 MHz, CDCl3) & ppm 0.8 (m, 3 H) 0.9 (d, J=6.6 Hz, 3 +1) 1.0 (d,

J=6.6 Hz, 3H) ¥.2 (m, 4 H) 1.8 (m, 1 H) 2.2 (m, 1 H) 9.6 (s, 1H).

4-Methyl-benzenesuifiinic acid ((2R,3R)-2,3-dimethyl-hexylidene)--amide

Titanium(lV) ssthoxide (5.16g, 22.6mmol) and (S)-(+)-p- toluenesulfinamide(=7.02g, 45.2mmol) were added to (2R,3R)-2,38-dimethyl- hexanal (2.9g, 22.6rnmol) in dry THF (30mi). The resulting mixtuare was stirred at room temperature for 18 hr and poured into a brine soluition (40m).

The slurry was rapidly stirred for 10 minutes and filtered. The filtrate was extracted into ethyl aacetate, washed with brine and dried over MSOs. The solvent was evapora ted and the residue was filtered through a silica plug, eluting with 50/50 so ution of hexane/ethyl acetate to afford the titled compound (3.1g, 51.6%) as an oil. 'H NMR (400 MHz, CDCl3) 8 ppm 0.8 (m," 6H) 1.1 (m, 4H) 1.3 (am, 3H) 1.7 (m, 1 H) 2.4 (s, 3H) 2.5 (m, 1H) #.3 (d, 8.3

Hz, 2 H) 7.5 (d, J=8.% Hz, 2 H) 8.1 (d, J=5.4 Hz, 1 H). MS, nvz (re3lative intensity): 266 [M+1i8, 100%). . (4R,5R)-4,5-Dimethyl—(R)-3-(toluene-4-sulfinylamino)-octanoic acid tert-butyl ester

Butyl lithium (2+6.3ml, 42.04mmol) was added to a solution eof diisopropylamine (4.64, 45.6mmol) in dry THF (40ml) under nitrog-en at 0°C and stirred for 20 minutes. The solution was cooled to -78°C foliowwed by the addition of t-butyl acetate (4.1g, 35.0mmol) and stirred at that temgperature for 45 minutes. Chlorofiteanium triisopropoxide (9.4g, 36.2mmol) was added dropwise and stirring v-vas continued for 30 minutes at -78°C. A -5 0°C solution of 4-methyl-benzenesuilfinic acid ((2R,3R)-2,3-dimethyl-hexylidenee)-amide (3.1g, 11.7mmol) in dry THF (10ml) was added to the reaction andl the resulting mixture was sstirred at -78°C for 4hr. The reaction was queenched with a saturated solution of NaH2PO, and extracted into ethyl acetate. The solution was dried over MgSO, and concentrated. The resulting residue was : chromatographed on silica, eluting with 15% ethyl acetate in hexare to give the titled compound (2.-4g, 53.9%) as white solid. 1H NMR (400 MHz, CDCl)

Sppm 0.9 (m, 6H) 1.0 {d, /=6.6 Hz, 3H)1.1(m, 1H)1.3(m,2H) 14(m,9

H) 1.5 (m, 2H) 2.4 (s,3H) 2.6 (m, 2 H) 3.8 (m, 1H) 4.4 (d, »=10.0 Hz, 1 H) 7.3(d, J=8.1 Hz, 2H) 7.6 (d,J=8.1 Hz, 2 H)e. MS, m/z (relative intensity): 382

M+1H, 100%), 326 [M+1H-C(CHa)s, 50%). (3R.4R, 5R)-3-Amino-4,5-dimethyl-octanoic - acid

To the solution of (4R,5R)-4,5-dimetyl-(R)-3-(toluene-4-sulfinylamino)- octanoic acid tert-butyl ester (1.8g, 4.71mm: ©) in dry methanol (30mi) at 0°C under nitrogen was added excess trifluoroacetic acid (256ml) and stirred for ) 2 hr at that temperature. The solution was concentrated to dryness followed by the addition of dry dichloromethane (20m) and trifluoroacetic acid (20ml).

The resulting mixture was stirred for 2 hr un-der nitrogen and concentrated to dryness. The residue was applied to Bond=lute SCX ion exchange resin and eluted with water until the eluent was at con stant pH of 6.5. The resin was then eluted with a 1:1 solution of methanol and with 10% ammonium hydroxide solution. The ammonium hydroxi=de solution was evaporated and the residue was crystallized with methanol-eacetonitrile mixture to afford the titled compound (0.717g, 81.2%) as a white solid. 'H NMR (400 MHz,

CD30D-D) § ppm 0.9 (m, 11 H) 1.1 (m, 2HP 1.3 (m, 1 H) 1.4 (m, 1 H) 1.6 (m,

CT 1H) 1.7 (m, 2 H) 2.3 (dd, J=16.6, 10.0 Hz, 1 H) 25 (dd, J=16.7, 3.5 Hz, 1 H) 3.3 (m, 1 H). MS, m/z (relative intensity): 1888 [M+1H, 100%], 186 [M-1H, 100%].

Example 3 (S)-4-Methyl-hexan-2-one (2)

The Grignard reagent made from (S)—1-bromo-2-methyl-butane (10 g, 66.2 mmol) and Mg (1.77 g, 72.8 mmol) in EE1,0 (65 ml) was added dropwise io a solution of acetic anhydride (8.1 g, 79.3 mmol) in Et2O (65 ml) at -78°C in : 1 h. Lots of white solid precipitated. The reaction mixture was stirred at -78°C for 1 h. Then the temperature was allowed fo slowly rise to RT. The reaction was quenched with saturated NH,C! agueouus solution (150 mi). The ether phase was washed by 1 N NaOH (150 mi) aznd brine (150 mi). Stripped ether at 0°C. The residual oil was dissolved in hexxane (50 mi). The solution was —g9—

dried by anhydrous Na,SO4 and evaporated at 0°C under reduced pressure to give (S)-4-methyl-hexan-2-one (5.7 g, 75%) as a light orange oil. 'H NBIMR (CDCl3) 52.26 (m, 2H), 2.08 (s, 3H), 1.86 (m; 1H), 1.21 (m, 2H), 0.83 (m, 6H);

MS (APC) (M+1)* 115.0. (S)-2-Methyi-propane-2-sulfinic acid ((3S)-1,3-dimethyl-pentylidene)-amid e.

A mixture of (S)-4-methyl-heexan-2-one (1.6 g, 14 mmol), (S)-2-methhyl- propane-2-sulffinic acid amide (1.7 g, 14 mmol) and titanium(lV) ethoxide (6.4 g, 28 mmol) in THF (30 ml) was refluxed for 10 h. Then the reaction mixtLire was poured into brine (150 mi). The mixture was filtered. The filtrate was extracted by EtOAc (3x70 ml). Strigoped EtOAc. The residue was purified by a silica gel column (Hexane/EtOAc 33:1) to give the titled compound (1.93 g, 63%) as a colorless oil. 'H NMR (CDCls) 62.24 (m, 2H), 2:27 (s, 3H), 1.85 (m, 1H), 1.22 (m, 2H), 1.20(s, 9H), 0.855 (m, 6H); MS (APCI) (M+1)* 218.1. : (38,5 S)-3,5-Dimethyl-3-((S)-2-methyl-propane-2-sulfinylamino)-heptanoic acid methyl ester

To a solution of diisopropyla mine (3.1 ml, 22.2 mmol) in THF (40 mB) at .78°C was added butyllithium (14.4. ml, 1.6 M, 23 mmol) slowly. The mixtusre was stirred at 0°C for 25 min and seabsequently cooled down to —78°C. Methyl acetate (1.76 mi, 22.2 mmol) in THIF (7 ml) was added. After Stirring for 2€0 min, chlorotitaniumtriisopropoxide ( 11 ml, 46.2 mmol) in THF (10 ml) was added and the resulting mixture wa stirred at =78°C for 20 min. (S)-2-

Methyi-propane-2-sulfinic acid ((3S)-1,3-dimethyl-pentylidene)-amide (1.9 +g, 8.9 mmol) in THF (10 ml) was added. The mixture was stirred at ~78°C overnight. The reaction was quencihed by NHC! solution (50 mi). The mixture was filtered. The filtrate wa_s extracted by EtOAc (3x70 ml). Stripped

EtOAc. The residue was purified by a silica gel column (Hexane/EtOAc 1:1) to give the titled compound (1.61 g, 62%) as a colorless oil. "HNMR (CDC Ip) 8 3.64 (s, 3H), 2.60 (m, 2H), 1.47 (m, 2H), 1.44 (m, 1H), 1.36(s, 3H), 1.27 (mm,

2H), 1.19 (s, 9H), 0.90 (d, J=6.4 Hz, 3H), 0.81 (t, J=7.6 Hz, 3H); MS (APClyp (M+1)* 292.2. (38,5S)-3-Amino-3, 5-dimethyl-heptanoic acid

A mixture of (35,59)-3,5-dimethyl-3-({S)-2-methyl-propane-2- sulfinylamino)-hepganoic acid methyl ester (0.4 g, 1.37 mmol) and concentrated hydrochloric acid (7.6m) in acetone (10 mi) was refluxed for 33 h.

The solvents were stripped under reduced pressure. The residue was dissolved in water 10 mi) and extracted by EtOAc (2x15 ml). The aqueouss phase was evaporated to dryness. The residue was dissolved in a mixture of water (10 ml) and triethylamine (0.5 ml). The mixture was stirred at 40°C for 20 min and then was evaporated to dryness. The residue was washed thoroughly with acestonitrile, filtered, and dried under vacuum to give the final ' product, (3S,5S)-3-.Amino-3,5-dimethyl-heptanoic acid (0.182 g, 77%) as a white solid. m.p. 285-217°C. 'H NMR (CDCl;) 54.85 (s, 3H), 2.38 (m, 2H), 1.75 (m, 1H), 1.39 Cm, 4H), 1.35(s, 3H), 0.98 (d, J=6.6 Hz, 3H), 0.90 {t, J=7".5

Hz, 3H); MS (APCIp (M+1)* 174.1.

Using the ab«ove methodology the following compounds were also made.

Compound Name MS, H NMR, 400 MHz, §, PPM,

I a = Sl (3R,55)-3-Amino-3,5- | 174 (M+1) | 4.84 (s, 3H), 2.38 (m, 2H), 1.58 dimethyl-heptanosic (m, 1H), 1.37 (m, 4H), 1.34(s, 3H). acid 0.98 (d, J=6.3 Hz, 3H), 0.91 (t, : J=7.4 Hz, 3H) (3S,5R)-3-Amino~3,5- | 174 (M+1) | 4.84 (s, 3H), 2.38 (m, 2H), 1.58 dimethyl-heptano-ic (m, 1H), 1.37 (m, 4H), 1.34(s, 3H). acid 0.98 (d, J=6.3 Hz, 3H), 0.91 (t, : J=7.4 Hz, 3H)

Compoun d Name MS, TH NMR, 400 NAHz, 5, PPM,

TE er foe (3R)-3-Armino-3,5- 188 (M+1) {4.84 (s, 3H), 2. 39 (m, 2H) 1.72 dimethyl- eoctanoic acid (m, 1H) 1.59 (ss, 3 H) 1.38 (m, 6 H) 0.98 (d, J=6.1 Hz, 3H), 0.91 (m, 3H) (3R, 4R/SD-3-Amino-4- | 160 (M+1) [ 0.98 (m, 6 H) 1 .20 (m, 1H) 1.32 methyl-hegotanoic acid (m, 1H) 1.43 (am, 2H) 1.78 (m, 1

H), 2.32 (m, 1 HH) 2.47 (m, 1 H) 3.30(m, 1 H) (3S,6R)-3-_Amino-8- 256 (M+1) | 0.87 (m, 2H) 0. 88 (dd, J=15.86, cyclohexyl—6-methyi- 6.10 Hz, 3H) 1 .20 (m, 11 H) 1.39 octanoic acid (m, 4 H) 1.69 (rm, 6 H) 2.53 (dd,

J=17.32, 8.05 t—iz, 1 H) 2.69 (m, 1

H) 3.44 (ddd, J=14.70, 6.89, 4.76

Hz, 1 H)

Example 4 (3R)-(3,7-Dimsethyl-oct-6-enyl)-cyclohexane

A flask was charged with 100 mL dry THF and coeoled to 0°C. To this "flask was addead 103 mL (205 mmol) 2 M cyclohexylmagsnesium chloride in diethylether. When 2.30 g (17 mmol) copper (ll) chloride was taken up in 60 mL THF and a_dded as a slurry to the Grignard reagent. To this mixture was added 0.73 g { 17.1 mmol) lithium chloride, and the mixture was stirred at 0°C for 30 min. Th en 13.5 mL (68.4 mmol) of (S)-citronellyl koromide was added, and the mixturee was stirred 2 h at 0°C. The reaction mixture was allowed to warm to room ®emperature and stirred ovemight. The re.action was quenched by the addition of sat. aq. NHC! until bubbling ceased. Whe THF was removed unde reduced pressure. The residue was take=n up in water and extracted with cdisthyl ether. The combined ether layers were dried over

MgSOs. The d rying agent was removed by filtration. Thee solvent was removed under reduced pressure to yield 11.48 g (76%) of a clear oil. The crude long-chain alkyl was not readily cha: racterized, and was carried on without further purification. 3-((R)-5-Cyclohexyl-3-methyl-pentyl)-2,2-cdimethyt-oxirane

A flask was charged with 11.48 g (51.6 mmol) of crude (3R)~(3,7-

Dimethyl-oct-6-enyl)-cyclohexane, 100 mL— of dichloromethane, and 9.33 g (111 mmol) of sodium bicarbonate. The nixture was cooled in a 0°C bath.

Slowly 11.6 mL (55.2 mmol) 32% peracetic acid was added. The mixture was stirred for 4 h at 0°C. Then 10% aqueous sodium sulfile was added slowly until bubbling ceased. The layers were se parated, and the organic layer was washed twice with 10 % aqueous sodium ssulfite and dried over magnesium sulfate. The drying agent was removed by filtration, and the solvent was removed under reduced pressure. The rermaining residue was 10.65 g (87%) of a clear oil. 'H NMR (400 MHz, CDCls) opm 0.86 (m, 5 H) 1.00 (d, J=6.59

Hz, 2 H) 1.14 (m, 7 H) 1.25 (s, 3 H) 1.29 (=, 3 H) 1.356 (m, 2 H) 1.50 (m, 3 H) 1.65 (m, 5 H) 2.68 (id, J=6.16, 1.83 Hz, 1 I). MS (APCI) m+1/z = 239. (R)-6-Cyclohexyl-4-methyi-hexanal

A flask was charged with 10.65 g (4-4.7 mmol) of 3-((R)-5-cyclohexyl-3- - methykpentyl)-2,2-dimethyl-oxirane, 70 mL of acetone, 12.3 g (53.6 mmol) of : potassium periodate, 70 mL of water, and #0.765 g (4 mmol) of tosic acid- monohydrate. The mixture was stirred for -46 h. The acetone was removed under reduced pressure, and the mixture wavas diluted with water. The aqueous layer was extracted with hexanes= and dried with sodium sulfate.

The drying agent was filtered off and solve: nt was removed under reduced pressure to get 7.12 g (81%) of a clear oil. 'H NMR (400 MHz, CDCl3) ppm 0.87 (m, 5 H) 1.13 (m, 3H) 1.25 (m, 5 H) 1 .66 (m, 8 H) 2.40 (m, 2 H) 8.75 (s, 1H). MS (APCl) m+1/z is inconclusive.

(R)-6-Cyclohexyl-4-methyl-hexaanoic acid

A flask was charged witt 7.12 g (36.3 mmol) of (R)-6-cyclohexyl-<- methyl-hexanal, 40 mL water, 220 mL acetone, 4 mL acetic acid, and 6.1 89 (39.9 mmol) potassium permanganate. The mixture was stirred vigorou sly overnight. The mixture was the=n treated with sat. aqueous sodium bisulfite until the liquid became clear. The liquid was extracted with hexanes. The combined hexane layers were vwashed with sat. aqueous sodium bisulfite until the hexane layer was clear. The hexane phases were dried with magne sium sulfate. The drying agent was fi ltered off and the solvent was removed under reduced pressure, which yielded 4.17 g (54%) of a clear oil. TH NMR (400

MHz, CDCl) ppm 0.89 (m, 5H), 1.13 (m, 3 H) 1.25 (m, 5 H) 1.66 (m, 8 HI) 2.40 (m, 2 H). MS (APCl) m+1/z =2 11. . (4R,5S)-3-((R)-6-Cyclohexyl-4-rmmethyl-hexanoyl)-4-methyl-5-phenyi- oxazolidin-2-one - Aflask was charged with =4.17 g (19.6 mmol) of (R)-6-cyclohexyi-4-- methyl-hexanoic acid, 40 mL of THF, and 8.56 mL (61.4 mmol) of triethylamine. The mixture was c=ooled in a 0°C bath, and 2.41 mL (19.6 mmol) pivaloyl chloride was adde=d. The mixture was stirred for 1 h at 0°C.

Then 2.79 g (16.4 mmol) of (4R,5S)-4-methyl-5-phenyl-2-oxazolidinone and 0.823 g (19.6 mmol) of lithium chloride were added as solids. The mixture : was allowed to warm to room temperature and stirred overnight. The resulting solids were filtered off. ~The solvent was stripped, and the residue was purified by column chromatography (eluent: 4:1 hexanes/ ethyl acetate) to give 6.09 g (quant.) of a clear cmil. 'H NMR (400 MHz, CDClg) 5 ppm 0.89 (m, 8 H) 1.16 (m, 6 H) 1.68 (m, 9 HH) 2.87 (m, 1 H) 2.99 (m, 1 H) 4.76 (ad,

J=6.83, 6.59 Hz, 1 H) 5.66 (d, J=77.32 Hz, 1 H) 7.30 (m, 2H) 7.40 (m, 3 H).

MS (APCI) m+1/z = 372.

V&0 2005/030700 PCT/IB2004/002985 (5R,3S)-7-Cyclohexyl-5-methyl-3-((4R,. 5R)-4-methyl-2-oxo-5-phenyl- oxazolidine-3-carbonyl)-heptanoic acidll tert-butyl ester

A dry flask was charged with 60 mL of THF, 2.87 mL (20.5 mmol) of diisopropyl amine, and the resulting solution was cooled in a ~78°C bath. To this solution was added 13.3 mL (19.7 mmmol) of 1.48 M n-butyl lithium solution. The mixture was allowed to warm to 0°C and was stirred for 30 min. at this temperature. The LDA solution wwvas cooled again to ~78°C, and 6.10 g (16.4 mmol) of (4R,55)-3-((R)-6-cyclohexyl-4-methyl-hexanoyl)-4-methyl-5- phenyl-oxazolidin-2-one was added drogowise as a solution in 35 mL of THF.

The mixture was stirred for 45 min. at —=278°C, and was then allowed to warm slowly to —20°C over 2.5 h. The reactiorn mixture was quenched by the addition of sat. aq. ammonium chloride. The solvent was removed under reduced pressure, and the residue was poartitioned between diethyl ether and water. The ether layer was collected aned washed successively with sat. aq. 16 ammonium chloride solution and sat. aq. sodium bicarbonate solution. The ether layer was dried with magnesium sialfate. The solvent was removed under reduced pressure, and the residues was purified by column chromatography (eluent 10:1 hexanes: e-thyl acetate). This gave 4.13 g (52%) of a white solid. "HNMR (400 MHz, CDCl) 8 ppm 0.88 (m, 8 H) 1.14 (m, 8 H) 20° 1.39 (m, 12 H) 1.67 (m, 6 H) 2.41 (dd, J= 16.47, 5.00 Hz, 1 H) 2.70 (dd,

J=16.47, 9.64 Hz, 1 H) 4.31 (m, J=9.58, 7.29, 7.29, 5.12 Hz, 1 H) 4.75 (qd,

J=6.75, 6.59 Hz, 1 H) 6.64 (d, J=7.08 Hz, 1H)7.31 (m, 2H) 7.38 (m, 3 H).

MS (APCI) m+1/z = 430 (loss of t-Bu gromup). - (8)-2-((R)-4-Cyclohexyl-2-methyl-butyl)-sLaccinic acid 4-tert-butyl ester

A flask was charged with 4.13 g (8. 50 mmal) of (5R,3S)-7-cyclohexyl-5- methyl-3-((4R,5R)-4-methyl-2-oxo-5-phen=yl-oxazolidine-3-carbonyl)-heptanoic acid tert-butyl ester, 100 mL of THF, 25 m.L of water, and the resulting mixture was cooled in a 0°C bath. To this solution was added 0.57 g (13.6 mmol) of lithium hydroxide monohydrate and 3.48 mL (34 mmol) of 30% hydrogen peroxide. The mixture was stirred 2.5 h. Whe reaction was quenched by the

Addition of 4.29 g (34 mmol) of sodium sulf¥ite in 26 mL water. The mixture was allowed to warm to room temperature and stirred overnight. The THF was removed under reduced pressure and the remaining material was further diluted with water. The water layer wass made acidic by the slow addition of conc. HCl aq. The aqueous layer was extracted with dichloromethane. The organic layers were dried with magnesium sulfate. The resulting oil was purified by column chromatography (eluient 3:1 hexanes: ethyl acetate). This gave 2.19 g (79%) of a clear oil. 'H NMR (400 MHz, CDCl) 8 ppm 0.88 (m, &

H) 1.17 (m, 10 H) 1.43 (s, 10 H) 1.68 (ran, 7 H) 2.35 (dd, J=16.35, 5.37 Hz, 1 H)2.60 (m, 1H) 2.87 (m, /=9.09, 9.09, 5.61, 5.49 Hz, 1 H). MS (APCl) m+1./z is inconclusive. (8S,5R)-3-Amino-7-cyclohexyi-5-methyR-heptanoic acid methyl ester

A flask was charged with 2.19 g {6.71 mmol) of (S)-2-((R)-4-cyclohexys|- 2-methyl-butyl)-succinic acid 4-tert-buty~l ester, 40 mL of toluene, 0.935 mL 15 . - (6.71 mmol) of triethylamine, and 1.45 rl (6.71 mmol) of diphenylphosphorylazide. The mixture “was stirred for 15 min. at room temperature and then heated to 110°C and stirred for 6 h. The toluene was removed under reduced pressure, and Ehe residue was taken up in diethyl : ether. The ether layer was washed withe 3M HCI aq., water, and brine. The ether was removed under reduced pressure, and the crude isocyanate was ‘taken up in 3M HC! aq. and heated at reflux for 8 h. The water was removed’ under reduced pressure, and the residu«e was friturated with ether. This provided 1.45 g of an impure white solid. A portion of the white solid was dissolved in methanol, and HC! gas wass bubbled through for 15 minutes. Thee acidic solution was stirred 2 hours. The methanol was removed under reduced pressure, and the crude ester vvas purified by column -chromatography (4:1 dichloromethane: wnethanol). This gave 0.356 g of the pure ester. 'H NMR (400 MHz, CDCl) & ppm 0.85 (m, 2H) 0.88 (d, J=8.00

Hz, 3H) 1.15(m, 6 H) 1.26 (m, 1 H) 1.3 (ddd, J=13.73, 9.21, 4.64 Hz, 1 H) 1.51 (m, 1 H) 1.65 (m, 7 H) 2.28 (dd, J~"15.86, 8.78 Hz, 1 H) 2.43 (dd, J= 16.0, 4.00 Hz, 1 H) 3.28 (m, J=8.97, 8.97, 4.39, 4.27 Hz, 1 H) 3.69 (s, 3H). MS (APCI) m+1/z = 256.

(8S,5R)-3-Amino-7-cyclohexyl-5-meRthyl-heptanoic acid

A flask was charged with 0.3586 g of (3S,5R)-3-amino-7-cyclohexyl-5- methyl-heptanoic acid methyl ester and 20 mL of 3 M HCI, and the mixture was heated at reflux overnight. The mixture was cooled to room temperature and the solvent was removed under reduced pressure. This provided 0.340 g (88%) of a white solid HCI salt. 'H NIMR (400 MHz, CD;0D) § ppm 0.87 (s, 2H) 0.95 (d, J/=6.34 Hz, 3H) 1.21 (ma 6 H) 1.35 (m, 1 H) 1.43 (ddd, J=13.85, 8.24, 5.98 Hz, 1 H) 1.55 (ddd, J~12.881, 6.34, 6.22 Hz, 1 H) 1.64 (dd, J=8.30, 5.37 Hz, 2 H) 1.71 (m, 5 H) 2.57 (dd, J=17.45, 7.44 Hz, 1 H) 2.70 (m, 1H) 3.59 (m, J=7.72,7.72,5.73, 5.43 Hz, 1 H@. MS (APC) m+1/z = 242.

Example 5 . (4R,5S)-3-{3-(2,4-Difluoro-phenyl)-pr-opionyl]-4-methyl-5-phenyl-oxazolidin-2- one :

A flask was charged with 29.5 g (158 mmol) of 3-(2,4-difluoro-phenyl)- propionic acid, 700 mL of THF, and 882.8 mL of triethylamine. The mixture was cooled to 0°C and 23.4 mL of treimethyl acetyl chloride was added slowly.

The mixture was stirred cold for 1 h. Then 8.06 g (190 mmol) of LiCl and 28.1 g of (4S,5R)-4-methyl-5-phenyl -oxazolidin-2-one was added. The mixture was allowed to warm room temperature and stirred overnight. The - solids were filtered off, and the solvent was removed under reduced pressure.

The residue was taken up in diethyl ether and washed with sat. aq. ammonium chloride, sat. ag. sodium bicarbonate, and the solvent was removed under reduced pressure. Whe crude residue was purified by column chromatography (3:1 dichloromethamne/ hexanes eluent) to give 54 g (99%) of the titled compound. (4R 5S)(S)-2-(2,4-Difluoro-benzyl)—butyryl}-4-methyl-5-phenyl-oxazolidin-2- one

A flask was charged with 54 3 (156 mmol) of (4R,5S)-3-[3-(2,4-difluoro- phenyl)-propionyl}-4-methyl-5-phenyyl-oxazolidin-2-one and 300 mL of dry

THF, and the solutiors was cooled to —78°C. To this solution was added 172 mL (172 mmol) of 1 M NaHMDS in THF, and the mixture was stirred cold for 1 h. Then 30.6 g (172 mmol) of ethyl! triflate was added dropwise to the enolate solution, and the reaction mixture was warmed to —40 to ~30°C an d stirred for 1.5 h. The reaction mixture was quenched by the addition of : aqueous brine. The THF was removed under reduced pressure and the residue was partitioned between EtOAc and water. The organics were collected, and EtOAc was removed under reduced pressure. The resulting crude oil was purified by column chromatography (3:1 hexanes/ EtOAc elu<ent) to get 29.5 g of an impure oil that was used without further purification. (S)-2-(2,4-Difluoro-berszyl)-butan-1-ol .

A flask was charged with 29.5 g (~78.6 mmol) of (4R,5S)-[(S)-2-(2,4—- Co difluoro-benzyl)-butyrylJ-4-methyk-5-phenyl-oxazolidin-2-one and 200 mL dry :

THF, and the solution was cooled to 0°C. In a separate flask, 11.9 g (314 mmol) of sodium borohydride was taken up in 70 mL water and added dropwise over 15 minutes to the imide solution. The mixture was allowed t© warm to room temperature and stirred overnight. The reaction mixture was quenched with conc. HCI until pH = 3 (keeping the reaction mixture temperature < 20°C). THF was removed under reduced pressure, and the residue was taken up int hexanes. The hexane layer was washed with sat. aq. sodium bicarbonate. The hexane layer was removed under reduced pressure, and the residue was purified by column chromatography ( 9:1

Hexanes/ EtOAc) which gave 7.2 g (46%) of (S)-2-(2,4-difluoro-benzyl)-but=an- 26 1-0l as a clear oil. (2S)-Methanesulfonic acid 2-(2,4-difluoro-benzyl)-butyl ester

A flask was charged with 7.2 g (36 mmol) of (S)-2-(2,4-difluoro-benzyl)- butan-1-ol and 30 mL of dichloromethane, and the solution was cooled to 0=C.

To this solution was added 7.53 mL (54 mmol) of triethylamine, and the mixture was stirred cold for § min. Then 3.1 mL (39.6 mmol) of methane sulfonyl chloride was added dropwise. The reaction mixture was stirred at room temperature for 16 h. The dichloromethane was removed under reduced pressure, and the residue was pa_rtitioned between 1 N HCI aq. and diethyl ether. The ether layer was collected and washed with sat. aq. sodium bicarbonate, water, and brine. The ether | ayer was dried over sodium sulfate, filtered, and the ether was removed under reduced pressure. This procedure gave 9.54 g (95%) of (2S)-methanesulfoniic acid 2-(2,4-difluoro-benzyi)-butyl : ester as an orange oil. This material was used without further purification. (S)-2,4-Difluoro-1-(2-iodomethyl-butyl)-bemnzene

A flask was charge with 9.54 g (34-3 mmol) of (25)-methanesulfonic acid 2-(2,4-difluoro-benzyl)-butyl ester, 108.3 g (68.6 mmol) of sodium iodide, and 60 mL of acetone. The solution was Bheated at reflux for 30 h. The acetone was removed under reduced presssure. The residue was partitioned between water and hexanes. The organic layer was collected and washed with sodium bisulfite solution and brine. The hexane was removed under reduced pressure, and the crude oil was purified by column chromatography (hexanes eluent). This procedure gave 8 .7g (91%) of (S)-2,4-difluoro-1-(2- * jodomethyl-butyl)-benzene as a clear oil. 2-tert-Butyl-5-[2-(2,4-difluoro-benzyl)-butywl}-3-methyi-4-oxo-tetrahydro- pyrimidine-1-carboxylic acid methyl ester : A flask was charged with 1.35 mL (9.64 mmol) diisopropyl amine and 15 mL dry THF. The solution was cooled to ~78°C and 6.0 mL (9.64 mmol) 1.6 M n-butyl lithium solution in hexanes “was added. The mixture was warmed to 0°C and stirred for 30 minutess. The mixture was cooled again to 78°C and 2.0 g (8.76 mmol) of (2S)-2-temrt-butyl-3-methyl-4-oxo-tetrahydro- pyrimidine-1-carboxylic acid methyl ester was added as a solution in 10 mL of

THF. This mixture was warmed to 0°C amd stirred for 1 h. The anion solution was cooled again to ~78°C and 2.99 g (9=.64 mmol) of (S)-2,4-difluoro-1-(2- iodomethyl-butyl)-benzene was added ass a solution in THF. The mixture was stirred at —78°C for 4 h. The reaction mixture was warmed to —21°C and stirred at that temperature for 5 days. The reaction mixture was quenched witha sat. aq. ammonium chloride solution. The cr ude reaction mixture was extracted with diethyl ether. The ether was removed under reduced pressure, and the crude residue was purified by column chromatography (9:1 hexanes/

EtOAc eluent) which gave 1.67 g (46%) of 2-tert—butyl-5-[2-(2,4-difluoro- berzyl)-butyl]-3-methyl-4-oxo-tetrahydro-pyrimid=ine-1-carboxylic acid methyl ester as a white solid. (2F 4R)-2-Aminomethyl-4-(2,4-difluoro-benzyl)-exanoic acid : A flask was charged with 0.5 g (1.2 mmoR) of 2-tert-butyl-5-{2-(2,4- dif luoro-benzyl)-butyl}-3-methyi-4-oxo-tetrahydrco-pyrimidine-1-carboxylic acid methyl ester, 20 mL dioxane, and 20 mL of cones. HCI solution. The mixture was stirred and heated at 110°C for 4 days. Th-e solvents were removed urder reduced pressure. The residue was take=n up in 20 mL water and 4 drops of conc. HC) solution. The aqueous layemr was washed with : dichloromethane. The aqueous layer was colleacted and the water was : reamoved under reduced pressure. The residue was treated with2 mL of triethylamine, and the excess triethylamine wass removed under reduced : p ressure. The remaining solid was purified by column chromatography (-1:8:27 NH OH, MeOH, dichioromethane eluert). The resulting white solid wwas washed with acetonitrile and dried under wacuum. This gave 80 mg (24%) of (2R,4R)-2-aminomethyl-4-(2,4-difluor-o-benzyl)-hexanoic acid as a : white solid. it should be noted that, as used in this sspecification and the appended claims, singular articles such as “a,” “an,” and “the,” may refer to a single «object or to a plurality of objects unless the context clearly indicates . «otherwise. Thus, for example, reference to a composition containing “a compound” may include a single compound or two or more compounds. it is to be understood that the above deescription is intended to be illustrative and not restrictive. Many embodirments will be apparent to those of skill in the art upon reading the above descrigption. The scope of the invention should, therefore, be determined not with ref: erence to the above description,

but should instead be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.

Claims

CLALMS WHAT IS CLAIMED IS:

1. A compound of formula { Rs Ay fis NH, COH 5 ] or a pharmaceutically acceplable salt th ereof, wherein R; is a hydrogen atom or (C4-Ce)aalkyl optionally substituted with frcasm one to five fluorine atoms; R; is a hydrogen atom or (C,-Cg)=alkyl optionally substituted with from one to five fluorine atoms; or R, and R;, together with the carbeon to which they are attached, foram a three- to six-membered cycloalkyl ring; R; is a hydrogen atom, (C4-Ce)all<yl, (Cs-Cg)cycloalkyl, (Ca- . Cs)cycloalkyl-(C1-Cs)alkyl, phenyl, phenzy-(Ci-Cs)alkyl, pyridyl, or pyridyl-CC:- Ca)alkyl, wherein the alkyl and cycloalky=l moieties or substituents are optionally substituted with from one to fi=ve fluorine atoms, and the phenyl and pyridyl substituents and the phenyl and pyridyl moieties of the phenyl-(C1— Cs)alky! and the pyridyi-(C-Cs)alkyl subsstituents are optionally substitutecd with from one to five substituents independently selected from chioro, fluro, amino, nitro, cyano, hydroxy, {C-Cs)alk-ylamino, (C4-Cs)alky! optionally substituted with from one to three fluorime atoms, and (C4-Cg)alkoxy optionally substituted with from one to three fluorire atoms; R, is a hydrogen atom or (C+-Cg)aalkyl optionally substituted with from one to five fluorine atoms; Rs is a hydrogen atom or (C+-Cg)aalkyl optionally substituted with from one to five fluorine atoms;

—11.2—

R. amd Rs, together with the carbon t© which they are attached, form a three- to six—~membered cycloalkyl ring; and Rsis a hydrogen atom or (Cy-Ce)alkyk; with ®the proviso that Rs, Rz, Rs, Rs, RRs, and Rg are not simultaneously hydrogen atoms.

2. A commpound of Claim 1 having a strusclure represented by formula - Ra ’ HaN Ra Ry HOC n or a pharmaceutically acceptable salt there«of, wherein Ry, Rs, and R, are defined as #in Claim 1 with the proviso that Fis not a hydrogen atom.

3. A cosmpound of Claim 1 having a straucture represented by formula 111 CH; HN Rs Ri [ or a pharmmaceutically acceptable salt therexof, wherein Rq and Rs are defined as in Clain— 1 with the proviso that Ry and IRs are not hydrogen atoms. 4, A compound of Claim 3 having a structure represented by formula I\/ Ets HN Ho Rs JERS

HO.C iv or a pharmaceutically acceptable salt thereof, wherein Rs is defined as in Claim 1 with the proviso that Rs is not a hydrogen atom.

5. A compound of Claim 1 having a structure represented by formula V R HOC" Rs Rg Ri R2 HN Vv or a pharmaceutically acceptable salt thereof, wherein Ry, Bz, Rs, Ry, and Rs are defined as in Claxim 1 with the proviso that Rs, Re, Rs, Rs, and Rs are not simultaneously hydrogen atoms.

6. A compound ©f Claim 1 having a structure represented by formula Vi ~ HoN R HO,C ® Rs { Ra vi or a pharmaceutically acceptable salt thereof, wherein Rs, R4, and Rs are defined as in Claim + with the proviso that Rs, Rs, and Rs are not simultaneously hydrogen atoms.

7. A pharmaceuatical composition comprising a therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, and a pharrmaceutically acceptable carrier.

8. A method of treating a disorder or condition in a mammal, including & human, the disorder or condition selected from:

epilepsy, faintness attacks, fibromyalgia, hypokinesia, cranial disorders, hot flashes, and essential tremor; chemical dependencies and addictions to alcohol, amphekamines or amphetamine-like substances, caffeine, cannabis, ***e, heroin, hallucinogens, tobacco, inhalants and aerosol propellants, nicotire, opioids, phenylglycidine derivatives, sedatives, hypnotics, benzodiazepin es and other anxiolytics; withdrawal symptoms associated with the dependencies, addictions, or . addictive behaviors, including gambling; and migraine, spasticity, muscle spasticity, hypotonia with paralysis, arthritis, irritable bowel syndrome, chronic pain, acute pain, neuropathic pain, post herpetic neuralgia, lower back pain, surgical pain, vascular headache, sinus headache, chronic headache, inflammatory disorders, rhetamatoid arthritis, osteoarthritis, psoriasis, disease modification of osteoarthritis disease, diuresis, premenstrual syndrome, premenstrual dysphoric disorder, tinnitus, and gastric damage; the method comprising administering to a mammal in need of such treatment a therapeeutically effective amount of a compound of Claim 1 ora pharmaceutically acceptable salt thereof.

9. A method of treating a disorder or condition in a mammal, includinga human, the disorder or condition selected from: delirium, dementia, and amnestic or other cognitive or neurodegenerative disorders, including Parkinson's disease, Hu ntington's disease, Alzheime rs disease, senile dementia, dementia of the Alzheimer's type, memory disorder, vascular dementia, and other dementias, including dementia due to RIV disease, head trauma, Parkinson's disease, Huntington's disease, Pick's dis ease, Creutzfeldt-Jakob disease, or due to multiple aetiologies; movement disorders including akinesias, dyskinesias, including familial paroxysmal dyskin esias, spasticities, Tourette’s syndrome, Scott syndrome, PALSYS and akinetic-rigid syndrome;

extra-pyramidal movement disorders including medica-tion-induced movernent disorders, including neuroleptic-induced Parkinsomnism, neuroleptic maligant syndrome, neuroleptic-induced acute dystonia, newuroleptic-induced acute akathisia, neuroleptic-induced tardive dyskinesia and nmedication- inducexd postural tremour; Down's syndrome; demyelinating diseases including multiple sclerosis arad amylolateral sclerosis, peripheral neuropathy, including diabetic and chenotherapy- inducexd-neuropathy, or postherpetic neuralgia, trigeminal newuralgia, segmeantal or intercostal neuralgia and other neuralgias; and cerebral vascular disorders due to acute or chronic ce-rebrovascular damage including cerebral infarction, subarachnoid haemorrhage or cerebral oedema; the method comprising administering to the mammal i n need of such treatm ent a therapeutically effective amount of a compound «of Claim 1 or a pharmaceutically acceptable salt thereof.

10. A method of treating a disorder or condition in a mamamal, including a human, the disorder or condition selected from sleep disorde=rs, insomnia, drug-a.ssociated sleeplessness, REM sleep disorders, hyperssomnia, narcoleepsy, sleep-wake cycle disorders, sleep apnea syndro mes, parasomnias, restless leg syndrome, jet lag, periodic limb meovement disorder, alterecd sleep architecture, or sleep disorders associated with shift work and irregulzar work hours, the method comprising administering t© the mammal in need Of such treatment a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof. :

11. A method of treating a disorder or condition in a mam mal, including a human, the disorder or condition selected from: mood disorders, including depression or depressive disorders, includi ng single episodic or recurrent major depressive disor-ders, dysthymic

30 . disorders, depressive neurosis and neurotic depression, melancholic depression, including anorexia, weight loss, insomnia, early moming waking and psychomotor retardatieon, atypical depression or reactive d-epression, including increased appetite, hypersomnia, psychomotor agitation or irritability, seasonal affectiwe disorder and pediatric depression ; bipolar disorders or manic depression, including bipolar | disorder, bipolar !I disorder and cyclecthymic disorder; conduct disorder amd disruptive behavior disorder; anxiety disorders, imcluding panic disorder with or witho ut agoraphobia, agoraphobia without history of panic disorder, specific phobiass, including specific animal phobias, social anxiety, social phobia, obsessiwe-compulsive disorder, stress disorders, including post-traumatic stress diso-rder and acute stress disorder, and generaalized anxiety disorders; borderline personality disorder; schizophrenia and Other psychotic disorders, including schizophreniform disorderss, schizoaffective disorders, delusiomnal disorders, brief psychotic disorders, shared psychotic disorders, psychotic disorders with delusions or hallucinationss, psychotic episodes of anxiety, aristy associated with psychosis, psychotic amood disorders including severe m&xjor depressive disorder; : mood disorders asssociated with psychotic disorders including acute mania and depression asssociated with bipolar disorder, moodl disorders associated with schizophrenia; and behavioral disturbasnces associated with mental retardation, autistic disorder, and conduct disorder; the method comprissing administering to the mammal ir need of such treatment a therapeutically effective amount of a compound oof Claim 1 or a pharmaceutically acceptakole salt thereof.

12. A compound selected from the following compounds amnd their pharmaceutically acceptable salts: 3-Amino-4,5-dimethyl-hexanoic acid; 3-Amino-4,5-dimetEyl-heptanoic acid;

3-A mino-4,5-dimethyl-octanoic acid; 3-A mino-4,5-dimethyl-nonanoic acid; 3-A mino-4,5-dimethyl-decanoic acid; 3-A- mino-4-ethyl-5-methyl-heptanoic acid;

3-Amnino-4-ethyl-5-methyl-octanoic acid; 3-Ammino-4-ethyl-5-methyl-nonanoic acid; 3-Ammino-4-ethyl-5,6-dimethyl-heptanoic acid; 3-Armino-4-ethyi-5,7-dimethyl-octanoic acid; 3-Armino-4-ethyl-5,8-dimethyl-nonanoic acid;

3-Armino-5-ethyl-4-methyl-octanoic acid; 3-Armino-5-ethyl-4-methyl-nonanoic acid; 3-Arnino-4,5-diethyl-heptanoic acid; 3-Arnino-4,5-diethyl-octanoic acid; :

3-Armino-4,5-diethyl-nonanoic acid;

3-Armino-5-ethyl-4,7-dimethyl-octanoic acid; 3-Armino-5-ethyl-4,8-dimethyl-nonanoic acid; 3-Armnino-4,5-disthyl-6-methyl-heptanoic acid; 3-Armnino-4,5-diethyl-7-methyl-octanoic acid; 3-Ammino-4,5-diethyl-8-methyi-nonanoic acid;

3-Amino-4,5 6-trimethyl-heptanoic acid;

3-Amino-4,5,7-trimethyl-octanoic acid; : : 3-Ammino-4,5,8-trimethyl-nonanoic acid; 3-Amino-4-ethyl-5-methyl-hexanoic acid;

3-Amiino-5-ethyl-4-methyl-octanoic acid;

3-Amino-5-ethyl-4-methyl-heptanoic acid;

3-Amiino-4-methyl-5-propyl-octanoic acid; 3-Amino-4-methyl-6-ethyl-octanoic acid, : 3-Armmino-4-methyl-6-ethyl-nonanoic acid; :

3-Amwino-4,6-diethyi-octanoic acid;

3-Ammino-4,6-diethyl-nonanoic acid; 3-Amuino-6-cyclopentyl-4,5-dimethyl-hexanoic acid; 3-Am ino-7-cyciopentyl-4,5-dimethyl-heptanoic aacid;

3-Amino-5-ethyl-4,6-dimethyl-heptaroic acid; 3-Amino-5-ethyl-4,7-dimethyl-octancoic acid; 3-Amino-5-ethyl-4,8-dimethyl-nonan: oic acid; (3R,4R)-3-Amino-4,5-dimethyl-hexamnoic acid;

(3R,4R,5R)-3-Amino-4,5-dimethyl-heaptanoic acid; (3R,4R,5R)-3-Amino-4,5-dimethyl-oc=tanoic acid; (3R,4R,5R)-3-Amino-4,5-dimethyl-ncnanoic acid; (3R,4R,5R)-3-Amino-4,5-dimethyl-deacanoic acid; 3-Amino-5-cyclopropyl-4-ethyl-hexaroic acid;

3-Amino-6-cyclopropyl-4-ethyl-5-met-hyl-hexanoic acid; 3-Amino-5-cyclobutyi~4-ethyl-hexanomic acid; 3-Amino-6-cyclobutyl-4-ethyl-56-meth=yl-hexanoic acid; 3-Amino-5-cyciopentyl-4-methyl-hex=anoic acid; 3-Amino-6-cyclopentyl-4-ethyl-5-metEyi-hexanoic acid;

3-Amino-5-cyclohexyl-4-ethyl-hexancic acid; 3-Amino-6-cyciohexyl-4-ethyl-5-meth-yl-hexanoic acid; 3-Amino-5-cyclopropyl-4-methyi-hexaanoic acid; 3-Amino-6-cyclopropyl-4,5-dimethyl-iaexanoic acid;

: 3-Amino-5-cyclobutyl-4-methyl-hexarmoic acid; - 20 3-Amino-6-cyciobutyl-4,5-dimethyl-he=xanoic acid;

: : 3-Amino-5-cyclopentyl-4-methyl-hexa_noic acid; 3-Amino-6-cyclopentyl-4,5-dimethyl-h exanoic acid; 3-Amino-5-cyclohexyl-4-methyl-hexaroic acid; 3-Amino-6-cyclohexyl-4,5-dimethyl-heaxanoic acid;

3-Amino-8-cyclohexyl-4,5-dimethyl-oc=tanoic acid; 3-Amino-8-cyclohexyl-4,5-dimethyl-oc=tanoic acid; 3-Amino-4,6-dimethyl-heptanoic acid; 3-Amino-4,6-dimethyl-octanoic acid; 3-Amino-4,6-dimethyl-nonanoic acid; .

=3-Amino-4,8-dimethyl-decanoic acid;

23-Amino-4,6,7-trimethyl-octanoic acid; =3-Amino-4,8,8-trimethyl-nonanoic acidt;

3-Amino-4,6,9-trimethyl-decanoic acid; 3-Amaino-6-cyclopropyl-4-methyl-heptanoic acid; 3-Armaino-6-cyclobutyl-4-methyl-heptanoic acid; 3-Arrmino-6-cyclopentyi-4-methyl-heptanoic acid; " 3-Armmino-6-cyclohexyl-4-methyl-heptanoic aci d; 3-Amaino-7-cyclopropyl-4,6-dimethyl-heptanois=c acid; 3-Ammino-7-cyclobutyl-4,6-dimethyl-heptanoic acid; 3-Am ino-7-cyclopentyl-4,6-dimethyl-heptanoiec acid;

. 3-Am ino-7-cyclohexyl-4,6-dimethyl-heptanoic= acid, 3-Am ino-8-cyclopropyl-4,6-dimethyl-octanoic acid;

. 3-Am ino-8-cyclobutyl-4,6-dimethyl-octanoic a-cid; 3-Am3no-8-cyclopentyl-4,6-dimethyl-octanoic -acid; 3-Amiino-8-cyclohexyl-4,6-dimethyl-octanoic &acid; 3-Amiino-8-(3-chloro-phenyl)-4-methyl-heptan oic acid; 3-Amano-6-(3,4-dichloro-phenyl)-4-methyl-hepotanoic acid; 3-AmiEno-4-methyl-6-(3-trifluoromethyl-phenyil® -heptanoic acid; 3-Amf no-4-methyl-6-(4-trifluoromethyl-phenyl-heptanoic acid; - 3-Ami no-7-(3-chloro-phenyl)-4,6-dimethyl-hefotanoic acid;

. 8-Ami no-7-(3,4-dichloro-phenyl)-4,6-dimethyl—heptanoic acid; 3-Ami_no-4,6-dimethyl-7-(3-trifluoromethyl-phesnyl)-heptancic acid; : : 3-Amimno-4,6-dimethyl-7-(4-trifluoromethyl-phesnyl)-heptanoic acid; 3-Amimo-8-(3-chloro-phenyl)~4,6-dimethyl-octeanoic acid; 3-Amimo-8-(3,4-dichloro-phenyl)-4,6-dimethyl—octanoic acid; 3-Amimo-4,6-dimethyl-8-(3-trifluoromethyl-phe=nyl)-octanoic acid; 3-Amimo-4,6-dimethyl-8-(4-trifluoromethyl-pheenyl)-octanoic acid; 3-Amimo-4-ethyl-6-methyl-octanoic acid; 3-Amiro-4-ethyl-6-methyl-nonanoic acid; 3-Amiro-4-ethyl-6-methyl-decanoic acid; 3-Amiro-4-ethyl-6,7-dimethyl-octanoic acid; 3-Amiro-4-ethyl-6,8-dimethyl-nonanoic acid; : 3-Amiro-4-ethyl-6,9-dimethyl-decanoic acid; 3-Amir10-6-cyclopropyli-4-ethyl-heptanoic acids

3-Amireo-6-cyclobutyl-4-ethyl-heptanoic acid; 3-Amirmo-6-cyclopentyl-4-ethyl-heptanoic acid; 3-Amirmo-6-cyclohexyl-4-ethyl-heptanoic acid; 3-Amirmo-7-cyclopropyl-4-ethyl-6-methyl-heptanoic acid;

3-Amirmo-7-cyclobutyl-4-ethyl-6-methyl-heptanoic acid; 3-Amimo-7-cyclopentyl-4-ethyl-68-methyl-heptanoic acid; 3-Amirmo-7-cyclohexyl-4-ethyl-6-methyi-heptanoic acid; 3-Amirmo-8-cyclopropyl-4-ethyl-6-methyi-octanoic acid; 3-Amins0-8-cyclobutyl-4-ethyl-6-methyl-octanoic acid; :

3-Amin o-8-cyclopentyl-4-ethyl-6-methyl-octanoic acid; 3-Amin o0-8-cyclohexyl-4-ethyl-6-methyl-octanoic acid; 3-Amin o-6-(3-chloro-phenyl)-4-ethyl-heptanoic acid; 3-Amin o-6-(3,4-dichloro-phenyl)-4-ethyl-heptanoic acid; 3-Amin o-4-ethyl-6-(3-trifluoromethyl-phenyt)-heptanoic acid;

3-Amin o-4-ethyl-6-(4-trifluoromethyl-phenyl)-heptanoic acid; 3-Amin«o-7-(3-chloro-phenyl)-4-ethyl-6-methyl-heptanoic acid; 3-Amin-o-7-(3,4-dichloro-phenyl)-4-ethyl-6-methyl-heptanoic acid 3-Amino-4-ethyl-6-methyl-7-(3-trifluoromethyi-phenyl)-heptanoic acid;

3-Amin«-8-(3-chloro-phenyl)-4-ethyl-6-methyl-octanoic acid;

: 3-Amin«-8-(3,4-dichloro-phenyl)-4-ethyl-6-methyl-octanoic acid; 3-Amino-4-ethyl-6-methyl-8-(3-trifluoromethyl-phenyl)-octanoic a_cid; 3-Amin©-4-ethyl-6-methyl-8-(4-trifluoromethyi-phenyl)-octanoic a_cid; 3-Amino-4-methyl-heptanoic acid;

3-Amin©-4,6-dimethyl-heptanoic acid; 3-Amin«o-4,7-dimethyl-octanoic. acid; 3-Amin«<©-4,8-dimethyl-nonanoic acid; 3-Amino-4-methyl-hexanoic acid; - 3-Amino-4-methyl-heptanoic acid;

3-Amaino-6-cyclopropyl-4-methyl-hexanoic aacid; ‘ 3-Amaino-7-cyclopropyl-4-methyl-heptanoic acid; 3-Armmino-5-cyclobutyl-4-methyl-pentanoic acid; 3-Amaino-6-cyclobutyl-4-methyl-hexanoic acid,

" 3-Ammino-7-cyclobutyl-4-methyl-heptanoic a~cid; 3-Ammino-5-cyclopentyl-4-methyl-pentanoic -acid; 3-Amwmino-6-cyclopentyl-4-methyl-hexanoic acid;

_ 3-Am ino-7-cyclopentyl-4-methyl-heptanoic acid; 3-Am ino-5-cyclohexyl-4-methyi-pentanoic amcid;

3-Am ino-6-cyclohexyi-4-methyl-hexanoic acid; 3-Am ino-7-cyclohexyl-4-methyl-heptanoic acid; : 3-Am3no-5-cyclopropyl-4-ethyi-pentanoic acid; 3-Am:ino-6-cyclopropyl-4-ethyi-hexanoic acid; 3-Amino-7-cyclopropyl-4-ethyl-heptanoic acid;

3-Amino-5-cyclobutyl-4-ethyl-pentanoic acid; 3-Amilino-6-cyclobutyl-4-ethyl-hexanoic acid; 3-AmiEno-7-cyclobutyl-4-ethyl-heptanoic acid; 3-AmiEno-5-cyclopentyl-4-ethyl-pentanoic acid; 3-Amiino-6-cyclopentyl-4-ethyl-hexanoic acid;

3-Amino-7-cyclopentyl-4-ethyl-heptanoic acid,

: 3-AmEno-5-cyclohexyl-4-ethyl-pentanoic acid; : 3-Ami~no-6-cycliohexyl-4-ethyl-hexanocic acicH; 3-AmiEno-7-cyclohexyl-4-ethyi-heptanoic acid, 3-Ami-no-4,4,5-trimethyl-heptanoic acid;

3-Ami no-4,4,5-trimethyl-octanoic acid; 3-Ami no-4,4,5-trimethyl-hexanoic acid; 3-Ami no-4,5,5-trimethyl-heptanoic acid; 3-Ami no-4,5,5-trimethyl-octanoic acid; 3-Ami no-4,5,5-trimethyl-hexanoic acid;

3-Ami.no-4-methyl-5-phenyl-pentanoic acids 3-Amizno-4-methyl-6-phenyl-hexanoic acid; 3-Amimno-4-methyl-7-phenyl-heptanoic acids

3-Amino-5-(2-chloro-pheanyl)-4-methyl-pentanoic acid; 3-Amino-5-(3-chloro-phenyl)-4-methyl-pentanoic acid; 3-Amino-5-(4-chloro-pheanyl)-4-methyl-pentanoic acid; 3-Amino-5-(2,4-dichioro—phenyi)-4-methyl-pentanoic acid;

3-Amino-5-(3,4-dichloro—phenyl)-4-methyl-pentanoic acid; 3-Amino-4-(2-chloro-berzyl)-hexanoic acid; : 3-Amino-4-(3-chloro-berzyt)-hexanoic acid; 3-Amino-4-(4-chloro-berzyl)-hexanoic acid; 3-Amino-4~(2,4-dichloro—benzyl)-hexanoic acid;

3-Amino-4-~(3,4-dichloro—~benzyl)-hexanoic acid; 3-Amino-6~(2-chloro-phenyl)-4-methyl-hexanoic acid;

~ 3-Amino-6-(3-chloro-pheanyl)-4-methyl-hexanoic acid; 3-Amino-6-(4-chloro-pheanyl)-4-methyl-hexanoic acid; 3-Amino-6-(2,4-dichloro—phenyl)-4-methyl-hexanoic acid;

3-Amino-6-(3,4-dichioro—phenyi)-4-methyl-hexanoic acid; 3-Amino-6-(2-chloro-phenyl)-4-ethyl-hexanoic acid; 3-Amino-6~(3-chloro-pheanyl)-4-ethyl-hexanoic acid; 3-Amino-6-(4-chloro-phenyl)-4-ethyl-hexanoic acid; 3-Amino-6-(2,4-dichloro—phenyl)-4-ethyl-hexanoic acid;

3-Amino-6-~(3,4-dichloro—phenyi)-4-ethyl-hexanoic acid;

3-Amino-7-(2-chloro-pheanyl)-4-methyl-heptanoic acid; 3-Amino-7-(3-chloro-phe=nyi)-4-methyl-heptanoic acid; 3-Amino-7-(4-chloro-phenyl)-4-methyl-heptanoic acid; 3-Amino-7-(2,4-dichloro~-phenyi)-4-methyl-heptanoic acid;

3-Amino-7-(3,4-dichloro=-phenyl)-4-methyl-heptanoic acid; 3-Amino-7-(2-chloro-pheenyl)-4-ethyl-heptanoic acid; 3-Amino-7-(3-chloro-pheenyl)-4-ethyl-heptanoic acid; 3-Amino-7-(4-chloro-pheenyi)-4-ethyl-heptanoic acid; 3-Amino-7-(2,4-dichloroe-phenyl)-4-ethyl-heptanoic acid; and

3-Amino-7-(3,4-dichiorae-phenyl)-4-ethyl-heptanoic acid. 2-Aminomethyl-4-(2-flucoro-phenyl)-pentanoic acid;

2-Aminomethyl-4-(3-flucro-phenyl)-pentanoic acid;

2-Aminomethyl-4-(4-fluoro-phenyl)-p entanoic acid; 2-Aminomethyi-4-(2,3-difluoro-phenysi)-pentanoic acid; 2-Aminomethyl-4-(2,4-difluoro-phenysi)-pentanoic acid; 2-Aminomethyl-4-(2,5-difluoro-phenyyl)-pentanoic acid; 2-Aminomethyl-4-(2,6-difluoro-phenyyl)-pentanoic acid; 2-Aminomethyl-4-(3,4-difluoro-phenyyl)-pentanoic acid; 2-Aminomethyl-4-(3,5-difluoro-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,3,4-trifluoro-phe=nyl)-pentanoic acid; 2-Aminomethyl-4-(2,3,5-trifluoro-phexnyl)-pentanoic acid; ~ 2-Aminomethyl-4-(2,3,6-trifluoro-phe=nyl)-pentanoic acid; 2-Aminomethyl-4-(2,4,6-trifluoro-phe-nyl)-pentanoic acid; 2-Aminomethyl-4-(2,3,4,5-tetrafluoro»-phenyl)-pentanoic acid; - 2-Aminomethyl-4-(2,3,4,6-tetrafluoro=-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,3,5,6-tetrafluoro=-phenyl)-pentanoic acid; 2-Aminomethyl-4-pentafiuorophenyl—pentanoic acid; 2-Aminomethyl-4-(2-fluoro-phenyl)-h exanoic acid; 2-Aminomethyl-4-(3-fluoro-phenyl)-h exanoic acid; 2-Aminomethyl-4-(4-fluoro-phenyl)-h exanoic acid; . 2-Aminomethyl-4-(2,3-difluoro-phenyrl)}-hexanoic acid;

20 . 2-Aminomethyl-4-(2,4-difluoro-phenyrl)-hexanoic acid, 2-Aminomethyl-4-(2,5-difluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-(2,6-difluoro-phenyrl)-hexanoic acid; 2-Aminomethyl-4-(3,4-difluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-(3,5-difluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-(2,3,4-trifluoro-phe nyl)-hexanoic acid; 2-Aminomethyl-4-(2,3,5-trifluoro-phe nyl)-hexanoic acid; 2-Aminomethyi-4-(2,3,6-triffuoro-phe nyl)-hexanoic acid; 2-Aminomethyl-4-(2,4,6-trifluoro-phe nyl)-hexanoic acid; 2-Aminomethyl-4-(2,3,4,5-tetrafluoro ~-phenyl)-hexanocic acid; 2-Aminomethyl-4-(2,3,4,6-tetrafluoro -phenyl)-hexanoic acid; 2-Aminomethyl-4-(2,3,5,6-tetrafluoro--phenyl)-hexanoic acid; 2-Aminomethyl-4-pentafluorophenyl- hexanoic acid;

2-Aminomethyi-5-(2-fluoro-phenwyl)-4-methyl-pentanoic acid; 2-Aminomethy}-5-(3-fluoro-phenwyl)-4-methyi-pentanoic acid;

2.Aminomethyl-5-(4-fluoro-phenzyl)~4-methyl-pentanoic acid; 2-Aminomethyl-5-(2;3-difluoro-pihenyi)-4-methyl-pentanoic acid; : 2-Aminomethyl-5-(2,4-difluoro-p henyl)-4-methyl-pentanoic acid; 2-Aminomethyl-5-(2,5-difluoro-p henyl)-4-methyl-pentanoic acid; 2-Aminomethyl-5-(2,6-difluoro-p henyi)-4-methyl-pentanoic acid; 2-Aminomethy}-5-(3,4-difluoro-p henyl)-4-methyl-pentanoic acid; 2-Aminomethyl-5-(3,5-difluoro-p henyi)-4-methyl-pentanoic acid; 2-Aminomethyl-4-methyl-5-(2,3,-4-trifluoro-phenyl)-pentanoic acid; : 2-Aminomethyl-4-methyl-5-(2,3, -5-trifluoro-phenyl)-pentanoic acid; 2-Aminomethyl-4-methyl-5-(2,3, €-trifluoro-phenyl)-pentanoic acid; 2-Aminomethyl-4-methyl-5-(2,4, 6-trifluoro-phenyl)-pentanoic acid; : : 2-Aminomethyl-4-methyl-5-(2,3, 4,5-tetrafluoro-phenyl)-pentanoic acid; 2-Aminomethyl-4-methyl-5-(2,3, 4,6-tetrafluoro-phenyl)-pentanoic acid; 2-Aminomethyl-4-methyl-5-(2,3, 5,6-tetrafluoro-phenyl)-pentanoic acid; 2-Aminomethyl-4-methyl-5-pent afluorophenyl-pentanoic acid; 2-Aminomethyl-5-(2-fluoro-pherayl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(3-fluoro-pheryl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(4-fluoro-pheryl)-4-methyl-hexanoic acid; 2-Aminomethyi-5-(2,3-difluoro-pahenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(2,4-difluoro-pohenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(2,5-difluoro-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(2,6-difluoro-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(3,4-difluoro-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(3,5-difluoro-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-4-methyl-5-(2,3 , 4-trifluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-methyl-5-(2,3 ,5-trifluoro-phenyl)-hexanoic acid;

2.Aminomethyl-4-methyl-5-(2,3 ,6-trifluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-methyl-5-(2,4 ,6-trifluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-methyl-5-(2,3 ,4,5-tetrafluoro-phenyl)-hexanoic acid;

2.Aminomethyl-4-methyl-5-(2,3 ,4,6-tetrafluoro-phenyl)-hexanoic acid; —R25—

2-Aminomethyl-4-methyl-5-(2,3,5 . 6-tetrafluoro-phenyl)-hexanoic acidz 2-Aminomethyl-4-methyl-5-pentaffiuorophenyi-hexanoic acid; 2-Aminomethy!-6-(2-fluoro-pheny 1)-4-methyl-hexanoic acid; 2-Aminomethyl-6-(3-fluoro-pheny1)-4-methyl-hexanoic acid;

2-Aminomethyl-6-(4-fluoro-pheny~1}-4-methyl-hexanoic acid; 2-Aminomethyl-6-(2,3-difluoro-prmenyl)-d-methyi-hexanoic acid; 2-Aminomethyl-6-(2,4-difluoro-phmenyl)-4-methyi-hexanoic acid; 2-Aminomethyl-6-(2,5-difluoro-phmenyl)-4-methy-hexancic acid; 2-Aminomethyl-6-(2,6-difluoro-phmenyl)-4-methyl-hexanoic acid;

2-Aminomethyl-6-(3,4-difluoro-phaenyl)-4-methyi-hexanoic acid; 2-Aminomethyl-6-(3,5-difluoro-phaenyl)-4-methyk-hexanoic acid; 2-Aminomethyl-4-methyi-6-(2,3,4--trifluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-methyl-6-(2,3,5-frifluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-methyl-6-(2,3,65-trifluoro-phenyl)-hexanoic acid;

2-Aminomethyl-4-methyl-6-(2,4,6-trifluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-methyl-6-(2,3,48 5-tetrafluoro-phenyl)-hexanaic acicl; 2-Aminomethyl-4-methyl-6-(2,3,48 6-tetrafluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-methyl-6-(2,3,5 6-tetrafluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-methyi-6-pentaafiuorophenyl-hexanoic acid, :

2-Aminomethyl-5-(2-fluoro-phenyyl}-4-ethyl-pentanoic acid;

: = 2-Aminomethyl-5-(3-fluoro-phenyyl)-4-ethyl-pentanoic acid;

2-Aminomethy}-5-(4-fluoro-phenyyl)-4-ethyl-pentanoic acid; 2-Aminomethyl-5-(2,3-difluoro-pjenyl)-4-ethyl-pentanoic acid; 2-Aminomethyl-5-(2,4-difluoro-penyl)-4-ethyi-pentanoic acid;

2-Aminomethyl-5-(2,5-difluoro-penyl)-4-ethyl-pentanoic acid; 2-Aminomethyl-5-(2,6-difluoro-pEnenyl)-4-ethyl-pentanoic acid; 2_Aminomethyl-5-(3,4-difluoro-plhenyl)-4-ethyl-pentanoic acid; 2-Aminomethyl-5-(3,5-difluoro-plhenyl)-4-ethyl-pentancic acid; 2-Aminomethyl-4-ethyl-5-(2,3,4-Rrifluoro-phenyl)-pentanoic acid;

2-Aminomethyi-4-ethyl-5-(2,3,5-Rriflucro-phenyl)-pentanoic acid; 2-Aminomethyl-4-ethyl-5-(2,3,6-Rrifluoro-phenyl)-pentanoic acid; 2-Aminomethyl-4-ethyi-5-(2,4,6-®Rrifluoro-phenyl)-pentanoic acid;

2-Aminomethyl-4-ethyl-5-(2,=3,4 5-tetrafluoro-phenyl)-pentanoic acid; 2-Aminomethyl-4-ethyl-5-(2,3,4,6-tetrafluoro-phenyl)-pentanoic acid; 2-Aminomethyl-4-ethyl-5-(2, 3,5,6-tetrafluoro-phenyl)-pentanoic acid; 2-Aminomethyl-4-ethyl-5-pe- ntafluorophenyl-pentanoic acid; : " 2-Aminomethyl-6-(2-fluoro-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(3-fluoro-phenyl)-4-sthyl-hexanoic acid; 2-Aminomethyl-6-(4-fluoro-phenyl)~4-ethyl-hexanoic acid; 2-Aminomethyl-6-(2,3-diflucro-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(2,4-diflucro-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(2,5-diflucro-phenyi)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(2,6-difluoro-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(3,4-diflucro-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(3,5-diflucro-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-4-ethyl-6-(2,3,4-trifluoro-phenyl)-hexanoic acidg 2-Aminomethyl-4-ethyl-6-(2,3,5-trifluoro-phenyl)-hexanoic acids 2-Aminomethyl-4-ethyl-6-(2,3,6-trifluoro-phenyl)-hexanoic acid 5

~. 2-Aminomethyl-4-ethyl-6-(2.4,6-trifluoro-phenyl)-hexanoic acid ; : 2-Aminomethyl-4-ethyl-6-(2,3,4, 5-tetrafluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-ethyl-6-(22,3,4,6-tetrafluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-ethyl-6-(2,3,5,6-tetrafluoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-ethyl-6-p-entafluorophenyi-hexanoic acid; 2-Aminomethyl-7-(2-fluoro—phenyl)-4-methyl-heptanoic acid; 2-Aminomethyl-7-(3-fluoro—phenyl)-4-methyl-heptanoic acid; 2-Aminomethyl-7-(4-fluoro -phenyl)-4-methyl-heptanoic acid;

2.Aminomethyl-7-(2,3-diflisoro-phenyl)-4-methyl-heptanoic ackd; 2-Aminomethyi-7-(2,4-difiLioro-phenyl)-4-methyl-heptanoic acid; 2-Aminomethyl-7-(2,5-difiLaoro-phenyl)-4-methyl-heptanoic acid;

-2.Aminomethyl-7-(2,6-diflioro-phenyl)-4-methyl-heptanoic acid,

2.Aminomethyl-7-(3,4-diflLioro-phenyl)-4-methyl-heptanoic acid;

2.Aminomethyl-7-(3,5-difliaoro-phenyl)-4-methyl-heptanoic acid;

2.Aminomethyl-4-methyl-27-(2,3,4-trifluoro-phenyl)-heptanoic acid; 2-Aminomethyl-4-methyl-27-2,3,5-trifluoro-phenyi)-heptanaic acid;

2-Aminomethyl-4-mehyl-7-(2,3,6-trifluoro-phenyl)-heptanoic acid;

2.Aminomethyl-4-meRhyl-7-(2,4,6-trifluoro-phenyl)-heptanoic ac’id; 2-Aminomethyl-4-meRhyl-7-(2,3,4,5-tetrafluoro-phenyl)-heptanofic acid; 2-Aminomethyl-4-meRhyl-7-(2,3,4,6-tetrafluoro-phenyl)-heptano ic acid; 2-Aminomethyl-4-me-thyl-7-(2,3,5,6-tetrafluoro-phenyl)-heptano-ic acid; 2-Aminomethyl-4-mehyl-7-pentafluorophenyl-heptanoic acid; 2-Aminomethyl-7-(2-Fluoro-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyi-7-(3-Fluoro-phenyl)-4-sthyl-heptanoic acid; 2-Aminomethyl-7-(4-Fluoro-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(2,3-difluoro-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethy}-7-(2,2-difluoro-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl7-(2,5-difluoro-phenyl)-4-ethyl-heptanoic acid; : 2-Aminomethy-7-(2,S-difluoro-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(3,4difluoro-phenyl)-4-ethyi-heptanoic acid; 2-Aminomethyl-7-(3,S-difluoro-phenyl)-4-ethyl-heptanoic acid;

2. Aminomethyl-4-eth=y}-7-(2,3,4-trifluoro-phenyl)-heptanoic acid; 2-Aminomethyl-4-eth=y}-7-(2,3,5-trifluoro-phenyl)-heptanoic acicl; 2-Aminomethyl-4-eth=y}7-(2,3,6-trifluoro-phenyl)-heptanoic acid; 2-Aminomethyl-4-eth-yl-7-(2,4,6-trifluoro-phenyl)-heptanoic acicH;

2.Aminomethyl<4-eth-yl-7-(2,3,4,5-tetrafiuoro-phenyl)-heptanocic acid; 2-Aminomethyl-4-eth-yi-7-(2,3,4,6-tetrafluoro-phenyl)-heptanoic acid; - 2-Aminomethy4-ethyi-7-(2,3,5,6-tetrafluoro-phenyl)-heptanoic acid; : 2-Aminomethyl-4-eth-yl-7-pentafluorophenyl-heptanoic acid; 2-Aminomethyl-4-(2-ehloro-phenyl)-pentanoic acid; 2-Aminomethyl-4-(3-echloro-phenyl)-pentanoic acid; 2-Aminomethyl-4-(4-echioro-phenyl)-pentanoic acid; : 2-Aminomethyl-4-(2,23-dichloro-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,«4-dichloro-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,%5-dichloro-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,&-dichloro-phenyl)-pentanoic acid; 2-Aminomethyl-4-(3,=4-dichloro-phenyl)-pentanoic acid; 2_Aminomethyl-4-(3,%5-dichloro-phenyl)-pentanoic acid,

2-Aminomethyl-4-(2,3,4-trichloro-pienyl)-pentanoic acid; 2-Aminomethyl-4-(2,3,5-trichioro-pienyl)-pentanoic acid; 2-Aminomethyl-4-(2,3,6-trichloro-pimienyl)-pentanoic acid; 2-Aminomethyl-4-(2,4,6-trichloro-penyl)-pentanoic acid; 2-Aminomethyl-4-(2,3,4,5-tetrachlosro-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,3,4,6-tetrachlosro-phenyl)-pentanaic acid; 2-Aminomethyl-4-(2,3,5,6-tetrachiosro-phenyl)-pentanoic acid; 2-Aminomethyl~4-pentachlorophen-yl-pentanoic acid; 2-Aminomethyl-4-(2-chloro-phenyl®-hexanoic acid; 2-Aminomethyl-4-(3-chloro-phenyll-hexanoic acid; 2-Aminomethyl-4-(4-chloro-phenyld-hexanoic acid; 2-Aminomethyl-4-(2,3-dichloro-pheanyl)-hexanoic acid; 2-Aminomethyl-4-(2,4-dichloro-pheanyl)-hexanoic acid;

2.Aminomethyl-4-(2,5-dichloro-pheanyl)-hexanoic acid; 2-Aminomethyl-4-(2,6-dichioro-pheanyl)-hexanoic acid; 2-Aminomethyl-4-(3,4-dichloro-pheanyl)-hexanoic acid; 2-Aminomethyl-4-(3,5-dichloro-pheanyl)-hexanoic acid; 2-Aminomethyl-4-(2,3,4-trichioro-pehenyl)-hexanoic acid; 2-Aminomethyl-4-(2,3,5-trichloro-pehenyi)-hexanoic acid; 2-Aminomethyl-4-(2,3,6-trichloro-pahenyl)-hexanoic acid;

2.Aminomethyl-4-(2,4,6-trichloro-pohenyl)-hexanoic acid; - 2-Aminomethyl-4-(2,3,4,5-tetrachleoro-phenyi)-hexanoic acid; 2-Aminomethyl-4-(2,3,4,6-tetrachleoro-phenyl)-hexanoic acid; 2-Aminomethyl-4-(2,3,5,6-tetrachi~oro-phenyl)-hexanoic acid; 2-Aminomethyl-4-pentachlorophemnyl-hexanoic acid; 2-Aminomethyl-5-(2-chloro-pheny~1)-4-methyi-pentanoic acid; 2-Aminomethyl-5-(3-chloro-pheny~1)-4-methyl-pentanoic acid; 2-Aminomethyl-5-(4-chloro-pheny~1)-4-methyl-pentanoic acid; 2-Aminomethyl-5-(2,3-dichioro-ptmenyl)-4-methyl-pentanoic acid; 2-Aminomethyl-5-(2,4-dichioro-ptmenyl)-4-methyl-pentanoic acid; 2-Aminomethyl-5-(2,5-dichioro-pimenyl)-4-methyl-pentanoic ac id; 2-Aminomethyl-5-(2,6-dichloro-ptenyl)-4-methyl-pentancic acid;

WeQ 2005/030700 PCT/IB2004/002985 2-Aminomethyl-5-(3,4-dichloro-phenyl)-4--methyl-pentanoic acid; 2-Aminomethyl-5-(3,5-dichloro-phenyl)-4-methyl-pentanoic acid; 2-Aminomethyl-4-methyl-5-(2,3,4-trichlomro-phenyl)-pentanoic acid; 2-Aminomethyl-4-methyl-5-(2,3,5-trichlowo-phenyl)-pentanoic acid; 2-Aminomethyl-4-methyl-5-(2,3,6-trichlo ro-phenyt)-pentanoic acid; 2-Aminomethyl-4-methyl-5-(2,4,6-trichlo ro-phenyl)-pentanoic acid;

2.Aminomethyl-4-methyl-5-(2,3,4,5-tetraachloro-phenyl)-pentanoic acid;

2.Aminomethyl-4-methyl-5-(2,3,4,6-tetraachloro-phenyi)-pentanoic acid;

o.Aminomethyl-4-methyl-5-(2,3,5,6-tetraachioro-phenyl)-pentanoic acid; 2 Aminomethyl-4-methyl-5-pentachlorophenyl-pentanoic acid; 2-Aminomethyl-5-(2-chioro-phenyl)-4-meethyl-hexanoic acid; 2-Aminomethyl-5-(3-chioro-phenyl)-4-m-ethyl-hexanoic acid; 2-Aminomethyl-5-(4-chloro-phenyl)-4-m ethyl-hexanoic acid; 2-Aminomethyl-5-(2,3-dichloro-phenyl)-«4-methyi-hexanoic acid; 2-Aminomethyl-5-(2,4-dichioro-phenyl)-<4-methyl-hexanoic acid; 2-Aminomethyl-5-(2,5-dichloro-phenyl)--4-methyl-hexanoic acid; : 2-Aminomethyl-5-(2,6-dichloro-phenyl)--4-methyl-hexanoic acid; 2-Aminomethyl-5-(3,4-dichloro-phenyl)--4-methyi-hexanoic acid;

2. Aminomethyl-5~(3,5-dichioro-phenyi)- 4-methyl-hexanoic acid; 2-Aminomethyl-4-methyl-5-(2,3,4-trichloro-phenyl)-hexanoic acid; " o-Aminomethyl-4-methyl-5-(2,3,5-trichloro-phenyl)-hexanoic acid;

2.Aminomethyl-4-methyl-5-(2,3,6-trichioro-phenyl)-hexanoic acid;

2.Aminomethyl-4-methyl-5-(2,4,6-trichioro-phenyl)-hexanoic acid;

2.Aminomethyl-4-methyl-5-(2,3,4,5-tetr-achloro-phenyl)-hexanoic acid;

2.Aminomethyi-4-methyl-5-(2,3,4,6-tetrachloro-phenyl)-hexanoic acid; 2-Aminomethyl-4-methyi-5-(2,3,5,6-tetrachloro-phenyl)-hexanoic acid; 2-Aminomethyl-4-methyi-5-pentachloraphenyl-hexanoic acid; 2-Aminomethyl-5-(2-chloro-phenyl)-4-rinethyl-hexanoic acid; 2-Aminomethyl-5-(3-chioro-phenyi)-4-rnethyl-hexanoic acid; 2-Aminomethyl-5-(4-chloro-phenyl)-4-rmethyl-hexanoic acid; 2-Aminomethyl-5-(2,3-dichloro-phenyl)—4-methyi-hexanoic acid; } 2-Aminomethyl-5-(2,4-dichloro-phenyl)—4-methyl-hexanoic acid;

2-Aminometinyl-5-(2,5-dichloro-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(2,6-dichloro-phenyi)-4-methyl-he=xanoic acid; 2-Aminometiyl-5-(3,4-dichloro-phenyl)-4-methyl-he-xanoic acid; 2-Aminometihyl-5-(3,5-dichloro-phenyl)-4-methyl-he-xanoic acid; 2-Aminomethhyl-4-methyl-5-(2,3,4-trichloro-phenyl)-Fexanoic acid; 2-Aminometthyl-4-methyl-5-(2,3,5-trichloro-phenyl)-Fiexanoic acid; 2-Aminometlhyl-4-methyl-5-(2,3,6-trichioro-phenyl)-Bhexanoic acid; : 2-Aminomethhyl-4-methyl-5-(2,4,6-trichioro-phenyl)-lihexanoic acid; 2-Aminometihyl-4-methyi-5-(2,3,4,5-tetrachloro-phe yl)-hexanoic acid; ~ 2-Aminometthyl-4-methyl-5-(2,3,4,6-tetrachioro-phe nyl)-hexanoic acid; 2-Aminomethhyl-4-methyl-5-(2,3,5,6-tetrachloro-phe=nyl)-hexanoic acid; 2-Aminometihyl-4-methyl-5-pentachlorophenyl-hexaanoic acid; 2-Aminomet thyl-5-(2-chloro-phenyl)-4-ethyl-pentanOic acid; 2-Aminomet hyl-5-(3-chioro-phenyl)-4-ethyl-pentancic acid;

15 . 2-Aminomethyl-5-(4-chloro-phenyl}-4-ethyl-pentancic acid; 2-Aminomet hyl-5-(2,3-dichloro-phenyl)-4-ethyl-permtanoic acid; 2-Aminomet hyl-5-(2,4-dichloro-phenyl)-4-ethyl-permtanoic acid; : 2-Aminomet hyl-5-(2,5-dichloro-phenyl)-4-ethyl-permtanoic acid; 2-Aminomet hyl-5-(2,6-dichloro-phenyl)-4-ethyl-peratanoic acid; 2-Aminomet hyl-5-(3,4-dichloro-phenyl)-4-ethyl-pertanoic acid; 2-Aminomethyl-5-(3,5-dichloro-phenyi)-4-ethyl-pertanoic acid; - : 2-Aminomethyl-4-ethyl-5-(2,3,4-trichloro-phenyl)-p entanoic acid; 2-Aminomethyl-4-ethyl-5-(2,3,5-trichloro-phenyl)-peentanoic acid; 2-Aminomethyl-4-ethy-5-(2,3,6-trichioro-phenyl)-peentanoic acid; 2-Aminometthyl-4-ethyi-5-(2,4,6-trichloro-phenyl)-psentanoic acid; 2-Aminomethyl-4-ethyl-5-(2,3,4 5-tetrachloro-pheryl)-pentanoic acid; 2-Aminomethyl-4-ethyl-5-(2,3,4,6-tetrachloro-pheryl)-pentanoic acid; 2-Aminome&hyl-4-ethyi-5-(2,3,5,6-tetrachioro-pheryl)-pentanoic acid; 2-Aminome hyl-4-ethyl-5-pentachlorophenyl-pentaanoic acid; 2-Aminome ghyl-6-(2-chloro-phenyl)-4-ethyl-hexaneoic acid; 2-Aminomegthyl-6-(3-chloro-phenyl)-4-ethyl-hexanscic acid; 2-Aminomehyl-6-(4-chloro-phenyl)-4-ethyl-hexan-cic acid;

2-Aminomethyl-6-(2,3-dichloro-phenyl)-4-ethyl-he»<anoic acid;

2. Aminomethyl-6-(2,4-dichloro-phenyl)-4-ethyl-hexxanoic acid;

2. Aminomethyl-6-(2,5-dichloro-phenyf)-4-ethy-hexanoic acid; 2-Aminomethyl-6-(2,6-dichloro-phenyl)-4-ethyl-he-xanoic acid, 2-Aminomethyl-6-(3,4-dichloro-phenyl)-4-ethyl-he-xanoic acid; 2-Aminomethyl-6-(3,5-dichloro-phenyl)-4-ethyl-he=xanoic acid; : 2-Aminomethyl-4-ethyl-6-(2,3,4-trichloro-phenyi)-Bhexanoic acid; 2-Aminomethyl-4-ethyi-6-(2,3,5-trichloro-phenyl)--hexanoic acid; o-Aminomethyl-4-ethyl-6-(2,3,6-trichloro-phenyl)—hexanoic acid; 5 Aminomethyl-4-sthyl-6-(2,4,6-trichloro-phenyl)—hexanoic acid;

o.Aminomethyl-4-sthyl-6-(2,3,4 5-tetrachloro-pheanyl)-hexanoic acid; o-Aminomethyl-4-thyl-6-(2,3,4,6-tetrachloro-pheanyl)-hexanoic acid; 2-Aminomethyl-4-ethyl-6-(2,3,5 ,6-tetrachloro-pheanyl)-hexanoic acid; 2-Aminomethyl-4-ethyl-6-pentachiorophenyl-hexcanoic acid; 2-Aminomethyl-7-(2-chloro-phenyl)-4-methyl-hegptanoic acid, 2-Aminomethyl-7-(3-chloro-phenyl)-4-methyl-hegptanoic acid; 2-Aminomethy}-7-(4-chloro-phenyl)-4-methyl-he pianoic acid; 2-Aminomethyl-7-(2,3-dichloro-phenyl)-4-methy T-heptanoic acid; 2_Aminomethyl-7-(2,4-dichloro-phenyl)-4-methy-l-heptanoic acid; 2-Aminomethyl-7-(2,5-dichloro-phenyl)-4-methy=I-heptanoic acid;

2.Aminomethyl-7-(3,5-dichloro-phenyl)-4-methyyl-heptanoic acid;

2.Aminomethyl-4-methyl-7-(2,3,4-trichloro-phemnyl)-heptanoic acid;

2.Aminomethyi-4-methyl-7-(2,3,5-trichloro-phemnyl)-heptanoic acid; 2-Aminomethyl-4-methyl-7-(2,3,6-trichloro-phe nyl)-heptanoic acid; o-Aminomethyl-4-methyl-7-(2,4,8-trichloro-phe nyl)-heptanoic acid; 2-Aminomethyl-4-methyl-7-(2,3,4,5-tetrachloros-phenyl)-heptanoic acid; 2-Aminomethyl-4-methyl-7-(2,3,4,6-tetrachlorca-phenyl)-heptanoic acid; 2-Aminomethyl-4-methyl-7-(2,3,5 ,6-tetrachloro>-phenyl)-heptanoic acid; 2-Aminomethyl-4-methyl-7-pentachlorophenyi—heptanoic acid; 2-Aminomethyl-7-(2-chloro-phenyl)-4-ethyl-he ptanoic acid;

2-Aminomethyl-7-(3-chioro-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(4-chioro-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(2,3-dichloro-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(2,4-dichloro-phenyi)-4-ethyl-heptanoic acid;

2-Aminomethyk7-(2,5-dichloro-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(2,6-dichloro-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(3,4-dichloro-phenyl)-4-ethyl-heptanoic acic; 2-Aminomethyk-7-(3,5-dichloro-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-4-ethyl-7-(2,3,4-trichloro-phenyi)-heptanoic aecid;

2-Aminomethyl-4-ethyl-7-(2,3,5-trichloro-phenyl)-heptanoic ascid; 2-Aminomethyl-4-ethyl-7-(2,3,6-trichloro-phenyl)-heptanoic arcid; 2-Aminomethyl-4-ethyl-7-(2,4,6-trichloro-phenyi)-heptanoic a-cid; 2-Aminomethyl-4-ethyl-7-(2,3,4,5-tetrachloro-phenyl)-heptaneoic acid, 2-Aminomethyl-4-ethyl-7-(2,3,4,6-tetrachioro-phenyl)-heptaneoic acid,

2-Aminomethyl-4-ethyl-7-(2,3,5,6-tetrachloro-phenyl)-heptaneoic acid; 2-Aminomethyl-4-ethyl-7-pentachlorophenyi-heptanoic acid; 2-Aminomethyl-4-(2-methoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4-(3-methoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4-(4-methoxy-phenyl)-pentanoic acid;

2-Aminomethyl-4-(2,3-dimethoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,4-dimethoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,6-dimethoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,6-dimethoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4-(3,4-dimethoxy-phenyl)-pentanoic acid;

255 2-Aminomethyl-4-(3,5-dimethoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,3,4~trimethoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,3,5-trimethoxy-phenyl)-pentanoic acid;

2-Aminomethyl-4-(2,3,6-trimethoxy-phenyl)-pentanoic acid;

2-Aminomethyl-4-(2,4,6~trimethoxy-phenyl)-pentanoic acid;

2-Aminomethyl-4-(2-methoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4-(3-methoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4-(4-methoxy-phenyl)-hexanoic acid;

o-Armninomethyl-4-(2,3-dimethoxy-phenyl)-hexanoic aacid; o-Arminomethyl-4-(2,4-dimethoxy-phenyl)-hexanoic acid; o-Arminomethyk4-(2,5-dimethoxy-phenyl)-hexanoic acid; 2-Armninomethyl-4-(2,6-dimethoxy-phenyl)-hexanoic acid; " 2-Armninomethyl-4-(3,4-dimethoxy-phenyl)-hexanoic acid; 2-Armninomethyl-4-(3,5-dimethoxy-phenyl)-hexanoic acid; 2-Arminomethyh4-(2,3 /4-trimethoxy-phenyl)-hexanoilic acid; 2-Arminomethyl-4-(2,3,5-trimethoxy-phenyl)-hexanoiiic acid; 2-Araninomethyl-4-(2,3,6-trimethoxy-phenyl)-hexanoiic acid; 2-Arminomethyl-4-(2,4,6-trimethoxy-phenyl)-hexanoiic acid; 2-Armninomethyl-5-(2-methoxy-phenyl)-4-methyl-pen tanoic acid; 2-Arminomethyl-5-(3-methoxy-phenyl)-4-methyi-pen_tanoic acid; 2-Anmninomethyl-5-(4-methoxy-phenyl)-4-methyl-penstanoic acid; 2-Arminomethyl-5-(2,3-dimethoxy-phenyl)-4-methyl- pentanoic acid; 2-Arminomethyl-5-(2,4-dimethoxy-phenyl)-4-methyl- pentanoic acid, : 2-Araninomethyl-5-(2,5-dimethoxy-phenyi)-4-methyl- pentanoic acid; 2-Armninomethyl-5-(2,6-dimethoxy-phenyl)-4-methyl--pentanoic acid;

2.Anmninomethyl-5-(3,4-dimethoxy-phenyl)-4-methyl--pentanoic acid; 2-Anminomethyl-5-(3,5-dimethoxy-phenyl)-4-methyi--pentanoic acid; 2-Armninomethyl-4-methyl-5-(2,3,4-trimethoxy-pheny-1)-pentanoic acid; 2-Armninomethyl-4-methyl-5-(2,3,5-trimethoxy-pheny~1)-pentanoic acid; ~ : 2-Armninomethyl-4-methyl-5-(2,3,6-trimethoxy-pheny~1)-pentanoic acid; o-Armninomethyl-4-methyl-5-(2,4,6-trimethoxy-pheny~1)-pentanoic acid; 2-Arminomethyl-5-(2-methoxy-pheny!)-4-methyl-hexxzanoic acid; 2-Arminomethyl-5-(3-methoxy-phenyl)-4-methyl-hexxzanoic acid; 2-Arminomethyl-5-(4-methoxy-phenyl)-4-methyl-hexxzanoic acid; 2-Amminomethyl-5-(2,3-dimethoxy-phenyl)-4-methyl—hexanoic acid; 2-Arminomethyl-5-(2,4-dimethoxy-phenyl)-4-methyl—hexanoic acid; 2-Arminomethyl-5-(2,5-dimethoxy-phenyl)-4-methyl—hexanoic acid;

2. Amninomethyl-5-(2,6-dimethoxy-phenyl)-4-methyl—hexanoic acid;

2. Amminomethyl-5-(3,4-dimethoxy-phenyl)-4-methyl—hexanoic acid; 2-Armminomethy}-5-(3,5-dimethoxy-phenyl)-4-methyl—hexanoic acid;

2.Aminomethyl-4-methyl-5-(2,3,4-trimethoxy-phenyl)-hexanoi c acid;

2.Aminomethyk4-methyl-5-(2,3,5-trimethoxy-phenyl)-hexanok.c acid;

5. Aminomethyk4-methyl-5-(2,3,6-trimethoxy-phenyl)-hexanolic acid;

2.Aminomethyl-4-methyl-5-(2,4 6-trimethoxy-phenyl)-hexanoiic acid;

o.Aminomethyi-6-(2-methoxy-phenyl)-4-methyl-hexanoic acid,

2.Aminomethy-6-(3-methoxy-phenyl)-4-methyl-hexanoic acicl;

2.Aminomethy!-6-(4-methoxy-phenyl)-4-methyl-hexanoic acict;

‘2. Aminomethyi-6-(2,3-dimethoxy-phenyl)-4-methyl-hexanoic acid;

o.Aminomethy-6-(2,4-dimethoxy-phenyl)-4-methyl-hexanoic acid;

2.Aminomethy\-6-(2,5-dimethoxy-phenyi)-4-methyl-hexanoic acid;

2.Aminomethy!-6-(2,6-dimethoxy-phenyl)-4-methyl-hexanoic acid;

2.Aminomethy}-6-(3,4-dimethoxy-phenyl)-4-methyl-hexanoic acid;

2.Aminomethy-6-(3,5-dimethoxy-phenyl)-4-methyl-hexanoic acid; : : 2.Aminomethyl-4-methyl-6-(2,3,4-trimethoxy-phenyl)-hexanosic acid;

2.Aminomethyl-4-methyi-6-(2,3,5-trimethoxy-phenyl)-hexanasic acid;

2. Aminomethyl-4-methyl-6-(2,3,6-trimethoxy-phenyl)-hexanaeic acid; 2-Aminomethyt-4-methyl-6-(2,4,6-trimethoxy-phenyl)-hexanasic acid;

2.Aminomethyl-5-(2-methoxy-phenyl)~4-ethyl-pentanoic acid ;

2.Aminomethyl-5-(3-methoxy-phenyl)-4-ethyl-pentanoic acid ; 2-Aminomethyl-5-(4-methoxy-phenyl)-4-ethyl-pentanoic acid ; 2-Aminomethyl-5-(2,3-dimethoxy-phenyl)-4-ethyl-pentanoic cid; 2-Aminomethyl-5-(2,4-dimethoxy-phenyl)-4-ethyl-pentanoic acid;

2.Aminomethyl-5-(2,5-dimethoxy-phenyl)-4-ethyl-pentanoic acid; 2-Aminomethyk5-(2,6-dimethoxy-phenyl)-4-ethyl-pentanoic acid; 2-Aminomethyt5-(3,4-dimethoxy-phenyl)-4-sthyl-pentanoic acid; 2-Aminomethyl-5-(3,5-dimethoxy-phenyl)-4-sthyl-pentanoic acid; 2-Aminomethyl-4-ethyl-5-(2,3 4-trimethoxy-phenyl)-pentanoi c acid; 2-Aminomethyl-4-ethyl-5-(2,3,5-frimethoxy-phenyl)-pentanokc acid; 2-Aminomethyl-4-ethyl-5-(2,3,6-trimethoxy-phenyl)-pentanoiic acid; 2-Aminomethyl-4-ethyl-5-(2,4,6-trimethoxy-phenyl)-pentanoiic acid;

2.Aminomethyl-4-ethyl-5-(2,3,4,5-tetramethoxy-phenyl)-penianoic acid; 2-Aminomethyli-4-sthyl-5-(2,3,4,6-tetramethoxy-phenyl)-pentanoic acid;

2-Aminomethayl-4-ethyl-5-(2,3,5,6-tetramethoxy-phenyl)-pentanoics acid; 2-Aminomethmyi-4-ethyl-5-pentamethoxyphenyl-pentanoic acid; 2-Aminomethayl-6-(2-methoxy-phenyi)-4-ethyl-hexanoic acid; 2-Aminometiyl-6-(3-methoxy-phenyl)-4-ethyi-hexanoic acid; 2-Aminometiyl-6-(4-methoxy-phenyl)-4-ethyl-hexanoic acid; 2-Aminometiyl-6-(2,3-dimethoxy-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(2,4-dimethoxy-phenyl)-4-ethyl-hexanoic acid; 2-Aminomettyl-6-(2,5-dimethoxy-phenyl)-4-ethyl-hexanoic acid; 2-Aminometinyi-6-(2,6-dimethoxy-phenyl)-4-ethyl-hexanoic acid; 2-Aminometinyl-6-(3,4-dimethoxy-phenyl)-4-ethyl-hexanoic acid; 2-Aminometlhyi-6-(3,5-dimethoxy-phenyl)-4-ethyl-hexanoic acid;

"2. Aminomethhyl-4-ethy-6-(2,3,4-trimethoxy-phenyl)-hexanoic acied; 2-Aminometthyl-4-ethyl-6-(2,3,5-trimethoxy-phenyl)-hexanoic acid; 2-Aminomet hyl-4-ethyl-6-(2,3,6-trimethoxy-pheny)-hexanoic acid; ‘2-Aminomet hyl-4-ethyl-6-(2,4,6-trimethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-7-(2-methoxy-phenyl)-4-methyi-heptancic acid; 2-Aminomethyl-7-(3-methoxy-phenyl)-4-methyl-heptanoic acid; 2-Aminomethyl-7-(4-methoxy-phenyl)-4-methyl-heptanoic acid; 2-Aminome&hyl-7-(2,3-dimethoxy-phenyl)-4-methyl-heptanoic acid; 2-Aminometthyl-7-(2,4-dimethoxy-phenyl)-4-methyl-heptanoic acid;

2.Aminome&hyl-7-(2,6-dimethoxy-phenyl)-4-methyl-heptanoic acid; 2-Aminomehyl-7-(3,4-dimethoxy-phenyl)-4-methyl-heptanoic a«cid; 2-Aminome-thyl-7-(3,5-dimethoxy-phenyl)-4-methyl-heptanoic a cid;

2.Aminome-thyl-4-methyl-7-(2,3,4-trimethoxy-phenyl)-heptanoics acid; 2-Aminome thyl-4-methyl-7-(2,3,5-trimethoxy-phenyl)-heptanoic acid; 2-Aminomexthyl-4-methyl-7-(2,3,6-trimethoxy-phenyl)-heptanoic acid;

2.Aminomenthyl-4-methyl-7-(2;4,6-trimethoxy-phenyl)-heptanoic acid; 2-Aminomesthyl-7-(2-methoxy-phenyl)-4-ethyl-heptanoic acid; 2-Aminomeathyl-7-(3-methoxy-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(4-methoxy-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(2,3-dimethoxy-phenyl)-4-ethyl-heptanoic ac-id;

2-Aminomethyl-7-(2,4-Aimethoxy-phenyl)-4-ethyl-heptanoic= acid; 2-Aminomethyl-7-(2,5-climethoxy-phenyl)-4-ethyl-heptanoic= acid; 2-Aminomethyi-7-(2,6-cllimethoxy-phenyl)-4-ethyl-heptanoic= acid; 2-Aminomethyl-7-(3,4-dlimethoxy-phenyl)-4-ethyl-heptanoics acid;

2-Aminomethyl-7-(3,5-dllimethoxy-phenyl)-4-ethyl-heptanoic= acid; 2-Aminomethyl-4-ethyl-"7-(2,3,4-trimethoxy-phenyl)-heptancoic acid; 2-Aminomethyl-4-ethyl-"7-(2,3,5-trimethoxy-phenyl)-heptancic acid; 2-Aminomethyl-4-ethyl-"7-(2,3,6-trimethoxy-phenyl)-heptancic acid; 2-Aminomethyl-4-sthyl-—7-(2,4,6-trimethoxy-phenyl)-heptancic acid;

2-Aminomethyl-4-(2-trifl uoromethyl-phenyl)-pentanoic acid; 2-Aminomethyl-4-(3-triflsuoromethyl-phenyl)-pentanoic acid; 2-Aminomethyl-4-(4-triflmuoromethyl-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,3-d i-trifluoromethyi-phenyl)-pentanoic &cid; 2-Aminomethyl-4-(2,4-d i-trifluoromethyl-phenyl)-pentanoic &xcid;

2-Aminomethyl-4-(2,5-d i-trifluoromethyl-phenyl)-pentanoic &xcid; 2-Aminomethyl-4-(2,6-dili-trifluoromethyi-phenyl)-pentanoic &acid; 2-Aminomethyi-4-(3,4-dii-trifluoromethyl-phenyl)-pentanoic &acid; 2-Aminomethyl-4-(3,5-di-trifluoromethyl-phenyl)-pentanoic &xcid; 2-Aminomethyl-4-(2,3,4—tri-trifluoromethyl-phenyl)-pentanoiec acid;

2-Aminomethyl-4-(2,3,5—tri-triftuoromethyl-phenyl)-pentanoiec acid; 2-Aminomethyl-4-(2,3,6—tri-trifluoromethyl-phenyl)-pentanoiec acid; -

: 2-Aminomethyl-4-(2,4,6—tri-trifluoromethyl-phenyl)-pentanoiec acid; : 2-Aminomethyl-4-(2-trifiicromethyl-phenyl)-hexanoic acid; 2-Aminomethyl-4-(3-trifluoromethyl-phenyl)-hexanoic acid;

2-Aminomethyl-4-(4-trifli_ioromethyl-phenyl)-hexanoic acid; 2-Aminomethyl-4-(2,3-di- -trifluoromethyl-phenyl)-hexanoic a«cid; 2-Aminomethyl4-(2,4-di—trifluoromethyl-phenyl)-hexanoic ascid; 2-Aminomethyl-4-(2,5-di—trifluoromethyl-phenyl)-hexanoic ascid; 2-Aminomethyl-4-(2,6-di—trifluoromethyl-phenyl)-hexanoic ascid;

2-Aminomethyl-4-(3,4-di—trifluoromethyl-phenyl)-hexanoic ascid; 2-Aminomethyl-4-(3,5-di~trifluoromethyl-phenyl)-hexanoic acid;

2-Aminomethyl-4-(2,3,4-#ri-trifluoromethyt-phenyf)-hexanoic acid;

2-Aminomethyl-4-(2,3,5~tri-trifluoromethyl-phenyl)-hexanosic acid; : 2-Aminomethyl-4-(2,3,6~tri-trifluoromethyl-phenyl)-hexanomic acid; 2-Aminomethyl-4-(2,4,6~tri-trifluoromethyl-phenyl)-hexancic acid; 2-Aminomethyl-5-(2-trifl uoromethyl-phenyi)-4-methyl-pen®anoic acid;

o-Aminomethyl-5-(3-trift uoromethyl-phenyl)-4-methyi-pen*tanoic acid; 2-Aminomethyl-5-(4-trifl uoromethyl-phenyl)-4-methyl-pen—tanoic acid; 2-Aminomethyl-5-(2,3-clli-trifluoromethyl-phenyl)-4-methyl—pentanoic acid; 2-Aminomethyl-5-(2,4-dli-trifluoromethyl-phenyl)-4-methyl—pentanoic

" acid; 2-Aminomethyl-5-(2,5-dlli-rifluoromethyi-phenyl)-4-methyl—pentanoic acid; 2-Aminomethyl-5-(2,6-dlli-trifluoromethyl-phenyl)-4-methyl -pentanoic acid; :

2-Aminomethyl-5-(3,4-clli-trifluoromethyl-phenyl)-4-methy B-pentanoic acid; 2-Aminomethyi-5-(3,5-dlli-trifluoromethyi-phenyl)-4-methy -pentanoic acid; 2-Aminomethyl-4-methywl-5-(2,3,4-tri-trifluoromethyl-phenzyl)-pentanoic

| acid; 2-Aminomethyk-4-methyw!-5-(2,3 5-tri-trifluoromethyl-phen-yi)-pentanoic

: acid; 2-Aminomethyl-4-methyw1-5-(2,3,6-tri-trifluoromethyl-phen’ yl)-pentanoic acid;

2-Aminomethyl-4-methyw1-5-(2,4,6-tri-trifluoromethyl-phenayl)-pentanoic acid; 2-Aminomethyi-5-(2-trifliuoromethyi-phenyl)-4-methyi-hex<anoic acid; 2-Aminomethyl-5-(3-trifEuoromethyl-phenyl)-4-methyi-he><anoic acid; 2-Aminomethyl-5-(4-trifli uoromethyl-phenyl)-4-methyl-he>=<anoic acid;

2-Aminomethyl-5-(2,3-cBii-trifluoromethyl-phenyl)-4-methy~l-hexanoic acid;

2.Aminomethyl-5-(2,4-di-triflucromethyl-phenyl)-4-methyl-hexanoic acid;

2.Aminomethyl-5-(2,5-di-triflucromethyl-phenyl)~4-methyl-hexanoic acid;

2.Aminomethyl-5-(2,6-di-triflucromethyi-phenyl)-4-methyi-hexanoic acid;

5. Aminomethyl-5-(3,4-di-triflucsromethyl-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(3,5-di-triflucsromethyl-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-4-methyl-5-(2,3 4-tri-trifluoromethyl-phenyl)-hexanoic acid; 2-Aminomethyl-4-methyl-5-(2,3 5-tri-trifluoromethyl-phenyl)-hexanoic acid;

2.Aminomethyk-4-methyl-5-(2,3 6-tri-trifluoromethyl-phenyl)-hexanoic acid; . 2.Aminomethyl-4-methyl-5-(2,4 6-tri-trifluoromethyl-phenyl)-hexanoic acid,

2.Aminomethyl-6-(2-trifluoromethyl-phenyl)-4-methyl-hexanoic acid; -0) 2.Aminomethyl-6-(3-triflucromesthyl-phenyl)-4-methyl-hexanoic acid; 2-Aminomethy}-6-(4-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;

2.Aminomethyl-6-(2,3-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyi-6-(2,4-di-trifluowomethyl-phenyl)-4-methyl-hexanoic acid;

2.Aminomethyl-6-(2,5-di-trifluowomethyl-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-6-(2,6-di-trifluorromethyl-phenyl)-4-methyi-hexanoic acid; 2-Aminomethyl-6-(3,4-di-trifluoromethyl-phenyl)-4-methyl-hexanoic acid;

2.Aminomethyl-6-(3,5-di-trifluoromethyl-phenyl)-4-methyl-hexanosic acid;

2.Aminomethyl-4-methyl-6—(2,3,4-tri-trifluoromethyl-phenyl)-hexa=noic acid;

2.Aminomethyl-4-methyl-6—(2,3,5-tri-trifluoromethyl-phenyl)-hexa_roic acid;

2.Aminomethyl-4-methyl-6-(2,3,6-tri-trifluoromethyl-phenyl)-hexemnoic acid;

2.Aminomethyl-4-methyl-6-(2,4,6-tri-triflucromethyl-phenyl)-hexamnoic acid;

2. Aminomethyl-5-(2-trifluoromethyl-phenyi)-4-ethyl-pentanoic ac=id;

2.Aminomethyl-5-(3-trifluo romethyi-phenyi)-4-ethyl-pentanoic acid;

2.Aminomethyl-5-(4-trifluoromethyl-phenyl)-4-ethyl-pentanoic acid;

2.Aminomethyl-5-(2,3-di-trifluoromethyl-phenyl)~4-ethyl-pentanosic acid;

2.Aminomethyl-5-(2,4-di-tr ifluoromethyl-phenyl)-4-ethyl-pentancaic acid; :

2. Aminomethyl-5-(2,5-di-tr ifiuoromethyl-phenyi)-4-ethyl-pentancaic acid;

2.Aminomethyl-5-(2,6-di-trifluoromethyl-phenyl)-4-ethyl-pentanoic acid;

2. Aminomethyl-5-(3,4-di-tr ifluoromethyl-phenyl)-4-ethyl-pentancic acid;

2. Aminomethyl-5-(3,5-di-tr ifluoromethyi-phenyl)-4-ethyl-pentancic acid;

2.Aminomethyl-4-ethyl-5-(2,3,4-tri-trifluoromethyl-phenyl)-pentas noic acid; : a Co

2.Aminomethyl-4-ethyl-5-(2,3,5-tri-trifluoromethyl-phenyl)-pentamnoic acid; 2-Aminomethyl-4-ethyl-5-(2,3,6-tri-trifluoromethyl-phe nyl)-pentaanoic acid;

2. Aminomethyl-4-ethyl-6-(2,4,6-tr-trifluoromethyl-phenyl)-pentenoic acid; 2-Aminomethyl-4-ethyl-5-( 2,3,4,5-tetra-trifluoromethyl-phenyl)- pentanoic acid; 30m 2-Aminomethyl-4-ethyl-5-(2,3,4,6-tetra-trifluoromethyi-phenyi)- pentanoic acid;

2-Aminomethyl-4-ethyl-5-(2,3,5,6-tetra-twrifluoromethyl-phenyl)- pentanoic acid, 2-Aminomethyl-4-ethyl-5-penta-trifiuoror methylphenyl-pentanoic acid; 2-Aminomethyl-6-(2-trifluoromethyl-pheryl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(3-triflucromethyi-pheryi)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(4-triflucromethyl-phemnyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(2,3-di-trifluoromethyl—phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(2,4-di-trifluoromethyl—phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(2,5-di-trifluoromethyl—phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyi-6-(2,6-di-triflucromethyl—phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(3,4-di-trifluoromethyl—phenyl)4-ethyl-hexanoic acid; 2-Aminomethyl-6-(3,5-di-trifluoromethyl—phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-4-ethyl-6-(2,3,4-tri-triflucaromethyi-phenyl)-hexanoic acid; | :

15 . 2-Aminomethyl-4-ethyl-6-(2,3,5-tri-trifucoromethyl-phenyl)-hexanoic acid; 2-Aminomethyl-4-ethyl-6-(2,3,6-tri-triflucromethyl-phenyl)-hexanoic acid, 2-Aminomethyl-4-ethyl-6-(2,4,6-tri-triflucromethyl-phenyl)-hexanoic acid; 2-Aminomethyl-7-(2-trifluoromethyl-phe : nyl)-4-methyl-heptanoic acid; 2-Aminomethyl-7-(3-trifluoromethyl-phe=nyi)-4-methyl-heptanoic acid; 2-Aminomethyl-7-(4-trifluoromethyl-phe=nyl)-4-methyl-heptanoic acid; 2-Aminomethyl-7-(2,3-di-trifluoromethyl -phenyl)-4-methyl-heptanoic acid; 2-Aminomethyl-7-(2,4-di-trifluoromethy@-phenyi)-4-methyl-heptanoic acid; 2-Aminomethyl-7-(2,5-di-trifluoromethy -phenyl)-4-methyl-heptanoic acid; . 2-Aminomethyl-7-(2,6-di-trifluoromethyl-phenyl)-4-methyl-heptanoic acid;

2-Aminomethyi-7-(3,4-di-trifluoromethyl-phenyl)-4-methyi-h eptanoic acid; : 2-Aminomethyi-7-(3,5-di-trifluoromethyl-phenyl)-4-methyl-teeptanoic acid; 2-Aminomethy/l-4-methyl-7-(2,3,4-tri-trifluoromethyl-phenyip-heptanoic acid; ’ 2-Aminomethy/i4-methyl-7-(2,3,5-tri-trifluoromethyl-phenyi®-heptanoic acid; A

2.Aminomethysl-4-methyl-7-(2,3,6-tri-trifluoromethyl-phenyi®-heptanoic acid; 2-Aminomethysl-4-methyl-7-(2,4,6-tri-trifluoromethyi-phenyi®-heptanoic acid; 2-Aminomethyri-7-(2-trifluoromethyl-phenyl)-4-sthyl-heptaneic acid; 2-Aminomethyrl-7-(3-trifluoromethyl-phenyl)-4-ethyl-heptaneic acid; 2-Aminomethyri-7-(4-trifluoromethyl-phenyl)-4-ethyl-heptaneoic acid; 2-Aminomethyrl-7-(2,3-di-trifluoromethyl-phenyl)-4-ethyl-hegotanoic acid; 2-Aminomethyrl-7-(2,4-di-trifluoromethyi-phenyl)-4-ethyl-hegotanoic acid; 2-Aminomethy1-7-(2,5-di-trifluoromethyl-phenyl)-4-ethyl-hegotanoic acid;

2.Aminomethyrl-7-(2,6-di-trifluoromethyl-phenyl)-4-ethyl-hegplanoic acid; 2-Aminomethy-1-7-(3,4-di-trifluoromethyl-phenyl)-4-ethyl-hegptanoic acid; 2-AminomethyrI-7-(3,5-di-trifluoromethyl-phenyl)-4-ethyl-hegptanoic acid; 2-Aminomethy 1-4-ethyl-7-(2,3,4-tri-triflucromethyl-phenyl)-Meptanoic acid; 2-Aminomethy I-4-ethyl-7-(2,3,5-tri-trifluoromethyl-phenyl)-neptanoic acid; 2-Aminomethy }-4-ethyl-7-(2,3,6-tri-trifluoromethyl-phenyl)-teptanoic acid; 2-Aminomethy 1-4-ethyl-7-(2,4,6-tri-trifluoromethyl-phenyl)-Feptanoic acid; 2-Aminomethy 8-4-(2-trifluoromethoxy-phenyl)-pentanoic acid; 2-AminomethyB-4-(3-trifluoromethoxy-phenyl)-pentanoic acid, 2-AminomethyB-4-(4-trifluoromethoxy-phenyl)-pentanoic acid;

2 Amminomethyl-4-(2,3-di-trifluoromethoxy-phenyl)-pentanoiic acid; o_Amminomethyk-4-(2,4-di-triflucromethoxy-phenyl)-pentanofiic acid; 2_Amminomethyl-4-(2,5-di-trifluoromethoxy-phenyl)-pentanoiic acid;

2. Amminomethyl-4-(2,6-di-rifluoromethoxy-phenyl)-pentanoiic acid; 2_Ammninomethyl-4-(3,4-di-trifluoromethoxy-phenyl)-pentanoiiic acid; 2-Amrminomethyi-4-(3,5-di-trifluoromethoxy-phenyl)-pentanotic acid; o_Amminomethyl4-(2,3,4-tri-trifluoromethoxy-phenyl)-pentaroic acid;

2. Amrninomethyl-4-(2,3,5-tri-trifluoromethoxy-phenyl)-pentaroic acid;

2. Arminomethyl-4-(2,3,6-tri-trifluoromethoxy-phenyl)-pentaroic acid; 2-Arninomethyl-4-(2,4,6-tri-trifluoromethoxy-phenyl)-pentaroic acid; 2-Arninomethyl-4-(2-trifluoromethoxy-phenyl)-hexanoic aci d; 2-Arninomethyl-4-(3-trifluoromethoxy-phenyl)-hexanoic aci d;

2.Arninomethyl-4-(4-trifluoromethoxy-phenyl)-hexanoic aci d; 2-Arninomethyl-4-(2,3-di-trifluoromethoxy-phenyl)-hexanoiec acid; 2-Arninomethyl-4-(2,4-di-trifluoromethoxy-phenyl)-hexanoiec acid;

2.Arninomethyl-4-(2,5-di-trifluoromethoxy-phenyl)-hexanoiec acid; 2-Arninomethyl-4-(2,6-di-trifluoromethoxy-phenyl)-hexanoisc acid;

2. Arninomethyl-4-(3,4-di-trifluoromethoxy-phenyl)-hexanoiec acid; : 2-Arninomethyl-4-(3,5-di-trifluoromethoxy-phenyl)-hexanoisc acid; 2-Arminomethyl-4-(2,3,4-tri-trifluoromethoxy-phenyl)-hexamoic acid; 2-Arninomethyl-4-(2,3,5-tri-trifluoromethoxy-phenyl)-hexarmoic acid; 2_Arninomethyl-4-(2,3,6-tri-trifluoromethoxy-phenyl)-hexarmoic acid; 2-Arminomethyl-4-(2,4,6-tri-trifluoromethoxy-phenyl)-hexarmsoic acid; 2-Armninomethyl-5-(2-triflucromethoxy-phenyl)-4-methyl-pe mtanoic acid; 2-Arminomethyl-5-(3-trifluoromethoxy-phenyl)-4-methyl-pemntanoic acid; o-Arminomethyl-5-(4-trifluoromethoxy-phenyl)-4-methy!-pemntancic acid; 2-Arminomethyl-5-(2,3-di-trifluoromethoxy-phenyl)-4-methywi-pentanoic acids ; 2-Arminomethyl-5-(2,4-di-trifluoromethoxy-phenyl)-4-methyl-pentanoic acids 2-Armninomethyl-5-(2,5-di-trifluoromethoxy-phenyl)-4-methywl-pentanoic acids”

2-Aminomettyl-5-(2,6-di-trifluoromethoxy-phenyl)-4-met-hyl-pentanoic acid; 2-Aminometiyl-5-(3,4-di-trifluoromethoxy-phenyl)-4-mefthyl-pentanoic acid;

2-Aminomethhyl-5-(3 5-di-trifluoromethoxy-phenyl)-4-me-thyl-pentanoic acid; 2-Aminometlhyl-4-methyl-5-(2,3,4-ri-trifluoromethoxy-pienyi)-pentanoic acid, 2-Aminomethhyl-4-methyl-5-(2,3,5-tri-trifluoromethoxy-plenyl)-pentanoic acid; 2-Aminometthyi-4-methyl-5-(2,3,6-tri-trifluoromethoxy-pnienyl)-pentanoic acid; 2-Aminometihyl-4-methyl-5-(2,4,6-tri-trifluoromethoxy-plhenyl)-pentanoic acid; 2-Aminomet tyl-5-(2-trifluoromethoxy-phenyl)-4-ethyl-peentanoic acid; 2-Aminomet tyl-5-(3-trifluoromethoxy-phenyi)-4-ethyl-peentanoic acid;

: 2-Aminomet thyl-5-(4-trifluoromethoxy-phenyl)-4-ethyl-psentanoic acid; 2-Aminomethyl-5-(2,3-di-trifluoromethoxy-phenyl)-4-etiyi-pentanoic acid;

2-Aminomet hyl-5-(2,4-di-trifluoromethoxy-phenyl)-4-etiyl-pentanoic acid; : 2-Aminomet hyl-5-(2,5-di-trifluoromethoxy-phenyi)-4-etlhyl-pentanoic acid; 2-Aminomethyl-5-(2,6-di-trifluoromethoxy-phenyl)-4-stlihyl-pentanoic acid; 2-Aminomethyl-5-(3,4-di-trifluoromethoxy-phenyl)-4-etshyl-pentanoic acid; 2-Aminomethyl-5-(3,5-di-trifluoromethoxy-phenyl)-4-et-hyl-pentanoic acid; 2-Aminomethyl-4-ethyl-5-(2,3,4-tri-trifluoromethoxy-phu enyl)-pentanoic acid;

o.Aminomethyl-4-ethyl-5-(2,3,5-tri-trifluorommethoxy-phenyl)-pentanoic acid;

2.Aminomethyl-4-ethyl-5-(2,3,6-tri-trifluorormiethoxy-phenyi)-pentanoic acid;

o.Aminomethyl-4-ethyl-5-(2,4,6-tri-trifluoroniethoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4-ethyl-5-(2,3,4,5-tetra-triflu oromethoxy-phenyl)- pentanoic acid;

2.Aminomethyl-4-ethyl-5-(2,3,4,6-tetra-trifluu oromethoxy-phenyl)- . ~ pentanoic acid; 2-Aminomethyl-d-ethyl-5-(2,3,5,6-tetra-triflumoromethoxy-phenyl)- pentanoic acid;

2.Arminomethyl-4-ethyl-5-penta-triflucromet-hoxyphenyl-pentanoic acid; : 2-Aminomethyl-5-(2-trifluoromethoxy-phenyyi)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(3-trifiuoromethoxy-phenyyl)-4-methyl-hexanoic acid;

2.Aminomethyl-5-(4-trifluoromethoxy-phenyi}-4-methyl-hexanoic acid; 2-Aminomethyl-5-(2,3-di-trifluoromethoxy-pehenyl)-4-methyl-hexanoic acid; 2-Aminomethyi-5-(2,4-di-trifluoromethoxy-ps henyl)-4-methyl-hexanoic “acid; 2 Aminomethyl-5-(2,5-di-trifluoromethoxy-pahenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(2,6-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(3,4-di-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid;

2.Aminomethyl-5-(3,5-di-trifluoromethoxy-pohenyl)-4-methyl-hexanoic acid, 2-Aminomethyl-4-methyl-5-(2,3,4-tri-trifluosromethoxy-phenyl)-hexanoiec acid; 2-Aminomethyl-4-methyl-5-(2,3,5-tri-trifluowromethoxy-phenyl)-hexanoiec acid;

Va’ 0 2005/030700 PCT/TB2004/002985 2-Aminomethyl-4-methyl-5-(2,3,6-tri-trifluoromethoxy-phenyl)-hexanoic acid, 2-Aminomethyl-4-methyi-5-(2,4,6-tri-trifluoromethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-6-(2-trifluorometinoxy-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-6-(3-trifluorometinoxy-phenyi)-4-methyl-hexanoic acid; 2-Aminomethyl-6-(4-trifluoromethoxy-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-6-(2,3-di-trifluoro amethoxy-phenyi)-4-methyl-hexanoic acid; 2-Aminomethyl-6-(2,4-di-trifluorommethoxy-phenyf)-4-methyl-hexanoic acid; 2-Aminomethyl-6-(2,5-di-trifluorosmethoxy-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-6-(2,6-di-trifluorommethoxy-phenyl)-4-methyl-hexanoic acid;

. 2-Aminomethyi-6-(3,4-di-trifluorosmethoxy-phenyi)-4-methyl-hexanoic acid; 2-Aminomethyl-6-(3,5-di-trifluorornethoxy-phenyl)-4-methyl-hexanoic acid; : 2-Aminomethyl-4-methyl-6-(2,3,4 -tri-trifluoromethoxy-phenyl)-hexanoic acid; : : 2-Aminomethyl-4-methyl-6-(2,3,5 —tri-trifluoromethoxy-phenyl)-hexanoic acid; - 2-Aminomethyl-4-methyl-6-(2,3,6 ~tri-trifluoromethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4-methyl-6-(2,4,6 —tri-trifluoromethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-6-(2-triluorometh«oxy-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyi-6-(3-trifluorometh«oxy-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(4-trifluorometheoxy-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(2,3-di-trifluorormnethoxy-phenyl)-4-ethyl-hexanoic acid;

2_Aminomethyl-6-(2,4-di-triflucromethoxy-phenyl)-4-ethyl-niexanoic acid;

2. Aminomethyl-6-(2,5-di-triflucromethoxy-phenyl)-4-ethyl-Fexancic acid; 2_Aminomethyl-6-(2,6-di-triflucomethoxy-phenyl)-4-ethyl-Fexanoic acid; 2-Aminomethyi-6-(3,4-di-triflusromethoxy-phenyl)-4-ethyl-finexanoic acid;

o. Aminomethyl-6-(3,5-di-triflucromethoxy-phenyl)4-ethyl-Bhexanoic acid;

: 2.Aminomethyl-4-ethyl-6-(2,3,. 4ri-trifluoromethoxy-phenyl)-hexanoic acid;

2. Aminomethyl-4-ethyl-6-(2,3,. S-tri-trifluoromethoxy-pheny 1)-hexanoic acid;

2.Aminomethyl-d-ethyl-6-(2,3 . 6-tri-trifluoromethoxy-phenyT)-hexanoic acid;

2. Aminomethyl-4-ethyl-6-(2,4,. 6-tri-trifluoromethoxy-pheny~1)-hexanoic acid;

2. Aminomethyl-7-(2-trifluororraethoxy-phenyl)-4-methyl-hesptanoic acid; > o-Aminomethyl-7-(3-trifluororrmethoxy-phenyi)-4-methyl-hesptanoic acid; 2-Aminomethyl-7-(4-trifluororrmethoxy-phenyl)-4-methyl-hesptanoic acid; 2-Aminomethyl-7-(2,3-di-triflucoromethoxy-phenyl)-4-meth=yl-heptanoic acid;

2.Aminomethyl-7-(2,4-di-trifluromethoxy-phenyl)-4-meth-yl-heptanoic acid;

2.Aminomethyl-7-(2,5-di-triflueoomethoxy-phenyl)-4-meth- yl-heptanoic acid;

o.Aminomethyl-7-(2,6-di-trifluecromethoxy-phenyl)-4-metheyi-heptanoic : acid; 0 2-Aminomethyl-7-(3,4-di-triflueoromethoxy-phenyl)-4-metheyl-heptanoic acid; —147— y

2-Aminomethyl-7— (3 5-di-trifluoromethoxy-phenyl)-4-methyl-heptanoic acid; 2-Aminomethyl-4- methyl-7~(2,3,4-tri-trifluoromethoxy-phenyl)-heptanoic acid;

~ 2-Aminomethyl-4- methyl-7-(2,3,5-tri-trifluoromethoxy-phenyl)-heptanoic acid; 2-Aminomethyl-4- mmethyl-7-(2,3,6-tri-trifluoromethoxy-phenyl)-heptanoic acid; 2-Aminomethyl-4-wmethyl-7-(2,4,6-tri-trifluoromethoxy-phenyl)-heptanoic acid; 2-Aminomethyl-7-g2-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(3-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(4-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyi-7-( 2,3-di-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-( 2 4-di-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(2 5-di-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(2 6-di-trifluoromethoxy-phenyl)-4-ethyl-heptanoic ~~ acid; oo 2-Aminomethyl-7-(3,4-di-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-7-(3,5-di-trifluoromethoxy-phenyl)-4-ethyl-heptanoic acid; 2-Aminomethyl-4-ethyl-7-(2,3,4-tri-trifluoromethoxy-phenyl)-heptanoic acid, 2-Aminomethyl-4-ethyl-7-(2,3,5-tri-trifluoromethoxy-phenyl)-heptanoic acid; 2-Aminomethyl-4-ethyl-7-(2,3,6-tri-trifluoromethoxy-phenyl)-heptanoic acid;

2-Aminomethyl-4-ethy-1-7-(2,4,6-tri-trifluoromethoxy-phenyl)-hegptanoic acid; 2-Aminomethyl-4-(2-ethoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4-(3-ethoxy-phenyl)-pentanoic acid;

2-Aminomethyk-4-(4-ehoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,3—diethoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,4—diethoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,5—diethoxy-phenyl)-pentanoic acid; 2-Aminomethyi-4-(2,6—diethoxy-phenyl)-pentanoic acid;

2-Aminomethyl-4-(3,4—diethoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4-(3,5—diethoxy-phenyl)-pentanoic acid; 2-Aminomethyi-4-(2,3,. 4-triethoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,3,. 5-triethoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2,3, 6-tristhoxy-phenyl)-pentanoic acid;

2-Aminomethyl-4-(2,4, 6-tristhoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4-(2-etthoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4-(3-ehoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4-(4-ethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4-(2,3—diethoxy-phenyl)-hexanoic acid;

- 2-Aminomethyl-4-(2,4—diethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4-(2,5—diethoxy-phenyl)-hexanoic acid; } 2-Aminomethyl-4-(2,6—diethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4-(3,4—diethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4-(3,5— diethoxy-phenyl)-hexanoic acid;

2-Aminomethyl-4-(2,3,4-triethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4-(2,3,$5-triethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4-(2,3,%6-triethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4-(2,4,@-triethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-5-(2-et hoxy-phenyl)-4-methyl-pentanoic acid;

2-Aminomethyl-5-(3-et hoxy-phenyl)-4-methyl-pentanoic acid; 2-Aminomethyl-5-(4-ethhoxy-phenyl)-4-methyl-pentanoic acid; 2-Aminomethyi-5-(2,3-«diethoxy-phenyi)-4-methyl-pentanoic acid;

2.Aminomethyl-5-(2,4-diethoxy-phenyl)-4-methyl-pemntanaic acid; 2-Aminomethyl-5-(2,5-diethoxy-phenyl)-4-methyl-pemntanoic acid; 2-Aminomethyl-5-(2,6-diethoxy-phenyl)-4-methyl-pe wntanoic acid; 2-Aminomethyl-5-(3,4-diethoxy-phenyl)-4-methyl-pe ntanoic acid; 2-Aminomethyl-5-(3,5-diethoxy-phenyl)-4-methyl-pe ntanoic acid; 2-Aminomethyl-4-methyl-5-(2,3,4-triethoxy-phenyl)-goentanoic acid; 2-Aminomethyl-4-methyl-5-(2,3,5-triethoxy-phenyl)-goentanoic acid; 2-Aminomethyl-4-methyl-5-(2,3,6-triethoxy-pheny)-goentanoic acid; 2-Aminomethyk4-methyl-5-(2,4,6-triethoxy-phenyl)-gpentanoic acid; 2-Aminomethyl-5-(2-ethoxy-phenyl)-4-ethyl-pentanoic acid; 2-Aminomethyl-5-(3-ethoxy-phenyl)-4-ethyl-pentancoic acid; 2-Aminomethyl-5-(4-ethoxy-phenyl)-4-ethyl-pentanoic acid; 2-Aminomethyl-5-(2,3-diethoxy-phenyl)-4-ethyl-pen-tancic acid; 2-Aminomethyl-5-(2,4-diethoxy-phenyl)-4-ethyl-pen-tanoic acid; 2-Aminomethyl-5-(2,5-diethoxy-phenyl)-4-ethyl-pen-tanoic acid;

2.Aminomethyl-5-(2,6-diethoxy-phenyl)-4-ethyl-pen tanoic acid; 2-Aminomethyi-5-(3,4-diethoxy-phenyl)-4-ethyl-perx tanoic acid, 2-Aminomethyl-5-(3,5-diethoxy-phenyl)-4-ethyl-perstanoic acid; 2-Aminomethyl-4-ethyl-5-(2,3,4-triethoxy-phenyl)-pentanoic acid; 2-Aminomethyl-4-ethyl-5-(2,3,5-triethoxy-phenyl)-peentanoic acid; : : o-Aminomethyl-4-ethyl-5-(2,3,6-triethoxy-phenyl)-peentanoic acid; - 2-Aminomethyl-4-ethyl-5-(2,4,6-triethoxy-phenyl)-peentanoic acid; 2-Aminomethyl-4-ethyl-5-(2,3,4,5-tetraethoxy-phen yl)-pentanoic acid; 2-Aminomethyi-4-ethyl-5-(2,3,4,6-tetraethoxy-phen yl)-pentanoic acid; 2-Aminomethyl-4-ethyl-5-(2,3,5,6-tetraethoxy-phersyl)-pentanoic acid, 2-Aminomethyl-4-ethyl-5-pentaethoxyphenyl-pentaenoic acid; 2-Aminomethyl-5-(2-ethoxy-phenyl)-4-methyl-hexa noic acid; 2-Aminomethyl-5-(3-ethoxy-phenyl)-4-methyl-hexa_noic acid; 2-Aminomethyl-5-(4-ethoxy-phenyl)-4-methyl-hexa noic acid; 2-Aminomethyl-5-(2,3-diethoxy-phenyl)-4-methyl-h exanoic acid; 2-Aminomethyi-5-(2,4-diethoxy-phenyl)-4-methyl-h exanoic acid; 2-Aminomethyl-5-(2,5-diethoxy-phenyl)-4-methyl-h-exanoic acid;

VW 2005/030700 PCT/IB2004/0029 “85 2-Aminomethyl-5-(2,6-disthoxy-pheanyl)-4-methyl-hexanoic acid; 2-Aminomethyl-5-(3,4-diethoxy-phenyl)4-methyl-hexanoic acid; 2-Aminomethyl-5-(3,5-diethoxy-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-4-methyl-5-(2,3,4-t riethoxy-phenyl)-hexanoic acid;

2.Aminomethyl-4-methyl-5-(2,3,5-t risthoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4-methyl-5-(2,3,6-t riethoxy-phenyl)-hexanoic acid; 2-Aminomethyi-4-methyl-5-(2,4,6-t ricthoxy-phenyt)-hexanoic acid; 2-Aminomethyl-6-(2-ethoxy-phenyll)-4-methyl-hexanoic acid; 2-Aminomethyl-6-(3-ethoxy-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-6-(4-ethoxy-phenyB)-4-methyl-hexanoic acid; 2-Aminomethyi-6-(2,3-diethoxy-phenyl}-4-methyl-hexanoic acid; 2-Aminomethyl-6-(2,4-diethoxy-pheanyl)-4-methyl-hexanoic acid; 2-Aminomethyl-6-(2,5-diethoxy-pheanyl)-4-methyl-hexanoic acid; 2-Aminomethyl-6-(2,6-diethoxy-phenyl)-4-methyl-hexanoic acid; . 2-Aminomethyl-6-(3,4-diethoxy-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyl-6-~(3,5-diethoxy-phenyl)-4-methyl-hexanoic acid; 2-Aminomethyi-4-methyl-6-(2,3,4-twriethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4-methyi-6-(2,3,5-twisthoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4-methyl-6-(2,3,6-twriethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4-methyl-6-(2,4,6-trristhoxy-phenyl)-hexanoic acid; 2-Aminomethyl-6-(2-ethoxy-phenyl }-4-ethyl-hexanoic acid; - 2-Aminomethyl-6-(3-ethoxy-phenyl )-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(4-ethoxy-phenyl)~4-ethyl-hexanoic acid; 2-Aminomethyl-6-(2,3-diethoxy-phenyl)-4-ethyi-hexanoic acid; 2-Aminomethyl-6-(2,4-diethoxy-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyi-6-(2,5-diethoxy-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(2,6-diethoxy-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(3,4-diethoxy-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-6-(3,5-diethoxy-phenyl)-4-ethyl-hexanoic acid; 2-Aminomethyl-4-ethyl-6-(2,3,4-trie thoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4-ethyl-6-(2,3,5-triethoxy-phenyl)-hexanoic acid; 2-Aminomethyl-4-ethyl-6-(2,3,6-trie-thoxy-phenyl)-hexanoic acid;